Substitutionsmittel

Initiation and Dose of Methadone Monotherapy vs Combination Therapy, 2015 to 2023.

29. August 2025 | Methadon zur Substitution

Initiation and Dose of Methadone Monotherapy vs Combination Therapy, 2015 to 2023. Garg R, Luo J, Bozinoff N, et al. JAMA Netw Open. 2025;8(8):e2527290. doi:10.1001/jamanetworkopen.2025.27290 https://jamanetwork.com/journals/jamanetwo…

Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting.

23. August 2025 | Buprenorphin

Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting. Waters RC, Hoog J, Bell C, et al. JAMA Netw Open. 2025;8(8):e2527016. doi:10.1001/jamanetworkopen.2025.27016 https://jamanetwork.com/journals/jama…

Dose-specific clinical outcomes in patients with opioid use disorder treated with 24-32 mg/day of buprenorphine.

23. August 2025 | Buprenorphin

Dose-specific clinical outcomes in patients with opioid use disorder treated with 24-32 mg/day of buprenorphine. D'Agata Mount J, Sun J, Davis A, Cover A, Sun L, Gannon C, Derenoncourt M, Garrett G, Eyasu R, Ebah E, Bijole P, Greenblatt A, Ka…

High-Dose Buprenorphine Treatment in the Setting of Fentanyl.

23. August 2025 | Buprenorphin

High-Dose Buprenorphine Treatment in the Setting of Fentanyl. Tsui JI, Bhatraju EP, Hallgren KA, Rhew IC, Samet JH. JAMA Netw Open. 2025;8(8):e2528119. doi:10.1001/jamanetworkopen.2025.28119 https://jamanetwork.com/journals/jamanetwor…

Retention of patients in opioid substitution treatment: A systematic review.

23. August 2025 | Substitutionsmittel Verschiedenes

Retention of patients in opioid substitution treatment: A systematic review. O’Connor AM, Cousins G, Durand L, Barry J, Boland F (2020) PLoS ONE 15(5): e0232086. doi.org/10.1371/journal.pone.0232086 https://journals.plos.org/plosone/a…

Berlin. Suchtmedizinische Grundversorgung Teil 1nach dem (Muster-)Kursbuch Suchtmedizinische Grundversorgung der Bundesärztekammer (Stand 02.05.2022) - 09.10.2025–10.10.2025

23. August 2025 | Diamorphin

Berlin. Suchtmedizinische Grundversorgung Teil 1nach dem (Muster-)Kursbuch Suchtmedizinische Grundversorgung der Bundesärztekammer (Stand 02.05.2022) - 09.10.2025–10.10.2025 Grundlagen der Suchtmedizinischen Grundversorgung (Teil 1 von 4) ink…

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT).

10. August 2025 | Diamorphin

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT). Beaumont S, Magel T, MacDonald S, Harrison S, Schechter M, Oviedo-Joekes E. Subst Abuse Treat P…

Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.

09. August 2025 | Substitutionsmittel Verschiedenes

Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. Somogyi AA, Larsen M, Abadi RM, Jittiwutikarn J, Ali R, White JM. Br J Clin Pharmacol. 2008 Nov;66(5):640-7. doi: 10.11…

Maintenance therapy with opium tincture for injecting drug users; implications for prevention from viral infections.

09. August 2025 | Substitutionsmittel Verschiedenes

Maintenance therapy with opium tincture for injecting drug users; implications for prevention from viral infections. Alam Mehrjerdi Z, Zarghami M. Hepat Mon. 2013 Apr 16;13(4):e8334. doi: 10.5812/hepatmon.8334. PMID: 23805161; PMCID: P…

Changes in self-reported mental health, anxiety and depression among patients in heroin-assisted treatment: Findings from a Norwegian trial project.

03. August 2025 | Diamorphin

Changes in self-reported mental health, anxiety and depression among patients in heroin-assisted treatment: Findings from a Norwegian trial project. Myklebust LHR, Eide D, Wüsthoff LEC, Melis F, Oldervoll AL, De Pirro S, Clausen T. Eur…

Extended-release injectable buprenorphine for the treatment of opioid use disorder among individuals at high risk of overdose: The FASTER-BUP udy.

03. August 2025 | Buprenorphin

Extended-release injectable buprenorphine for the treatment of opioid use disorder among individuals at high risk of overdose: The FASTER-BUP udy. Socias ME, Dickhout P, Langlois J, Grant C, Nolan S. Drug Alcohol Depend. 2025 Jul 19;27…

Accidental Methadone Toxicity in a 3-Year-Old Leading to Severe Cerebellitis and Death: A Case Report.

03. August 2025 | Methadon zur Substitution

Accidental Methadone Toxicity in a 3-Year-Old Leading to Severe Cerebellitis and Death: A Case Report. Pappin J, Hansen G, Holt T. Case Rep Pediatr. 2025 Jul 10;2025:1045330. doi: 10.1155/crpe/1045330. PMID: 40686917; PMCID: PMC1227170…

Methadone-Induced Toxicity - An Unexpected Challenge for the Brain and Heart in ICU Settings: Case Report and Review of the Literature.

03. August 2025 | Methadon zur Substitution

Methadone-Induced Toxicity - An Unexpected Challenge for the Brain and Heart in ICU Settings: Case Report and Review of the Literature. Cristina BG, Isac S, Teodorescu GD, Isac T, Martac C, Cobilinschi C, Pavel B, Andreescu CV, Droc G. …

Pomegranate Juice Consumption Improves Sleep Quality and Melatonin Concentration of Patients With Opioid Use Disorders Under Medication-Assisted Treatment With Methadone and Buprenorphine: A Randomized Controlled Trial.

03. August 2025 | Substitutionsmittel Verschiedenes

Pomegranate Juice Consumption Improves Sleep Quality and Melatonin Concentration of Patients With Opioid Use Disorders Under Medication-Assisted Treatment With Methadone and Buprenorphine: A Randomized Controlled Trial. Leventelis C, Barmpas…

UK. Time for a new HAT – Heroin Assisted Treatment

22. Juli 2025 | Diamorphin

UK. Time for a new HAT – Heroin Assisted Treatment One hundred years ago, the UK became the first country in the world to prescribe heroin (diamorphine) to heroin users as a treatment for opioid dependency. The ‘British system’ was formally establi…

Substitutionstherapie: Depotpräparate schenken Lebensqualität

20. Juli 2025 | Buprenorphin

Substitutionstherapie: Depotpräparate schenken Lebensqualität Depotpräparate mit Buprenorphin sind eine effektive Möglichkeit in der Substitutionstherapie opioidabhängiger Patienten. Sie ermöglichen eine stabile Versorgung, reduzieren Praxisb…

Cognitive functioning in subjects with Substance Use Disorder: retrospective observational study on the transition from Methadone to Levomethadone

12. Juli 2025 | Opioidsubstitution

Cognitive functioning in subjects with Substance Use Disorder: retrospective observational study on the transition from Methadone to Levomethadone Silvia Pinna, Giuseppe Gagliardo, Selene Regio, Francesca Pagliari, Lorenzo Finocchiaro, Maria Cristi…

Cognitive functioning in subjects with Substance Use Disorder: retrospective observational study on the transition from Methadone to Levomethadone

12. Juli 2025 | Methadon zur Substitution

Management of Patients in an Unstable Phase of Opioid Use Disorder: Challenges, Goals, and Emerging Evidence on Long-Acting Buprenorphine.

12. Juli 2025 | Buprenorphin

Management of Patients in an Unstable Phase of Opioid Use Disorder: Challenges, Goals, and Emerging Evidence on Long-Acting Buprenorphine. Matheson C., Soyka M., Hard B., Brousse G., Meyner S., Seibold C., Torrens M.: Heroin Addict Rel…

Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada.

06. Juli 2025 | Diamorphin

Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada. Mayer S, Fairbairn N, Fowler A, Boyd J, Kerr T, McNeil R.&…

Changing trends in safer opioid supply uptake, dose and hydromorphone volume in Ontario: A population-based cross-sectional study.

05. Juli 2025 | Substitutionsmittel Verschiedenes

Changing trends in safer opioid supply uptake, dose and hydromorphone volume in Ontario: A population-based cross-sectional study. Xu F, Wang T, Kolla G, Campbell T, Watts T, Ledlie S, Koncz D, Tadrous M, Gomes T. Int J Drug Policy. 2025 Jun…

Cortisol and β-Endorphin Responses During a Two-Month Exercise Training Program in Patients with an Opioid Use Disorder and on a Substitution Treatment.

05. Juli 2025 | Substitutionsmittel Verschiedenes

Cortisol and β-Endorphin Responses During a Two-Month Exercise Training Program in Patients with an Opioid Use Disorder and on a Substitution Treatment. Psarianos AE, Philippou A, Papadopetraki A, Chatzinikita E, Chryssanthopoulos C, Theos A…

Duration of Methadone and Buprenorphine-Naloxone Treatment.

05. Juli 2025 | Buprenorphin

Duration of Methadone and Buprenorphine-Naloxone Treatment. Kleinman RA, Kurdyak P. JAMA Netw Open. 2025 Jul 1;8(7):e2518389. doi: 10.1001/jamanetworkopen.2025.18389. PMID: 40591359; PMCID: PMC12215571. https://pmc.ncbi.nlm.nih.gov/ar…

Duration of Methadone and Buprenorphine-Naloxone Treatment.

05. Juli 2025 | Methadon zur Substitution

Pain Management Strategies for Patients Receiving Extended-Release Buprenorphine for Opioid Use Disorder: A Scoping Review.

05. Juli 2025 | Buprenorphin

Pain Management Strategies for Patients Receiving Extended-Release Buprenorphine for Opioid Use Disorder: A Scoping Review. Azar P, Kim JJ, Azarmju F, Sirohi K, Machado J, Lau A, Siu J, Ignaszewski MJ, Montaner JSG, Krausz M. Subst Use…

Essen. Eröffnung der Diamorphin-Ambulanz

03. Juli 2025 | Diamorphin

Essen. Eröffnung der Diamorphin-Ambulanz Am Mittwoch, 11. Juni, wurde die Diamorphin-Ambulanz bei der Suchthilfe direkt Essen gGmbH offiziell eröffnet. Auch Oberbürgermeister Thomas Kufen war vor Ort und begrüßte die Gäste zum offiziellen Sta…

Medication experiences in the treatment of opioid use disorders: Insights from Reddit.

02. Juli 2025 | Substitutionsmittel Verschiedenes

Medication experiences in the treatment of opioid use disorders: Insights from Reddit. Almeida A, Conway M, Grelotti DJ, Gupta A, Frank D, Bórquez A. Addiction. 2025; 120…

Effectiveness of methadone versus buprenorphine in the treatment of opioid use disorder: secondary analyses of prospective cohort study data.

02. Juli 2025 | Methadon zur Substitution

Effectiveness of methadone versus buprenorphine in the treatment of opioid use disorder: secondary analyses of prospective cohort study data. Naji L, Rosic T, Dennis B, Worster A, Paul J, Thabane L, Samaan Z. BMJ Open. 2025 Jun 17;15(6…

Effectiveness of methadone versus buprenorphine in the treatment of opioid use disorder: secondary analyses of prospective cohort study data.

02. Juli 2025 | Buprenorphin

Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada.

24. Juni 2025 | Substitutionsmittel Verschiedenes

Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada. Young S, Fairbairn N, Cui Z, Bach&…

Stimulant use with opioid use disorder medication increases overdose risk for methadone but not buprenorphine/naloxone

24. Juni 2025 | Substitutionsmittel Verschiedenes

Stimulant use with opioid use disorder medication increases overdose risk for methadone but not buprenorphine/naloxone People receiving treatment for opioid use disorder sometimes also need medications for other conditions like ADHD. But do stimula…

Why I Microdose Suboxone, While Continuing to Use Lots of Fentanyl

23. Juni 2025 | Buprenorphin

Why I Microdose Suboxone, While Continuing to Use Lots of Fentanyl Buprenorphine, one of the three Food and Drug Administration-approved medications for opioid use disorder (MOUD) does not mix well with fentanyl. You don’t want both of them in your…

Memory function in patients with opioid dependence treated with buprenorphine and methadone in comparison with healthy persons.

07. Juni 2025 | Methadon zur Substitution

Memory function in patients with opioid dependence treated with buprenorphine and methadone in comparison with healthy persons. Ardakani SK, Mahmoudi S, Rahmani K, Shamsalizadeh N. Sci Rep. 2025 May 22;15(1):17780. doi: 10.1038/s41598-…

Memory function in patients with opioid dependence treated with buprenorphine and methadone in comparison with healthy persons.

07. Juni 2025 | Buprenorphin

Hydromorphone Hopes: A Qualitative Study of People Initiating Supervised Short-Acting Injectable Opioid Treatment in Australia.

07. Juni 2025 | Diamorphin

Hydromorphone Hopes: A Qualitative Study of People Initiating Supervised Short-Acting Injectable Opioid Treatment in Australia. Rance, J., Belackova, V., Bell, J., Dunlop, A.J., Ezard, N., Jauncey, M., Lintzeris, N., Oviedo-Joekes, E., Ritter…

The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review.

07. Juni 2025 | Methadon zur Substitution

The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review. Recarey-Rama S, Gómez-Trigo J, Gil-Rodriguez A, Dominguez E, Sánchez-Martínez I, Riveiro-Recimil Á, Barral-Raña A, de Leon J, Rodriguez-Viyue…

ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder.

07. Juni 2025 | Methadon zur Substitution

ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder. Ait Tayeb AEK, Laforgue EJ, Schreck B, Grall-Bronnec M, Hardouin JB, Leb…

Experiences of Women Prescribed Methadone.

07. Juni 2025 | Methadon zur Substitution

Experiences of Women Prescribed Methadone. Wimberly AS, Rawlett K, Smith J, Murray-Browne S. Subst Use Misuse. 2025 May 14:1-9. doi: 10.1080/10826084.2025.2499604. Epub ahead of print. PMID: 40367277. Abstract https://www.tandfonline…

Structural Determinants of Buprenorphine Partial Agonism at the μ-Opioid Receptor.

07. Juni 2025 | Buprenorphin

Structural Determinants of Buprenorphine Partial Agonism at the μ-Opioid Receptor. Gomes AAS, Giraldo J. J Chem Inf Model. 2025 May 26;65(10):5071-5085. doi: 10.1021/acs.jcim.5c00078. Epub 2025 May 6. PMID: 40328437; PMCID: PMC12117568…

BfArM. Liste der Fertigarzneimittel mit einer Verpflichtung zur regelmäßigen Datenübermittlung nach § 52b Abs. 3f AMG

05. Juni 2025 | Substitutionsmittel Verschiedenes

BfArM. Liste der Fertigarzneimittel mit einer Verpflichtung zur regelmäßigen Datenübermittlung nach § 52b Abs. 3f AMG In der 11. Beiratssitzung vom 05.06.2023 ist die Erweiterung der am 21.10.2020 festgelegten Kriterien einstimmig beschlossen worde…

Approved medications for opioid use disorder : current update.

03. Juni 2025 | Substitutionsmittel Verschiedenes

Approved medications for opioid use disorder : current update. Soyka M. Expert Opin Pharmacother. 2025 May 21:1-15. doi: 10.1080/14656566.2025.2507124. Epub ahead of print. PMID: 40370106. https://www.tandfonline.com/doi/full/10.1080/…

Rapid Titration of Methadone for Opioid Use Disorder in the Emergency Department: A Case Report.

03. Juni 2025 | Methadon zur Substitution

Rapid Titration of Methadone for Opioid Use Disorder in the Emergency Department: A Case Report. Lamberson M, King R, Waters CT, Jackson P, Brooklyn J, Riser E, Wolfson D. Clin Pract Cases Emerg Med. 2025 May;9(2):188-192. doi: 10.5811…

Do some operations still need more diamorphine? Leslie D, Stranix N. Anaesthesia. 2025 Jun;80(6):723. doi: 10.1111/anae.16535. Epub 2024 Dec 29. PMID: 40350697. https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/epdf/10.1111/ana

03. Juni 2025 | Diamorphin

Do some operations still need more diamorphine? Leslie D, Stranix N. Anaesthesia. 2025 Jun;80(6):723. doi: 10.1111/anae.16535. Epub 2024 Dec 29. PMID: 40350697. https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/epd…

Patient-elected low-dose intravenous naloxone for rapid buprenorphine induction: a case report.

03. Juni 2025 | Buprenorphin

Patient-elected low-dose intravenous naloxone for rapid buprenorphine induction: a case report. Azar P, Machado J, Kim JJ, Wong JSH, Nikoo M, Li VW. Addict Sci Clin Pract. 2025 May 14;20(1):42. doi: 10.1186/s13722-025-00572-z. PMID: 40…

A Path Forward for Extended-Release Buprenorphine—Optimizing Implementation Strategies.

01. Juni 2025 | Buprenorphin

A Path Forward for Extended-Release Buprenorphine—Optimizing Implementation Strategies. Assoumou SA, Morgan JR. JAMA Netw Open. 2025;8(5):e2513010. doi:10.1001/jamanetworkopen.2025.13010 https://jamanetwork.com/journals/jama…

Initiating Injectable Buprenorphine in People Hospitalized With Infections: A Randomized Clinical Trial.

01. Juni 2025 | Buprenorphin

Initiating Injectable Buprenorphine in People Hospitalized With Infections: A Randomized Clinical Trial. Seval N, Roth P, Frank CA, et al. JAMA Netw Open. 2025;8(5):e2513000. doi:10.1001/jamanetworkopen.2025.13000…

USA. Seattle nonprofit rolling out potential ‘game changer’ for fentanyl addiction

12. Mai 2025 | Buprenorphin

USA. Seattle nonprofit rolling out potential ‘game changer’ for fentanyl addiction (…) In the past year, a Seattle-based behavioral health treatment provider has pioneered a method to start people on low doses of injectable, slow-releasing bu…

buprenorphine/naloxone (Rx)

12. Mai 2025 | Buprenorphin

buprenorphine/naloxone (Rx) Brand and Other Names:Suboxone, Zubsolv, Cassipa: Dosing & Uses, Interactions https://reference.medscape.com/drug/suboxone-zubsolv-buprenorphine-naloxone-343334

Relative risks of adverse effects across different opioid agonist treatments—A systematic review and meta-analysis.

08. Mai 2025 | Substitutionsmittel Verschiedenes

Relative risks of adverse effects across different opioid agonist treatments—A systematic review and meta-analysis. Meyer M, Strazdins E, Guessoum A, Westenberg JN, Appenzeller-Herzog C, Cattaneo MEGV, et al. Addicti…

A Review of the Prospective Effects of Methadone on Peripheral Neuropathic Pain in Diabetic Patients.

08. Mai 2025 | Methadon zur Substitution

A Review of the Prospective Effects of Methadone on Peripheral Neuropathic Pain in Diabetic Patients. Poursamimi J. ScientificWorldJournal. 2025 Mar 5;2025:8483881. doi: 10.1155/tswj/8483881. PMID: 40225355; PMCID: PMC11986196. https…

In brief: New labeling for once-monthly subcutaneous buprenorphine (Sublocade).

08. Mai 2025 | Buprenorphin

In brief: New labeling for once-monthly subcutaneous buprenorphine (Sublocade). Med Lett Drugs Ther. 2025 Apr 14;67(1726):63-64. doi: 10.58347/tml.2025.1726e. PMID: 40254731. https://secure.medicalletter.org/TML-article-1726e

Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series.

08. Mai 2025 | Buprenorphin

Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series. Hayes V, Mills L, Byron G, Stubley C, Black E, Trevitt BT, Somogyi AA, Sahid A, Lintzeris N. Drug Alcohol Depend Rep. 2025 Apr 5;15:1003…

Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages.

08. Mai 2025 | Buprenorphin

Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages. Gilbert MK, Daughton AR, Chilcoat HD, Laffont CM, Strafford S, DeVeaugh-Geiss AM. J Med Internet Res. 2025 Apr…

Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial.

08. Mai 2025 | Buprenorphin

Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial. Lofwall MR, Nunes EV, Walsh SL, Bailey GL, Frost M, Budilovsky-Kelley NR, Banke Nordbeck E, Meyner S, Alm…

Long acting injectable buprenorphine: Perspectives from service-users, staff and stakeholders.

08. Mai 2025 | Buprenorphin

Long acting injectable buprenorphine: Perspectives from service-users, staff and stakeholders. Fish R, Mateus C, Maiden H, Lawson E, Limmer M. Drug Alcohol Depend Rep. 2025 Mar 29;15:100328. doi: 10.1016/j.dadr.2025.100328. PMID: 40247911; P…

Escalating Doses of Buprenorphine for the Treatment of Buprenorphine-Induced Opioid Withdrawal.

02. Mai 2025 | Buprenorphin

Escalating Doses of Buprenorphine for the Treatment of Buprenorphine-Induced Opioid Withdrawal. Laxton SJ. Cureus. 2025 Mar 13;17(3):e80527. doi: 10.7759/cureus.80527. PMID: 40225488; PMCID: PMC11993309. https://pmc.ncbi.nlm.nih.gov/a…

Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl.

02. Mai 2025 | Buprenorphin

Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl. Stein BD, Sheng F, Saloner BK, Gordon AJ, Merlin JS. Addict Sci Clin Pract. 2025 Apr 9;20(1):33. doi: 10.1186…

Outpatient Initiation of 7-Day Injectable Buprenorphine: A Direct-to-Inject Case Series.

02. Mai 2025 | Buprenorphin

Outpatient Initiation of 7-Day Injectable Buprenorphine: A Direct-to-Inject Case Series. Rosenwohl-Mack S, Suen LW, Logan AA, Peterson D, Snyder HR. Subst Use Addctn J. 2025 Apr 4:29767342251330412. doi: 10.1177/29767342251330412. Epub…

Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States.

20. April 2025 | Buprenorphin

Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States. Ivasiy R…

Methadone and Buprenorphine as Medication for Addiction Treatment Diversely Affect Inflammation and Craving Depending on Their Doses.

18. April 2025 | Buprenorphin

Methadone and Buprenorphine as Medication for Addiction Treatment Diversely Affect Inflammation and Craving Depending on Their Doses. Leventelis C, Veskoukis AS, Rojas Gil AP, Papadopoulos P, Garderi M, Angeli A, Kampitsi A, Tsironi M. …

Methadone and Buprenorphine as Medication for Addiction Treatment Diversely Affect Inflammation and Craving Depending on Their Doses.

18. April 2025 | Methadon zur Substitution

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.

18. April 2025 | Buprenorphin

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. Nosyk B, Min JE, Homayra F, et al. JAMA. 2024;332(21):1822–1831. doi:10.1001/jama.2024.16954 https://jamanetwork.com/journals/jama/fullarticl…

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.

18. April 2025 | Methadon zur Substitution

Initiation and Dosing of Extended-Release Buprenorphine: A Narrative Review of Emerging Approaches for Patients Who Use Fentanyl.

18. April 2025 | Buprenorphin

Initiation and Dosing of Extended-Release Buprenorphine: A Narrative Review of Emerging Approaches for Patients Who Use Fentanyl. Lee KW, Mead A, Ghauri I, Hollett B, Drolet M, Kozicky JM. Subst Abuse Rehabil. 2025 Mar 25;16:71-82. doi…

Trends in Extended-Release and Non-Extended-Release Buprenorphine Dispensing.

18. April 2025 | Buprenorphin

Trends in Extended-Release and Non-Extended-Release Buprenorphine Dispensing. Stopka TJ, Dalvi N, Young LD, Shrestha S, Valerio DD, Walley AY. JAMA Netw Open. 2025 Apr 1;8(4):e253158. doi: 10.1001/jamanetworkopen.2025.3158. PMID: 40184…

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.

18. April 2025 | Buprenorphin

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. Nosyk B, Min JE, Homayra F, Kurz M, Guerra-Alejos BC, Yan R, Piske M, Seaman SR, Bach P, Greenland S, Karim ME, Siebert U, Bruneau J, Gustafson P, Kampman K, Korthu…

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.

18. April 2025 | Methadon zur Substitution

The Impact of CYP2D6 metabolizer phenotypes on the EDDP/methadone metabolic ratio: A comprehensive analysis.

08. April 2025 | Methadon zur Substitution

The Impact of CYP2D6 metabolizer phenotypes on the EDDP/methadone metabolic ratio: A comprehensive analysis. Wilmes V, Kettner M, Corvest E, Verhoff MA, Kauferstein S. Forensic Sci Int. 2025 Mar 7;370:112445. doi: 10.1016/j.forsciint.2…

Diversion of diacetylmorphine in heroin-assisted treatment - a focus group study among patients and treatment providers.

08. April 2025 | Diamorphin

Diversion of diacetylmorphine in heroin-assisted treatment - a focus group study among patients and treatment providers. Strickler E, Wicki Z, Westenberg JN, Strasser J, Lang UE, Dürsteler KM, Meyer M, Vogel M. Eur Addict Res. 2025 Mar…

Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs.

20. März 2025 | Methadon zur Substitution

Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs. Sherrick RC. J Addict Med. 2025 Mar 10. doi: 10.1097/ADM.0000000000001473. Epub ahead of print. PMID: 40062577. Abstract https:/…

The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021.

15. März 2025 | Buprenorphin

The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021. Stringfellow EJ, Dong H, Khatami SN, Lee H, J…

Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study.

11. März 2025 | Substitutionsmittel Verschiedenes

Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study. Bouthillier A, Bastien G, McA…

Cognitive function among methadone assisted treatment patient in Malaysia.

11. März 2025 | Methadon zur Substitution

Cognitive function among methadone assisted treatment patient in Malaysia. Surohedin IH, Ganes T, Yee A, Abd Rashid R, Lim PK. J Ethn Subst Abuse. 2025 Feb 16:1-15. doi: 10.1080/15332640.2025.2457618. Epub ahead of print. PMID: 3995563…

High BMI is a specific risk factor for drug-related mortality in patients receiving methadone: A case control study.

11. März 2025 | Methadon zur Substitution

High BMI is a specific risk factor for drug-related mortality in patients receiving methadone: A case control study. Algahtani T, Le Ruez T, Strang J, Morgan D, Smith M, Copeland CS. Addiction. 2025. doi.o…

The effectiveness of Transcranial Photobiomodulation therapy (tPBM) on reducing anxiety, depression, and opioid craving in patients undergoing methadone maintenance treatment: a double-blind, randomized, controlled trial.

11. März 2025 | Methadon zur Substitution

The effectiveness of Transcranial Photobiomodulation therapy (tPBM) on reducing anxiety, depression, and opioid craving in patients undergoing methadone maintenance treatment: a double-blind, randomized, controlled trial. Helali H, Samani N…

Switching to levomethadone improves methadone-induced hyperhidrosis: A case report.

11. März 2025 | Opioidsubstitution

Switching to levomethadone improves methadone-induced hyperhidrosis: A case report. Serfilippi, T., Piccirillo, S., Romagnoli, F., Tarini, M., Lariccia, V., & Magi, S. (2025). Journal of Addictive Diseases, 1–5. doi.org/10.1080/105…

A heroin overdose laboratory model: How do escalating doses of diamorphine alter respiratory function in a diamorphine-treated population?

11. März 2025 | Diamorphin

A heroin overdose laboratory model: How do escalating doses of diamorphine alter respiratory function in a diamorphine-treated population? Tas B, Kalk NJ, Chesney E, van der Waal R, Boyd A, Bell J, Kelleher M, Moxham J, Lawn W, Jolley CJ, Str…

Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain.

11. März 2025 | Diamorphin

Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain. Cai L, Zhai J, Ji B, Han F, Niu T, Wang L, Wang J. CPT Pharmacometrics Syst Pharmacol. 2025 Feb 13. doi: 10.1002/psp4.13186. Epu…

USA. Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

11. März 2025 | Buprenorphin

USA. Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatmen…

Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: an updated systematic review.

11. März 2025 | Buprenorphin

Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: an updated systematic review. Adams KK, Waters K, Sobieraj DM. Addict Sci Clin Pract. 2025 Feb 20;20(1):19. doi: 10.1186/s13722-025-00548-z. PMID: 3…

Investigating outcomes in a substance use treatment provider: a cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder

11. März 2025 | Buprenorphin

Investigating outcomes in a substance use treatment provider: a cross-sectional comparison of long-acting injectable buprenorphine and oral medication for opioid use disorder Montgomery C, Abbasi Y, De Silva D, Gittins R, Jones A, Van Hout MC. …

Navigating Buprenorphine Therapy: A Closer Look at Microdosing vs. Macrodosing for Pain Management and Opioid Addiction - A Narrative Review.

11. März 2025 | Buprenorphin

Navigating Buprenorphine Therapy: A Closer Look at Microdosing vs. Macrodosing for Pain Management and Opioid Addiction - A Narrative Review. Merhavy ZI, Flores M, Rivera E, Gizzarelli J, Ruxmohan S, Quinonez J. Addict Health. 2024 Oct…

Emergency Clinician Buprenorphine Initiation, Subsequent Prescriptions, and Continuous Prescriptions.

11. März 2025 | Buprenorphin

Emergency Clinician Buprenorphine Initiation, Subsequent Prescriptions, and Continuous Prescriptions. Dekker AM, Schriger DL, Herring AA, Samuels EA. JAMA. Published online February 19, 2025. doi:10.1001/jama.2024.2…

Exploring the Lived Experiences of Medication for Opioid use Disorder Treatment: A Qualitative Study among a Crowdsourced Convenience Sample.

11. März 2025 | Substitutionsmittel Verschiedenes

Exploring the Lived Experiences of Medication for Opioid use Disorder Treatment: A Qualitative Study among a Crowdsourced Convenience Sample. Victor G, Kheibari A, Strickland JC. Community Ment Health J. 2025 Apr;61(3):411-419. doi: 10…

First Results of Ibogaine Research to Reverse Methadone Tolerance

08. Februar 2025 | Methadon zur Substitution

First Results of Ibogaine Research to Reverse Methadone Tolerance A study conducted in Catalonia by ICEERS and Sant Joan de Reus University Hospital has published preliminary results showing how the use of low-dose ibogaine can reduce methadone tol…

Early Results of Implementing Rapid Methadone Titration for Hospitalized Patients: A Case Series.

03. Februar 2025 | Methadon zur Substitution

Early Results of Implementing Rapid Methadone Titration for Hospitalized Patients: A Case Series. Martin M, Baisey T, Skinner S, Ly L, Slown K, Harter K, Nguyen OK, Steiger S, Suen LW. J Gen Intern Med. 2025 Jan 13. doi: 10.1007/s11606-024-0…

Examining the association between fentanyl use and perceived adequacy of methadone dose: A retrospective cohort study.

03. Februar 2025 | Methadon zur Substitution

Examining the association between fentanyl use and perceived adequacy of methadone dose: A retrospective cohort study. Young S, Raboud J, Dodd Z, DeBeck K, Milloy MJ, Wilson D, Hayashi K, Bayoumi AM, Fairbairn N. Drug Alcohol Depend. 2…

Cognitive control in individuals with heroin use disorder after prolonged methadone maintenance treatment.

03. Februar 2025 | Methadon zur Substitution

Cognitive control in individuals with heroin use disorder after prolonged methadone maintenance treatment. Zhao W, Duan F, Li X, Li J, Xia L, Ren Z, Li Y, Song L, Song P, Mu L, Wang L, Zhang J, Song X, Wang Z, Chen J, Zhang X, Jiao D. …

Associations Among Sleep, Pain, and Medications for Opioid Use Disorder: a Scoping Review.

03. Februar 2025 | Substitutionsmittel Verschiedenes

Associations Among Sleep, Pain, and Medications for Opioid Use Disorder: a Scoping Review. Hsaio C, DiMeola KA, Jegede OO, Funaro MC, Langstengel J, Yaggi HK, Barry DT. Curr Addict Rep. 2024 Dec;11(6):965-981. doi: 10.1007/s40429-024-0…

Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance.

03. Februar 2025 | Buprenorphin

Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance. Tsakiridou G, Angelerou MF, Efentakis P, Margaritis A, Papanastasiou AM, Kalantzi L. Pharmaceutics. 2024 Dec 26;17(1):21…

Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl.

03. Februar 2025 | Buprenorphin

Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl. Suen LW, Chiang AY, Jones BLH, Soran CS, Geier M, Snyder HR, Neuhaus J, Myers JJ, Knight KR, Bazazi AR, Coffin PO. JAMA Netw Open. 2025 Jan 2;8(1):e2456253. doi…

Low-Dose Initiations of Buprenorphine in the Fentanyl Era—A Search for Evidence-Based Approaches to an Evolving Crisis.

28. Januar 2025 | Buprenorphin

Low-Dose Initiations of Buprenorphine in the Fentanyl Era—A Search for Evidence-Based Approaches to an Evolving Crisis. Berk J, Rose M, Thakrar AP. JAMA Netw Open. 2025;8(1):e2456261. doi:10.1001/jamanetworkopen.2024.562…

Methadone’s Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction).

17. Januar 2025 | Methadon zur Substitution

Methadone’s Resurgence in Bridging the Treatment Gap in the Overdose Crisis: Position Statement of AMERSA, Inc (Association for Multidisciplinary Education, Research, Substance Use, and Addiction). Suen LW, Incze M, Simon C, et al. Sub…

Diamorphin. „Das sind Menschen, die einen klaren Kopf bekommen wollen“

05. Januar 2025 | Diamorphin

Diamorphin. „Das sind Menschen, die einen klaren Kopf bekommen wollen“ In der Praxis PATRIDA (griech. „Heimat“) wird die Echtstoffvergabe als Teil eines nachhaltigen Entwicklungsprozesses gesehen, der die Fähigkeit zur Selbsthilfe stärken soll. Wir…

Evaluating the effect of chronic and continuous use of methadone on the glomerular filtration rate of patients receiving oral methadone (syrup).

05. Januar 2025 | Substitutionsmittel Verschiedenes

Evaluating the effect of chronic and continuous use of methadone on the glomerular filtration rate of patients receiving oral methadone (syrup). Chegini VG, Kazemifar AM, Tavakolian AE, Karimi AG, Sofi AJP, Ipchian D, Kamali S, Varkiani ME, Y…

Janus LAAM-loaded electrospun fibrous buccal films for treating opioid use disorder.

05. Januar 2025 | Substitutionsmittel Verschiedenes

Janus LAAM-loaded electrospun fibrous buccal films for treating opioid use disorder. Sudarjat H, Qin C, Ingabire D, Moothedathu Raynold AA, Pangeni R, Pearcy A, Meng T, Zhao L, Arriaga M, Chow WN, Puetzer JL, Lu X, Moeller FG, Halquist MS, O'…

Methadone in Cancer-Related Neuropathic Pain: A Narrative Review.

05. Januar 2025 | Methadon in der Krebsmedizin

Methadone in Cancer-Related Neuropathic Pain: A Narrative Review. Ragaban F, Purohit O, Del Fabbro E. Curr Oncol. 2024 Dec 1;31(12):7613-7624. doi: 10.3390/curroncol31120561. PMID: 39727684; PMCID: PMC11674659. https://pmc.ncbi.nlm.ni…

Medications for Opioid Use Disorder in People Who Inject Substances: Reflection on the Potential Place of Morphine Sulfate as Substitution Treatment? Results of COSINUS Cohort Study.

05. Januar 2025 | Morphin ret.

Medications for Opioid Use Disorder in People Who Inject Substances: Reflection on the Potential Place of Morphine Sulfate as Substitution Treatment? Results of COSINUS Cohort Study. Lalanne L, Davalos JR, Audran M, Hamelin N, Chauvin C, Bria…

"It's a delicate balance": clinicians' experiences of providing heroin-assisted treatment.

05. Januar 2025 | Diamorphin

"It's a delicate balance": clinicians' experiences of providing heroin-assisted treatment. Ellefsen R, De Pirro S, Haukland V, Wüsthoff LEC, Arnevik EA. Harm Reduct J. 2024 Dec 31;21(1):230. doi: 10.1186/s12954-024-01135-2. PMID…

Diamorphin. „Diamorphin muss jedem Menschen mit Opiatkonsum zugänglich gemacht werden“

04. Januar 2025 | Diamorphin

Diamorphin. „Diamorphin muss jedem Menschen mit Opiatkonsum zugänglich gemacht werden“ Seit 2009 ist die Behandlung von Drogengebraucher*innen mit pharmazeutischem Heroin (Diamorphin) in Deutschland zugelassen, bleibt aber unter ihren Möglichkeiten…

Schweiz. Revolutionäre Therapieform: Heroingestützte Behandlung – eine Schweizer Pionierleistung

04. Januar 2025 | Diamorphin

Schweiz. Revolutionäre Therapieform: Heroingestützte Behandlung – eine Schweizer Pionierleistung Seit 30 Jahren wird in der Schweiz die heroingestützte Behandlung praktiziert. Ein Fachmann erklärt, weshalb dieses «Jubiläum» gleichzeitig ein Weckruf…

BtMVV - Vierte Verordnung zur Änderung der Betäubungsmittel-Verschreibungsverordnung (Diamorphin)

04. Januar 2025 | Diamorphin

BtMVV - Vierte Verordnung zur Änderung der Betäubungsmittel-Verschreibungsverordnung (Diamorphin) Die Verordnung regelt insbesondere die Grundsätze zur Verschreibung und Abgabe der für therapeutische Zwecke zugelassenen Betäubungsmittel, eins…

Diamorphin. Schmerz und Vorurteil

03. Januar 2025 | Diamorphin

Diamorphin. Schmerz und Vorurteil Im sonnigen Gemeinschaftsraum der Diamorphin-Ambulanz in Berlin-Reinickendorf ruhen sich einige Patient*innen aus, andere unterhalten sich im kleinen Raucherraum nebenan. Einer von ihnen ist Stephan Raabe, f…

USA. FDA recommends changes to labeling for transmucosal buprenorphine products indicated to treat opioid use disorder

27. Dezember 2024 | Buprenorphin

USA. FDA recommends changes to labeling for transmucosal buprenorphine products indicated to treat opioid use disorder Today, FDA issued the Federal Register notice, Modifications to Labeling Buprenorphine-Containing Transmucosal Products for the T…

Buprenorphine Injection Among Rural Persons Who Inject Drugs.

15. Dezember 2024 | Buprenorphin

Buprenorphine Injection Among Rural Persons Who Inject Drugs. Zinsli KA, Bhatraju EP, Feinberg J, et al. JAMA Netw Open. 2024;7(12):e2450108. doi:10.1001/jamanetworkopen.2024.50108 https://jamanetwork.com/journals/jaman…

Challenges for the implementation of injectable opioid agonist treatment: a scoping review.

11. Dezember 2024 | Diamorphin

Challenges for the implementation of injectable opioid agonist treatment: a scoping review. Schwarz T, Akartuna D, Busch M, Krausz RM, Uhl A. Harm Reduct J. 2024 Dec 4;21(1):217. doi: 10.1186/s12954-024-01102-x. PMID: 39633369; PMCID…

24-Hour Induction of Transdermal Buprenorphine to Buprenorphine Extended-Release.

11. Dezember 2024 | Buprenorphin

24-Hour Induction of Transdermal Buprenorphine to Buprenorphine Extended-Release. Azar P, Li VW, Wong JSH, Nikoo M, Machado J, Ignaszewski MJ, Mathew N, Raheemullah A, Wakeman SE, Mullen R, Krausz RM, Montaner JSG, Maharaj AR. J Psycho…

Buprenorphine Salivary Gland Accumulation Sustaining High Oral Fluid Exposure and Increasing the Risk of Streptococcus mutans Biofilm Formation.

11. Dezember 2024 | Buprenorphin

Buprenorphine Salivary Gland Accumulation Sustaining High Oral Fluid Exposure and Increasing the Risk of Streptococcus mutans Biofilm Formation. Zheng Z, Chen J, Srinual S, Tumbas Šaponjac V, Yin T, Wang BY, Sun R, Hu M. J Addict Med…

Buprenorphine initiation and rates of associated precipitated withdrawal in patients with fentanyl use in an urban emergency department.

11. Dezember 2024 | Buprenorphin

Buprenorphine initiation and rates of associated precipitated withdrawal in patients with fentanyl use in an urban emergency department. Checkley L, Ly J, Geier C, LeSaint KT. Am J Emerg Med. 2024 Nov 25;88:152-155. doi: 10.1016/j.ajem…

Impact of Alternative Ways to Operationalize Buprenorphine Treatment Duration on Understanding Continuity of Care for Opioid Use Disorder.

11. Dezember 2024 | Buprenorphin

Impact of Alternative Ways to Operationalize Buprenorphine Treatment Duration on Understanding Continuity of Care for Opioid Use Disorder. Dong H, Stringfellow EJ, Russell WA, Bearnot B, Jalali MS. Int J Ment Health Addict. 2024 Aug;22…

Buprenorphine 'microdosing' method for switching patients with opioid dependence from methadone to buprenorphine.

11. Dezember 2024 | Buprenorphin

Buprenorphine 'microdosing' method for switching patients with opioid dependence from methadone to buprenorphine. Singh YC, Singh S, Bhad R, Rao R. BMJ Case Rep. 2024 Nov 7;17(11):e259716. doi: 10.1136/bcr-2024-259716. PMID: 39510616…

Buprenorphine 'microdosing' method for switching patients with opioid dependence from methadone to buprenorphine.

11. Dezember 2024 | Methadon zur Substitution

Buprenorphine-Naloxone for Opioid Use Disorder: Reduction in Mortality and Increased Remission.

11. Dezember 2024 | Buprenorphin

Buprenorphine-Naloxone for Opioid Use Disorder: Reduction in Mortality and Increased Remission. Paul KK, Frey CG, Troung S, Paglicawan LVQ, Cunningham KA, Preston Hill T, Bothwell LG, Golovko G, Pillay Y, Jehle D. West J Emerg Med. 202…

Strategies for improving treatment retention for buprenorphine/naloxone for opioid use disorder: a qualitative study of issues and recommendations from prescribers.

11. Dezember 2024 | Buprenorphin

Strategies for improving treatment retention for buprenorphine/naloxone for opioid use disorder: a qualitative study of issues and recommendations from prescribers. Young GJ, Young LD, Noor-E-Alam M. Addict Sci Clin Pract. 2024 Nov 21;…

Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl.

11. Dezember 2024 | Buprenorphin

Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl. Thakrar AP, Christine PJ, Siaw-Asamoah A, et al. JAMA Netw Open. 2024;7(9):e2435895. doi:10.1001/jamanetworkopen.2024.35895 https://jamanetwork.com…

Methadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-Label, Nonrandomized Clinical Trial.

11. Dezember 2024 | Methadon zur Substitution

Methadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-Label, Nonrandomized Clinical Trial. Tremonti C, Blogg J, Jamshidi N, Harjanto R, Miles N, Ismay C, Page R, Mills L, Buckley N, Perananthan V, Lintzeris N, Haber P.&…

Methadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-Label, Nonrandomized Clinical Trial.

11. Dezember 2024 | Buprenorphin

Patient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative research.

11. Dezember 2024 | Substitutionsmittel Verschiedenes

Patient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative research. Lowry N, Najia C, Kelleher M, Mitcheson L, Marsden J. BMJ Open. 2024 Dec 4;14(12):e088617. doi: 10.1136/bmjopen-…

Data cleaning and harmonization of clinical trial data: Medication-assisted treatment for opioid use disorder.

11. Dezember 2024 | Substitutionsmittel Verschiedenes

Data cleaning and harmonization of clinical trial data: Medication-assisted treatment for opioid use disorder. Balise RR, Hu M-C, Calderon AR, Odom GJ, Brandt L, Luo SX, et al. (2024) PLoS ONE 19(11): e0312695. https://doi.org/10…

Rate Variability for Supplementing Withdrawal Assessment in Patients with Opioid Dependence: An Exploratory Study.

11. Dezember 2024 | Substitutionsmittel Verschiedenes

Rate Variability for Supplementing Withdrawal Assessment in Patients with Opioid Dependence: An Exploratory Study. Sarkar S, Kochhar KP, Sood E, Chandran D, Jangra S, Verma A. Heart Indian J Psychol Med. 2024 Nov 15:02537176241292590…

Mental and physical health characteristics of older and younger adults receiving medication for opioid use disorder.

11. Dezember 2024 | Substitutionsmittel Verschiedenes

Mental and physical health characteristics of older and younger adults receiving medication for opioid use disorder. Walker TJ, Mohankumar R, Kraus SW, Cotton BP, Renn BN. Front Public Health. 2024 Nov 12;12:1418690. doi: 10.3389/fpubh…

Extended-release subcutaneous buprenorphine. The 3rd therapeutic revolution

04. Dezember 2024 | Buprenorphin

Extended-release subcutaneous buprenorphine. The 3rd therapeutic revolution Marc Reisinger Heroin Addiction and Related Clinical Problems: 2024, 26, 42, doi.org/10.62401/2531-4122-2024-42 https://www.heroinaddictionrelatedclinicalproblems.org/art…

Beginning with buprenorphine depot: characteristics and experiences of the first patients in a French addictions centre.

04. Dezember 2024 | Buprenorphin

Beginning with buprenorphine depot: characteristics and experiences of the first patients in a French addictions centre. Alice Deschenau, Amir Al Tabchi, Marie-Charlotte Noury, Léa Micheletti, Husen Ali-Diabacte, Elisa Vodislav, Nathalie Texier, Sa…

Randomised clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper.

04. Dezember 2024 | Buprenorphin

Randomised clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper. Armeni K, Chambers LC, Peachey A, Berk J…

The maintenance treatment with opium tincture and exercise normalize the electroencephalographic changes and reduce visual image-induced craving in opioid use disorder patients

04. Dezember 2024 | Substitutionsmittel Verschiedenes

The maintenance treatment with opium tincture and exercise normalize the electroencephalographic changes and reduce visual image-induced craving in opioid use disorder patients Mahya Bavisi, Roshanak Tirdad, Raheb Ghorbani, Masoud Hajirasouli, Reza…

Methadone metabolism and cytochrome P450 polymorphisms: a systematic review and meta-analysis.

01. Dezember 2024 | Methadon zur Substitution

Methadone metabolism and cytochrome P450 polymorphisms: a systematic review and meta-analysis. Eum S, Vernacchia NP, Doughty N, Mehrzad S, Talal AH, Chalabianloo F, Kharasch ED. Expert Opin Drug Metab Toxicol. 2024 Nov 28:1-16. doi: 10…

Methadone metabolism and cytochrome P450 polymorphisms: a systematic review and meta-analysis.

01. Dezember 2024 | Opioidsubstitution

Hexal AG – Mitteilung an die Diamorphinambulanzen und Schwerpunktpraxen

18. November 2024 | Diamorphin

Hexal AG – Mitteilung an die Diamorphinambulanzen und Schwerpunktpraxen Wir möchten Sie darüber informieren, dass das Bundesministerium für Gesundheit im Bundesanzeiger einen Versorgungsmangel gem. § 79 Abs. 5 AMG für Diaphin 5 g Pulver zur Herstel…

Diamorphin: BMG erklärt Versorgungsmangel

18. November 2024 | Diamorphin

Diamorphin: BMG erklärt Versorgungsmangel Das Bundesgesundheitsministerium (BMG) hat einen Versorgungsmangel für diamorphinhaltige Arzneimittel zur Herstellung einer Injektionslösung festgestellt. Nach Mitteilung des Bundesinstituts für Arzneimitt…

Systematic Review on Mortality in the Elderly on Methadone Maintenance Treatment.

16. November 2024 | Methadon zur Substitution

Systematic Review on Mortality in the Elderly on Methadone Maintenance Treatment. Nazmin F, Nath TS, Limbaña TA, Murugan V, Garcia J, Singareddy S. Cureus. 2024 Sep 7;16(9):e68910. doi: 10.7759/cureus.68910. PMID: 39381465; PMCID: PMC1…

Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline

16. November 2024 | Diamorphin

Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline Nadia Fairbairn, Josey Ross, Michael Trew, Karine Meador, Jeff Turnbull, Scott MacDonald, Eugenia Oviedo-Joekes, Bernard Le Foll, Marie-Ève Goyer, Michel Per…

Narrative review: Managing buprenorphine and opioid use disorder in the perioperative setting.

11. November 2024 | Buprenorphin

Narrative review: Managing buprenorphine and opioid use disorder in the perioperative setting. Kohan L, Barreveld A, Potru S, Abd-Elsayed A, Viscusi ER. Pain Pract. 2024 Oct 25. doi: 10.1111/papr.13427. Epub ahead of print. PMID: 39450…

Enhancing Outcomes in Opioid Use Disorder Treatment: An Economic Evaluation of Improving Medication Adherence for Buprenorphine Through Blister-Packaging.

11. November 2024 | Buprenorphin

Enhancing Outcomes in Opioid Use Disorder Treatment: An Economic Evaluation of Improving Medication Adherence for Buprenorphine Through Blister-Packaging. Borrelli EP, Saad P, Barnes NE, Nelkin H, Dumitru D, Lucaci JD. Subst Abuse Reha…

Characteristics of patients who are initiated on long-acting buprenorphine (Buvidal®) in France: A retrospective cross-sectional study.

11. November 2024 | Buprenorphin

Characteristics of patients who are initiated on long-acting buprenorphine (Buvidal®) in France: A retrospective cross-sectional study. Deschenau A, Trojak B, Brousse G, Blecha L, Azuar J, Chappuy M, Touchon B, Kosim M, Rolland B. Ther…

Repurposing prescribed hydromorphone: Alternative uses of safer supply and tablet-injectable opioid agonist treatment to meet unaddressed health needs.

11. November 2024 | Substitutionsmittel Verschiedenes

Repurposing prescribed hydromorphone: Alternative uses of safer supply and tablet-injectable opioid agonist treatment to meet unaddressed health needs. Ivsins A, Bowles JM, Mansoor M, Kerr T, Bardwell G. Int J Drug Policy. 2024 Nov;133…

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.

24. Oktober 2024 | Buprenorphin

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. Nosyk B, Min JE, Homayra F, et al. JAMA. Published online October 17, 2024. doi:10.1001/jama.2024.16954 https://jamanetwork.com/journals/jama/article-a…

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.

24. Oktober 2024 | Methadon zur Substitution

Listening Session: Use of High Dose Buprenorphine for the Treatment of Opioid Use Disorder

24. Oktober 2024 | Buprenorphin

Listening Session: Use of High Dose Buprenorphine for the Treatment of Opioid Use Disorder This report provides important insights into the effectiveness of high-dose buprenorphine for treating opioid use disorder, especially among individual…

Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts.

24. Oktober 2024 | Buprenorphin

Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts. Chatterjee A, Stewart EA, Assoumou SA, et al. JAMA Netw Open. 2024;7(10):e2437233. doi:10.1001/jamanetworkopen.2024.37233 https://jaman…

Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization.

06. Oktober 2024 | Buprenorphin

Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization. Axeen S, Pacula RL, Merlin JS, Gordon AJ, Stein BD. JAMA Netw Open. 2024 Sep 3;7(9):e2435478. doi: 10.1001/jamanetworkopen.2024.35478. PMID: 39320889; PMC…

Trends in injectable buprenorphine prescribing in Canada: A descriptive analysis in five Canadian Provinces.

06. Oktober 2024 | Buprenorphin

Trends in injectable buprenorphine prescribing in Canada: A descriptive analysis in five Canadian Provinces. Boilard P, Wang T, Iacono A, Ghosh SM, Gomes T. Drug Alcohol Depend. 2024 Sep 24;264:112451. doi: 10.1016/j.drugalcdep.2024.11…

Switch from methadone to buprenorphine with microinduction in outpatient setting.

06. Oktober 2024 | Buprenorphin

Switch from methadone to buprenorphine with microinduction in outpatient setting. Juya F, Askjer JF, Dahl LMK, Holtan L, Mordal J. Tidsskr Nor Laegeforen. 2024 Sep 5;144(10). English, Norwegian. doi: 10.4045/tidsskr.24.0073. PMID: 3925…

Initiation of Low-Dose Intravenous Buprenorphine for Opioid Use Disorder: A Case Series and Literature Review.

06. Oktober 2024 | Buprenorphin

Initiation of Low-Dose Intravenous Buprenorphine for Opioid Use Disorder: A Case Series and Literature Review. Elmati PR, Waseem H, Kogilathota Jagirdhar GS, Stewart CM, Bautista A. Cureus. 2024 Aug 28;16(8):e68007. doi: 10.7759/cureus…

Use of Injectable Opioid Agonist Therapy in a In-Patient Setting for a Pregnant Patient With Opioid Use Disorder: A Case Report.

06. Oktober 2024 | Diamorphin

Use of Injectable Opioid Agonist Therapy in a In-Patient Setting for a Pregnant Patient With Opioid Use Disorder: A Case Report. Griffiths, Sarah MD, CCFP (AM); Campbell, Douglas M MD, MSc, FRCPC; Caudarella, Alexander MD, CCFP (AM); Guimond…

Patient Characteristics From Norway's First Heroin-Assisted Treatment Clinics.

06. Oktober 2024 | Diamorphin

Patient Characteristics From Norway's First Heroin-Assisted Treatment Clinics. Melis F, Clausen T, Castel C, Dadras O, De Pirro S, Myklebust LH, Oldervoll A, Wüsthoff LE, Eide D. Subst Use Addctn J. 2024 Sep 23:29767342241271991. doi…

Navigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era.

06. Oktober 2024 | Morphin ret.

Navigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era. Weleff J, Christian NJ, Wang JX, Singh M, De Aquino JP, Saxon AJ, Vassallo GG. Am J Addict. 2024 Oct 4. do…

Methadone Initiation in the Emergency Department for Opioid Use Disorder.

04. Oktober 2024 | Methadon zur Substitution

Methadone Initiation in the Emergency Department for Opioid Use Disorder. Wolfson D, King R, Lamberson M, Lyttleton J, Waters CT, Schneider SH, Porter BA, DeWitt KM, Jackson P, Stevens MW, Brooklyn J, Rawson R, Riser E. West J Emerg Me…

Effect of Opium Versus Methadone on Polysomnographic Characteristics of Patients With Obesity Hypoventilation Syndrome.

04. Oktober 2024 | Methadon zur Substitution

Effect of Opium Versus Methadone on Polysomnographic Characteristics of Patients With Obesity Hypoventilation Syndrome. Amra B, Narimani H, Soltaninejad F, Salmasi M, Mansourian M, Penzel T, Schöbel C, Fietze I. Basic Clin Neurosci. 20…

Preferred pharmaceutical-grade opioids to reduce the use of unregulated opioids: A cross-sectional analysis among people who use unregulated opioids in Vancouver, Canada.

04. Oktober 2024 | Substitutionsmittel Verschiedenes

Preferred pharmaceutical-grade opioids to reduce the use of unregulated opioids: A cross-sectional analysis among people who use unregulated opioids in Vancouver, Canada. Speed KA, Choi J, Felicella G, Sedgemore KO, Mok WY, Milloy MJ, DeBeck…

NIH/NIDA. Higher doses of buprenorphine may improve treatment outcomes for people with opioid use disorder

25. September 2024 | Buprenorphin

NIH/NIDA. Higher doses of buprenorphine may improve treatment outcomes for people with opioid use disorder NIH-funded analysis suggests higher doses of buprenorphine were associated with lower rates of future behavioral health-related emergency dep…

Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type.

22. September 2024 | Substitutionsmittel Verschiedenes

Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type. Hayes CJ, Raciborski RA, Nowak M, Acharya M, Nunes EV Jr, Winhusen TJ. Addiction. 2024…

A qualitative evaluation of a fentanyl patch safer supply program in Vancouver, Canada.

10. September 2024 | Substitutionsmittel Verschiedenes

A qualitative evaluation of a fentanyl patch safer supply program in Vancouver, Canada. Norton A, Ivsins A, Holliday E, Sutherland C, Kerr T, Kennedy MC. Int J Drug Policy. 2024 Aug 17;131:104547. doi: 10.1016/j.drugpo.2024.104547. Epu…

Healthcare utilisation and associated costs for methadone versus buprenorphine recipients: Examination of interlinked primary and secondary care electronic health records in England.

09. September 2024 | Substitutionsmittel Verschiedenes

Healthcare utilisation and associated costs for methadone versus buprenorphine recipients: Examination of interlinked primary and secondary care electronic health records in England. Domzaridou E, Allen T, Carr MJ, Millar T, Webb RT, Ashcroft…

Long-Acting Injectable Buprenorphine for Opioid Use Disorder: A Qualitative Analysis of Patients' Interpersonal Relationships during the First Year of Treatment.

09. September 2024 | Buprenorphin

Long-Acting Injectable Buprenorphine for Opioid Use Disorder: A Qualitative Analysis of Patients' Interpersonal Relationships during the First Year of Treatment. Neale J, Strang J. Subst Use Misuse. 2024 Aug 20:1-9. doi: 10.1080/108260…

Reconsidering the usefulness of long-term high-dose buprenorphine.

04. September 2024 | Buprenorphin

Reconsidering the usefulness of long-term high-dose buprenorphine. Jain L, Meeks TW, Blazes CK. Front Psychiatry. 2024 Jul 23;15:1401676. doi: 10.3389/fpsyt.2024.1401676. PMID: 39114740; PMCID: PMC11303732. https://www.ncbi.nlm.nih.go…

Ketamine-assisted buprenorphine initiation: a pilot case series.

04. September 2024 | Buprenorphin

Ketamine-assisted buprenorphine initiation: a pilot case series. Grande, L., Hutch, T., Jack, K. et al. Addict Sci Clin Pract 19, 60 (2024). doi.org/10.1186/s13722-024-00494-2 https://ascpjournal.biomedcentral.com/articles/10.1186…

Induction to Methadone 80 mg in the First Week of Treatment of Patients Who Use Fentanyl: A Case Series From an Outpatient Opioid Treatment Program.

04. September 2024 | Methadon zur Substitution

Induction to Methadone 80 mg in the First Week of Treatment of Patients Who Use Fentanyl: A Case Series From an Outpatient Opioid Treatment Program. Steiger S, McCuistian C, Suen LW, Shapiro B, Tompkins DA, Bazazi AR. J Addict Med. 202…

The fentanyl made me feel like I needed more methadone": changes in the role and use of medication for opioid use disorder (MOUD) due to fentanyl.

04. September 2024 | Methadon zur Substitution

The fentanyl made me feel like I needed more methadone": changes in the role and use of medication for opioid use disorder (MOUD) due to fentanyl. Bolshakova M, Simpson KA, Ganesh SS, Goldshear JL, Page CJ, Bluthenthal RN. Harm Reduct…

Direct effects of heroin and methadone on T cell function.

04. September 2024 | Methadon zur Substitution

Direct effects of heroin and methadone on T cell function. Ninnemann A, Hock K, Luppus S, Scherbaum N, Temme C, Buer J, Westendorf AM, Hansen W. Int Immunopharmacol. 2024 Oct 25;140:112736. doi: 10.1016/j.intimp.2024.112736. Epub 2024…

Buprenorphine for Opioid Use Disorder—An Essential Medical Treatment.

31. August 2024 | Buprenorphin

Buprenorphine for Opioid Use Disorder—An Essential Medical Treatment. Weimer MB, Morford KL. JAMA Intern Med. Published online August 26, 2024. doi:10.1001/jamainternmed.2024.3977 Abstract https://jamanetwork.com/journals/jamain…

What is Suboxone and how does it work?

24. August 2024 | Buprenorphin

5 myths about using Suboxone to treat opioid addiction What is Suboxone and how does it work? Suboxone, a combination medication containing buprenorphine and naloxone, is one of the main medications used to treat opioid addiction. Buprenorph…

Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best-worst scaling task.

11. August 2024 | Diamorphin

Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best-worst scaling task. Metcalfe RK, Dobischok S, Bansback N, MacDonald S, Byres D, Lajeunesse J, Harrison S, Koch B, Topping B, B…

Adherence to buprenorphine-XR through hybrid telehealth contingency management procedures: a case series.

11. August 2024 | Buprenorphin

Adherence to buprenorphine-XR through hybrid telehealth contingency management procedures: a case series. Gorman JA, Lindvig-Springborn A, Lee J, Khazanov GK, DePhilippis D. J Subst Use. 2024 May 9;2024:1-6. doi: 10.1080/14659891.2024…

Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.

11. August 2024 | Buprenorphin

Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. D’Onofrio G, Herring AA, Perrone J, et al. JAMA Netw Open. 2024;7(7):e2420702. doi:10.1001/jamanetworkopen.2024.20702…

Buprenorphine/naloxone - one formulation that doesn't fit all: a case report.

11. August 2024 | Buprenorphin

Buprenorphine/naloxone - one formulation that doesn't fit all: a case report. Braun HM, Taylor JL, Axelrath S. Harm Reduct J. 2024 Jul 30;21(1):143. doi: 10.1186/s12954-024-01054-2. PMID: 39080714; PMCID: PMC11287853. https://www.ncbi…

Opium tincture versus methadone for opioid agonist treatment: a randomized controlled trial.

11. August 2024 | Methadon zur Substitution

Opium tincture versus methadone for opioid agonist treatment: a randomized controlled trial. Nikoo M, Kianpoor K, Nikoo N, Javidanbardan S, Kazemi A, Choi F, Vogel M, Gholami A, Tavakoli S, Wong JSH, Moazen-Zadeh E, Givaki R, Jazani M, Mohamm…

Effect of Acupuncture for Methadone Reduction : A Randomized Clinical Trial.

11. August 2024 | Methadon zur Substitution

Effect of Acupuncture for Methadone Reduction : A Randomized Clinical Trial. Lu L, Chen C, Chen Y, Dong Y, Chen R, Wei X, Tao C, Li C, Wang Y, Fan B, Tang X, Xu S, He Z, Mo G, Liu Y, Gu H, Li X, Cao F, Xu H, Zhang Y, Li G, Liu X, Zeng J, Tang…

Traitements par agonistes opioïdes (TAO) et à la diacétylmorphine (DAM) : similitudes et différences de ces approches thérapeutiques.

25. Juli 2024 | Substitutionsmittel Verschiedenes

Traitements par agonistes opioïdes (TAO) et à la diacétylmorphine (DAM) : similitudes et différences de ces approches thérapeutiques. Substitut Amos J., Gmel G. (2024). BRENNPUNKT | ÉCLAIRAGE 2024. Addiction Suisse. doi: 10.58758/eclai…

Methadon: Akupunktur könnte bei Entzug helfen

13. Juli 2024 | Methadon zur Substitution

Methadon: Akupunktur könnte bei Entzug helfen Guangzhou – Eine Akupunktur hat in einer randomisierten Studie aus China Opiatabhängigen geholfen, die Dosis ihrer Methadon-Substitution zu senken. Laut dem Bericht in den Annals of Internal Medici…

Acupuncture reduces methadone dose and opioid cravings in patients undergoing methadone maintenance therapy

13. Juli 2024 | Methadon zur Substitution

Acupuncture reduces methadone dose and opioid cravings in patients undergoing methadone maintenance therapy (American College of Physicians, Annals of Internal Medicine Tip She, USA, 08.07.2024) https://www.eurekalert.org/n…

Narkotikapolitikk i endring: Heroinklinikkenes oppkomst i Norge.

07. Juli 2024 | Diamorphin

Narkotikapolitikk i endring: Heroinklinikkenes oppkomst i Norge. Ellefsen R. Nordisk Alkohol Nark. 2024 Jun;41(3):307-325. Norwegian. doi: 10.1177/14550725231207251. Epub 2023 Nov 9. PMID: 38903889; PMCID: PMC11186453. https://pu…

'Matters-of-concern' associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study.

07. Juli 2024 | Buprenorphin

'Matters-of-concern' associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study. Parkin S, Neale J, Strang J. Int J Drug Policy. 2024 Jun 5;129:104470. doi: 10.1016/j.drugpo…

Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland.

06. Juli 2024 | Buprenorphin

Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland. Mariottini C, Häkkinen M, Kriikku P, Ojanperä I. Int J Legal Med. 2024 Jun 24. doi: 10.1007/s00414-024-03273-5. Epub ah…

Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder.

06. Juli 2024 | Buprenorphin

Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder. Szczesniak L, Britton S, Rn TB, Sullivan R. Harm Reduct J. 2024 Jun 7;21(1):114. doi: 10.1186/s12954-02…

Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder.

06. Juli 2024 | Buprenorphin

Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder. White AM, Eglovitch M, Parlier-Ahmad AB, Dzierzewski JM, James M, Bjork JM, et al. (2024) PLoS ONE 19(6): e0304461. doi…

Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.

06. Juli 2024 | Buprenorphin

Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder. Azar P, Schneiderman H, Barron H, Wong JSH, Meyer M, Newman-Azar D, Narimani M, Ignaszewski MJ, Mathew N, Mu…

Rotation from methadone to buprenorphine using a micro-dosing regime in patients with opioid use disorder and serious mental illness: A case series.

06. Juli 2024 | Buprenorphin

Rotation from methadone to buprenorphine using a micro-dosing regime in patients with opioid use disorder and serious mental illness: A case series. Praeger VC, Frei MY, Pham D, Praeger AJ, Lubman DI, Arunogiri S. Drug Alcohol Rev. 2024 Jun…

Rotation from methadone to buprenorphine using a micro-dosing regime in patients with opioid use disorder and serious mental illness: A case series.

06. Juli 2024 | Methadon zur Substitution

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy.

06. Juli 2024 | Methadon zur Substitution

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy. Robinson KM, Eum S, Desta Z, Tyndale RF, Gaedigk A, Crist RC, Haidar CE, Myers AL, Samer CF, Somogyi AA, Zubiaur P, Iwuchukwu OF, Whirl-C…

Predictors of retention in heroin-assisted treatment in Denmark 2010-2018 - A record-linkage study.

06. Juli 2024 | Diamorphin

Predictors of retention in heroin-assisted treatment in Denmark 2010-2018 - A record-linkage study. Brummer J, Thylstrup B, Melis F, Hesse M. J Subst Use Addict Treat. 2024 Jul 1:209449. doi: 10.1016/j.josat.2024.209449. Epub ahead of…

La sexualité au féminin chez les patientes traitées par diacétylmorphine [Sexual health in female under treatment for opiate dependence using diacetylmorphine].

06. Juli 2024 | Diamorphin

La sexualité au féminin chez les patientes traitées par diacétylmorphine [Sexual health in female under treatment for opiate dependence using diacetylmorphine]. Khatcherian E, Soulignac R, Zullino D, Achab S. Rev Med Suisse. 2024 Jun 5;20(87…

Piloting a Hospital-Based Rapid Methadone Initiation Protocol for Fentanyl.

02. Juli 2024 | Methadon zur Substitution

Piloting a Hospital-Based Rapid Methadone Initiation Protocol for Fentanyl. Liu P, Chan B, Sokolski E, Patten A, Englander H. J Addict Med. 2024 Jun 4. doi: 10.1097/ADM.0000000000001324. Epub ahead of print. PMID: 38832695. https://jo…

Stellungnahme der Deutschen Gesellschaft für Suchtmedizin zur Zulassung von Diamorphin Tabletten

25. Juni 2024 | Diamorphin

Stellungnahme der Deutschen Gesellschaft für Suchtmedizin zur Zulassung von Diamorphin Tabletten Die Deutsche Gesellschaft für Suchtmedizin (DGSuchtmedizin) und die AG Diamorphin sprechen sich für die Zulassung von Diamorphin Tabletten aufgrund öff…

Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure.

20. Juni 2024 | Diamorphin

Oral diacetylmorphine (heroin) yields greater morphine bioavailability than oral morphine: bioavailability related to dosage and prior opioid exposure. Halbsguth U, Rentsch KM, Eich-Höchli D, Diterich I, Fattinger K. Br J Clin Pharmaco…

Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'.

05. Juni 2024 | Methadon zur Substitution

Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'. Pappagallo M, Kosten TR, Gorodetzky CW, Vocci FJ, Sapienza FL, De Martin S, Comai S, Mattarei A, Inturri…

The effect of a pilot brief educational intervention on preferences regarding treatments for opioid use disorder.

05. Juni 2024 | Substitutionsmittel Verschiedenes

The effect of a pilot brief educational intervention on preferences regarding treatments for opioid use disorder. Irani E, Macleod C, Slat S, Kehne A, Madden E, Jaffe K, Bohnert A, Lagisetty P. Drug Alcohol Depend Rep. 2024 Apr 24;11:1…

Short-Acting, Full Agonist Opioids During Initiation of Opioid Agonist Treatment in the Fentanyl Era.

05. Juni 2024 | Substitutionsmittel Verschiedenes

Short-Acting, Full Agonist Opioids During Initiation of Opioid Agonist Treatment in the Fentanyl Era. Saxon AJ. JAMA Netw Open. 2024;7(5):e2411398. doi:10.1001/jamanetworkopen.2024.11398 https://jamanetwork.com/journals/jamanetwo…

Buprenorphine Use for Analgesia in Palliative Care.

05. Juni 2024 | Buprenorphin

Buprenorphine Use for Analgesia in Palliative Care. Jackson LK, Poon IO, Garcia MA, Imam S, Braun UK. Pharmacy (Basel). 2024 May 13;12(3):78. doi: 10.3390/pharmacy12030078. PMID: 38804470; PMCID: PMC11130940. https://www.ncbi.nlm.nih…

Surgical removal of extended-release buprenorphine depot due to adverse reactions.

05. Juni 2024 | Buprenorphin

Surgical removal of extended-release buprenorphine depot due to adverse reactions. Burton A, DeBona DJ, Handzel M, Kelly-Pisciotti S, Qiao M, Rojek D, Acquisto NM. Am J Emerg Med. 2024 Apr 27;81:127-128. doi: 10.1016/j.ajem.2024.04.047…

Development and verification of a full physiologically-based pharmacokinetic model for sublingual buprenorphine in healthy adult volunteers that accounts for nonlinear bioavailability.

05. Juni 2024 | Buprenorphin

Development and verification of a full physiologically-based pharmacokinetic model for sublingual buprenorphine in healthy adult volunteers that accounts for nonlinear bioavailability. van Hoogdalem MW, Tanaka R, Johnson TN, Vinks AA, Mizuno…

Vorteile der inhalativen Verabreichungsformen von Drogen

21. Mai 2024 | Diamorphin

Vorteile der inhalativen Verabreichungsformen von Drogen Von politischer Seite und in den Massenmedien wird wieder vermehrt die Drogenabgabe durch das Medizinalsystem gefordert. Meines Erachtens ist dies grundsätzlich richtig. Das Medizinalsystem k…

Schweiz. Zürcher Drogenpolitik - Süchtige dealen am Hauptbahnhof Zürich mit medizinischem Heroin

13. Mai 2024 | Diamorphin

Schweiz. Zürcher Drogenpolitik - Süchtige dealen am Hauptbahnhof Zürich mit medizinischem Heroin Das medizinische Heroin beziehen sie legal bei der Drogenabgabestelle. (srf – Schweizerischer Rundfunk, Rundschau, 24.04.2024) https://www.srf.ch/news…

Questioning methadone split-dosing for analgesia among hospitalized patients with opioid use disorder.

05. Mai 2024 | Methadon zur Substitution

Questioning methadone split-dosing for analgesia among hospitalized patients with opioid use disorder. Terasaki D, Abts D, Ferraro K. Addiction. 2024 Apr 14. doi: 10.1111/add.16502. Epub ahead of print. PMID: 38615677. https://onlinel…

Building Capacity for Injectable Diacetylmorphine and Hydromorphone for the Treatment of Opioid Use Disorder: Identifying Typical Doses.

05. Mai 2024 | Diamorphin

Building Capacity for Injectable Diacetylmorphine and Hydromorphone for the Treatment of Opioid Use Disorder: Identifying Typical Doses. Magel T, Arreola LAG, Guh D, MacDonald S, Harrison S, Schechter M, Oviedo-Joekes E. J Psychoactive Drugs…

Prolonged diacetylmorphine take-home during the COVID-19 pandemic-Results of a retrospective cohort study.

05. Mai 2024 | Diamorphin

Prolonged diacetylmorphine take-home during the COVID-19 pandemic-Results of a retrospective cohort study. Brezan F, Meyer M, Vogel M, Heimer J, Falcato L, Montagna J, Bruggmann P. Addiction. 2024 Apr 21. doi: 10.1111/add.16503. Epub ahead o…

Reduced emergency department use among insured individuals receiving extended-release buprenorphine in a health system setting.

05. Mai 2024 | Buprenorphin

Reduced emergency department use among insured individuals receiving extended-release buprenorphine in a health system setting. Yarborough BJH, Stumbo SP, Janoff SL, Keast EM, Leo MC, Leitz SJ. Drug Alcohol Depend Rep. 2024 Apr 7;11:10…

The Effectiveness of Buprenorphine Transdermal Patch and Low Dose Sublingual Buprenorphine Induction to Transition to Long-Acting Subcutaneous Buprenorphine Injection in Opioid Use Disorder in Inpatient Setting.

05. Mai 2024 | Buprenorphin

The Effectiveness of Buprenorphine Transdermal Patch and Low Dose Sublingual Buprenorphine Induction to Transition to Long-Acting Subcutaneous Buprenorphine Injection in Opioid Use Disorder in Inpatient Setting. Gorham JW, Ansari F, Sethi R.&…

Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder.

05. Mai 2024 | Buprenorphin

Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder. Walsh SL, Comer SD, Zdovc JA, Sarr C, Björnsson M, Strandgården K, Hjelmström P, Tiberg F…

Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study.

04. Mai 2024 | Buprenorphin

Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study. Jones BLH, Geier M, Neuhaus J, Coffin PO, Snyder HR, Soran CS, Knight KR, Suen LW. Harm Reduct J. 2024 Apr 9;21(1)…

Positionspapier der Deutschen Hauptstelle für Suchtfragen: Versorgung und Behandlung Opioidabhängiger mit Diamorphin

04. Mai 2024 | Diamorphin

Positionspapier der Deutschen Hauptstelle für Suchtfragen: Versorgung und Behandlung Opioidabhängiger mit Diamorphin Einleitung Nach mehr als vierzehn Jahren der praktischen Erfahrung mit der Diamorphinbehandlung in der Regelversorgung gibt es ein…

Opioid overdose after extended-release buprenorphine injection: a case report.

03. Mai 2024 | Buprenorphin

Opioid overdose after extended-release buprenorphine injection: a case report. Isenberg R. Am J Drug Alcohol Abuse. 2024 Jan 22:1-2. doi: 10.1080/00952990.2023.2292011. Epub ahead of print. PMID: 38252881. https://www.tandfonline…

Evaluation of Serum Cortisol Levels and Response to Cosyntropin Test in Methadone-treated Opium Addicts.

03. Mai 2024 | Methadon zur Substitution

Evaluation of Serum Cortisol Levels and Response to Cosyntropin Test in Methadone-treated Opium Addicts. Zojaji F, Khalesi A, Bahrami A, Ebrahimi SA, Ganjifard M. Anesth Pain Med. 2023 Jun 3;13(3):e135206. doi: 10.5812/aapm-135206. PMI…

Psychometric evaluation of two patients monitored for 12 weeks after switching from racemic methadone to levomethadone agonist therapy

19. April 2024 | Opioidsubstitution

Psychometric evaluation of two patients monitored for 12 weeks after switching from racemic methadone to levomethadone agonist therapy Gabriele Pasquale De Luca, Gaia Anibaldi, Danilo Paolucci, Paola Motta, and Simone De Persis Heroin Addiction an…

The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences.

19. April 2024 | Buprenorphin

The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences. Barnett A, Pienaar K, Lubman DI, Arunogiri S, Phan V, Hayes V, Lintzeris N, Savic M. Int J Drug Poli…

Micro-dosing with buprenorphine when switching from full agonists (methadone, SR-morphine) to buprenorphine treatment in opioid agonist-assisted treatment programmes in Slovenia

19. April 2024 | Buprenorphin

Micro-dosing with buprenorphine when switching from full agonists (methadone, SR-morphine) to buprenorphine treatment in opioid agonist-assisted treatment programmes in Slovenia Miha Lavre, and Andrej Kastelic Heroin Addiction and Related Clinical…

Development and validation of an LC-MS/MS method for quantifying diamorphine and its major metabolites 6-monoacetylmorphine, morphine, morphine-3-glucuronide, and morphine-6-glucuronide in human plasma.

07. April 2024 | Diamorphin

Development and validation of an LC-MS/MS method for quantifying diamorphine and its major metabolites 6-monoacetylmorphine, morphine, morphine-3-glucuronide, and morphine-6-glucuronide in human plasma. Thomann J, Vogt SB, Guessoum A, Meyer M…

Evaluation of heroin-assisted treatment in Norway: protocol for a mixed methods study.

06. April 2024 | Diamorphin

Evaluation of heroin-assisted treatment in Norway: protocol for a mixed methods study. Myklebust LH, Eide D, Arnevik EA, Dadras O, De Pirro S, Ellefsen R, Fadnes LT, Hesse M, Kvamme TL, Melis F, Oldervoll A, Thylstrup B, Wusthoff LEC, Clausen…

Long access heroin self-administration significantly alters gut microbiome composition and structure.

06. April 2024 | Diamorphin

Long access heroin self-administration significantly alters gut microbiome composition and structure. Greenberg JM, Winters AD, Zagorac B, Kracht DJ, Francescutti DM, Cannella N, Ciccocioppo R, Woods LCS, Mackle J, Hardiman GT, Kuhn BN, Kaliv…

Co-located Heroin Assisted Treatment within primary care: A preliminary analysis of the implications for healthcare access, cost, and treatment delivery in the UK.

06. April 2024 | Diamorphin

Co-located Heroin Assisted Treatment within primary care: A preliminary analysis of the implications for healthcare access, cost, and treatment delivery in the UK. Poulter HL, Moore HJ, Ahmed D, Riley F, Walker T, Harris M. Int J Drug…

Case report: Successful induction of buprenorphine in medically complex patients concurrently on opioids: a case series at a tertiary care center.

06. April 2024 | Buprenorphin

Case report: Successful induction of buprenorphine in medically complex patients concurrently on opioids: a case series at a tertiary care center. Shelton T, Nama S, Hall O, Williams M. Front Pharmacol. 2024 Mar 8;15:1335345. doi: 10.3…

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.

06. April 2024 | Buprenorphin

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial. Farrell M, Shahbazi J, Chambers M, Byrne M, Gholami J, Zahra E…

Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.

06. April 2024 | Buprenorphin

Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study. Johnson B, Monwell B, Capusan AJ. Harm Reduct J…

Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder.

06. April 2024 | Buprenorphin

Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder. McHugh RK, Bailey AJ, Weiss RD, Fitzmaurice GM. Drug Alcohol Depend Rep. 2024 Mar 13;11:100226. doi: 1…

Buprenorphine for High-dose Tramadol Dependence: A Case Report of Successful Outpatient Treatment.

06. April 2024 | Buprenorphin

Buprenorphine for High-dose Tramadol Dependence: A Case Report of Successful Outpatient Treatment. Mukau L, Wormley K, Tomaszewski C, Ahmad B, Vohra R, Herring AA. Clin Pract Cases Emerg Med. 2024 Feb;8(1):81-82. doi: 10.5811/cpcem.491…

Therapeutic Potential of Buprenorphine in Depression: A Meta-Analysis of Current Evidence.

06. April 2024 | Buprenorphin

Therapeutic Potential of Buprenorphine in Depression: A Meta-Analysis of Current Evidence. Bhivandkar S, Sarfraz Z, Jain L, Bachu A, Malo PK, Hsu M, Ayub S, Poudel L, Kumar H, Loh H, Tazin F, Ahmed S, Suzuki J. J Clin Med Res. 2024 Mar…

Patients' perspectives on buprenorphine subcutaneous implant: a case series.

06. April 2024 | Buprenorphin

Patients' perspectives on buprenorphine subcutaneous implant: a case series. Pierlorenzi C, Nunzi M, Cirulli S, Direnzo GFM, Curatella L, Liberatori S, Pascucci A, Petrone E, Ventre G, Varango C, Pulito ML, Varango A, Dandolo C, Occupati B, M…

Healthcare staff’s perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study.

06. April 2024 | Buprenorphin

Healthcare staff’s perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study. Nordgren, J., Monwell, B., Johnson, B. et al. Addict Sci Clin Pract 19, 25 (2024). doi.org/10.1186/s13722-024-00458-6…

Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial.

06. April 2024 | Methadon zur Substitution

Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial. McAnulty C, Bastien G, Ledjiar O, Eugenia Socias M, Le Foll B, Lim R, Jutras-Aswad D; OPTIM…

Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial.

06. April 2024 | Buprenorphin

The IMPOWR Network Divided or Single Exposure Study (DOSE) Protocol: A Randomized Controlled Comparison of Once Versus Split Dosing of Methadone for the Treatment of Comorbid Chronic Pain and Opioid Use Disorder.

06. April 2024 | Methadon zur Substitution

The IMPOWR Network Divided or Single Exposure Study (DOSE) Protocol: A Randomized Controlled Comparison of Once Versus Split Dosing of Methadone for the Treatment of Comorbid Chronic Pain and Opioid Use Disorder. McKendrick G, Davis W, Sklar…

Webinar. Hydromorphone for Opioid Use Disorder: Insights from the Feasibility of Opioid Injecting Trial

26. März 2024 | Diamorphin

Webinar. Hydromorphone for Opioid Use Disorder: Insights from the Feasibility of Opioid Injecting Trial Penington Institute invites you to join us for a discussion featuring an expert panel on the trial of short-acting injectable opioid treatment –…

Buprenorphine use in the emergency department safe for people who use fentanyl

25. März 2024 | Buprenorphin

Buprenorphine use in the emergency department safe for people who use fentanyl Researchers found that buprenorphine can be safely started in the emergency department by people who use fentanyl either alone or with other drugs. Wider use of bupreno…

Substitution. Vorschläge für die Überarbeitung der Diamorphinbehandlung

25. März 2024 | Diamorphin

Substitution. Vorschläge für die Überarbeitung der Diamorphinbehandlung Die Behandlung mit Diamorphin in der Substitution – wird sie bald flächendeckend möglich sein? Darüber wird gerade intensiv diskutiert. Klar ist: Notwendig ist dafür eine Anpas…

Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients.

12. März 2024 | Buprenorphin

Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients. Ross RK, Nunes EV, Olfson M, Shulman M, Krawczyk N, Stuart EA, Rudolph KE medRxiv [Prep…

Buprenorphine induced opioid withdrawal syndrome relieved by adjunctive Magnesium: A clinical trial.

12. März 2024 | Buprenorphin

Buprenorphine induced opioid withdrawal syndrome relieved by adjunctive Magnesium: A clinical trial. Moshiri M, Chaeideh B, Ebrahimi M, Dadpour B, Ghodsi A, Haghighizadeh A, Etemad L. J Subst Use Addict Treat. 2024 Feb 2;160:209307. do…

The Devil's in the Depot Details: Case of Iatrogenic Opioid Intoxication After Buprenorphine Injection Requiring Surgical Excision.

12. März 2024 | Buprenorphin

The Devil's in the Depot Details: Case of Iatrogenic Opioid Intoxication After Buprenorphine Injection Requiring Surgical Excision. Vais S, Starr N, Castro M, Brand N, Murphy A, Tesoriero R, Kryzhanovskaya I. J Addict Med. 2024 Feb 12…

Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence.

12. März 2024 | Buprenorphin

Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence. Lancaster K, Gendera S, Treloar C, Rhodes T, Shahbazi J, Byrne M, Nielsen S, Degenhardt L, Farrell M. Int J Drug Policy. 2024 Feb 2…

Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended - Release Subcutaneous Injection: A Case Report.

12. März 2024 | Buprenorphin

Early Remission of Opioid Use Disorder in an Adolescent Using Buprenorphine Extended - Release Subcutaneous Injection: A Case Report. Schmuhl KK, Golec A, Ebersole AM. J Adolesc Health. 2024 Feb 24:S1054-139X(24)00050-8. doi: 10.1016/j…

Severe cerebral edema related to oral methadone: A case report and literature review.

12. März 2024 | Methadon zur Substitution

Severe cerebral edema related to oral methadone: A case report and literature review. Cañas CA, Posso-Osorio I, Rivera-Londoño R, Bolaños JD, Granados AM. Heliyon. 2024 Feb 13;10(4):e26111. doi: 10.1016/j.heliyon.2024.e26111. PMID…

Methadone Dose and Timing of Administration as Predictors of Sleep Apnea Syndrome During Methadone Maintenance Treatment: A Retrospective Cross-sectional Study.

12. März 2024 | Methadon zur Substitution

Methadone Dose and Timing of Administration as Predictors of Sleep Apnea Syndrome During Methadone Maintenance Treatment: A Retrospective Cross-sectional Study. Guillet C, Endomba FT, Aravantinos D, Hussami A, Beye F, Girod JC, Glélé LSA.&nbs…

Opioid use disorder: current trends and potential treatments.

15. Februar 2024 | Substitutionsmittel Verschiedenes

Opioid use disorder: current trends and potential treatments. Lee YK, Gold MS, Blum K, Thanos PK, Hanna C, Fuehrlein BS. Front Public Health. 2024 Jan 25;11:1274719. doi: 10.3389/fpubh.2023.1274719. PMID: 38332941; PMCID: PMC10850316…

USA. NIH/NIDA: Division of Therapeutics and Medical Consequences (DTMC) - DTMC Pipelines of Therapeutics - Opioid Use Disorder and Overdose

04. Februar 2024 | Substitutionsmittel Verschiedenes

USA. NIH/NIDA: Division of Therapeutics and Medical Consequences (DTMC) - DTMC Pipelines of Therapeutics - Opioid Use Disorder and Overdose aufgerufen am 04.02.2024 https://nida.nih.gov/about-nida/organization/divisions/division-the…

New strategies for medications to treat substance use disorders.

04. Februar 2024 | Substitutionsmittel Verschiedenes

New strategies for medications to treat substance use disorders. Montoya ID, Volkow ND. Pharmacol Res. 2024 Jan 20;200:107078. doi: 10.1016/j.phrs.2024.107078. Epub ahead of print. PMID: 38246477. https://www.sciencedirect.com/science…

Effect on QTc interval by switching from methadone to equipotent R-methadone dose in methadone maintenance treatment patients.

04. Februar 2024 | Opioidsubstitution

Effect on QTc interval by switching from methadone to equipotent R-methadone dose in methadone maintenance treatment patients. Havig SM, Berg-Pedersen RM, Krabseth HM, Müller LD, Haugaa K, Zare HK, Gjesdal K, Krajci P, Opdal MS. Basic…

Effect on QTc interval by switching from methadone to equipotent R-methadone dose in methadone maintenance treatment patients.

04. Februar 2024 | Methadon zur Substitution

Buprenorphine.

04. Februar 2024 | Buprenorphin

Buprenorphine. Kumar R, Viswanath O, Saadabadi A., 2023 Nov 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 29083570. https://www.ncbi.nlm.nih.gov/books/NBK459126/

High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants.

04. Februar 2024 | Diamorphin

High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants. Fox AD, Riback L, Perez-Correa A, Ohlendorf E, Ghiroli M, Behrends CN, López-Castro T. Subst Use Addctn J. 2024 J…

Optimizing methadone dose adjustment in patients with opioid use disorder.

04. Februar 2024 | Methadon zur Substitution

Optimizing methadone dose adjustment in patients with opioid use disorder. Liu PS, Kuo TY, Chen IC, Lee SW, Chang TG, Chen HL, Chen JP. Front Psychiatry. 2024 Jan 8;14:1258029. doi: 10.3389/fpsyt.2023.1258029. PMID: 38260800; PMCID: PM…

Zugang zur Diamorphin-Behandlung erleichtern!

25. Januar 2024 | Diamorphin

Zugang zur Diamorphin-Behandlung erleichtern! Die Diamorphin-Behandlung muss als gleichwertige und gleichrangige Form der Substitutionstherapie anerkannt werden. Das fordern Deutsche Aidshilfe (DAH), Akzept e. V. und JES-Bundesverband in eine…

Stellungnahme für die Neufassung der BetäubungsmittelVerschreibungsverordnung (BtMVV) - § 5a Verschreiben von Substitutionsmitteln mit dem Stoff Diamorphin

25. Januar 2024 | Diamorphin

Stellungnahme für die Neufassung der BetäubungsmittelVerschreibungsverordnung (BtMVV) - § 5a Verschreiben von Substitutionsmitteln mit dem Stoff Diamorphin Nach mehr als zehn Jahren der praktischen Erfahrung mit der Dia morphinbehandlung in der Reg…

Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022.

21. Januar 2024 | Substitutionsmittel Verschiedenes

Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022. Bharat C, Chidwick K, Gisev N, Farrell M, Ali R, Degenhardt L. Int J Drug Policy. 2024 Jan;123:104255. doi: 10.1016/j.drugpo.2023.104255. Epub 2023 Nov 28…

Blood Oxygenation and Heart Rate Changes after Diamorphine Intravenous Injection during Opioid Agonist Treatment for Outpatients With Heroin Dependence.

08. Januar 2024 | Diamorphin

Blood Oxygenation and Heart Rate Changes after Diamorphine Intravenous Injection during Opioid Agonist Treatment for Outpatients With Heroin Dependence. Thiessen KA, Dilg C, Schütz CG. J Addict Med. 2023 Dec 21. doi: 10.1097/ADM.000000…

Psychometric Characteristics of the Persian Version of the Opiate Dosage Adequacy Scale (ODAS).

08. Januar 2024 | Methadon zur Substitution

Psychometric Characteristics of the Persian Version of the Opiate Dosage Adequacy Scale (ODAS). Golnezhad A, Torkaman-Boutorabi A, Mohammad Razaghi E, Zarrindast MR, Yadollahi S, Dousti Kataj P, Vousooghi N. Basic Clin Neurosci. 2023 J…

Natural Products Inhibition of CYP2B6 Activity and Methadone Metabolism.

08. Januar 2024 | Methadon zur Substitution

Natural Products Inhibition of CYP2B6 Activity and Methadone Metabolism. Wang PF, Yang Y, Patel V, Neiner A, Kharasch ED. Drug Metab Dispos. 2023 Dec 22:DMD-AR-2023-001578. doi: 10.1124/dmd.123.001578. Epub ahead of print. PMID: 38135504. h…

Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications.

08. Januar 2024 | Methadon zur Substitution

Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications. Chalabianloo F, Fadnes LT, Johansson KA, et al. Basic Clin Pharmacol Toxicol. 2023. doi.org/10.1111/bc…

Use of intravenous buprenorphine microdosing to initiate medication for opioid use disorder in a patient with co-occurring pain: case report,

08. Januar 2024 | Buprenorphin

Use of intravenous buprenorphine microdosing to initiate medication for opioid use disorder in a patient with co-occurring pain: case report, Alia Bodnar , Christine Diffenderffer , Lindsay A. Jablonski ,&nbs…

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.

08. Januar 2024 | Buprenorphin

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder. Greenwald MK, Wiest KL, Haight BR, Laffont CM, Zhao Y. Harm Reduct J. 2023 Dec 2;20(…

Development and validation of a brief screening tool for over-the-counter codeine dependence.

08. Januar 2024 | Codein

Development and validation of a brief screening tool for over-the-counter codeine dependence. McCoy J, Nielsen S, Bruno R. Res Social Adm Pharm. 2023 Nov 24:S1551-7411(23)00469-2. doi: 10.1016/j.sapharm.2023.11.002. Epub ahead of print…

Drogenkurier. Über einen „Tanker“, der nur schwer den Kurs ändert - Ein Beitrag zur Debatte um die Diamorphinbehandlung

05. Januar 2024 | Diamorphin

Drogenkurier. Über einen „Tanker“, der nur schwer den Kurs ändert - Ein Beitrag zur Debatte um die Diamorphinbehandlung Dirk Schäffer in Drogenkurier 136 – Dezember 2023, Seite 3-6 https://www.jes-bundesverband.de/wp-content/uploads/2023/12/Kurier…

Exploring Patients' Perceptions on Injectable Opioid Agonist Treatment: Influences on Treatment Initiation and Implications for Practice.

05. Januar 2024 | Diamorphin

Exploring Patients' Perceptions on Injectable Opioid Agonist Treatment: Influences on Treatment Initiation and Implications for Practice. Friedmann Z, Binder A, Kinkel HT, Kühner C, Zsolnai A, Mick I. Eur Addict Res. 2023 Dec 15:1-11…

Who receives heroin-assisted treatment? A comparison of patients receiving opioid maintenance treatment in Denmark.

01. Januar 2024 | Diamorphin

Who receives heroin-assisted treatment? A comparison of patients receiving opioid maintenance treatment in Denmark. Melis F, Hesse M, Eide D, Thylstrup B, Tjagvad C, Brummer JE, Clausen T. Drug Alcohol Depend. 2023 Dec 2;254:111051. do…

Structural Basis of μ-Opioid Receptor-Targeting by a Nanobody Antagonist.

01. Januar 2024 | Substitutionsmittel Verschiedenes

Structural Basis of μ-Opioid Receptor-Targeting by a Nanobody Antagonist. Yu J, Kumar A, Zhang X, Martin C, Raia P, Koehl A, Laeremans T, Steyaert J, Manglik A, Ballet S, Boland A, Stoeber M. bioRxiv [Preprint]. 2023 Dec 7:2023.12…

Initiation and rapid titration of methadone and slow-release oral morphine (SROM) in an acute care, inpatient setting: a case series.

01. Januar 2024 | Morphin ret.

Initiation and rapid titration of methadone and slow-release oral morphine (SROM) in an acute care, inpatient setting: a case series. Rodger L, Nader M, Turner S, Lurie E. Eur J Med Res. 2023 Dec 8;28(1):573. doi: 10.1186/s40001-023-01…

Initiation and rapid titration of methadone and slow-release oral morphine (SROM) in an acute care, inpatient setting: a case series.

01. Januar 2024 | Methadon zur Substitution

Long-term detoxification of opioid use disorder with opium tincture assisted treatment.

01. Januar 2024 | Substitutionsmittel Verschiedenes

Long-term detoxification of opioid use disorder with opium tincture assisted treatment. Omidvar Tehrani S, Rezaei Ardani A, Akhlaghi S, Shayesteh Zarrin M, Talaei A. Front Psychiatry. 2023 Dec 7;14:1273587. doi: 10.3389/fpsyt.2023.1273…

Methadone Treatment for Opioid Use Disorder

17. Dezember 2023 | Methadon zur Substitution

Methadone Treatment for Opioid Use Disorder To help navigate a complex evidence base, this page is a quick stop for policymakers considering MOTAA. It provides access to high quality studies of policy affecting methadone treatment for OUD, and othe…

Safety and feasibility of intranasal heroin-assisted treatment: 4-week preliminary findings from a Swiss multicentre observational study.

12. Dezember 2023 | Diamorphin

Safety and feasibility of intranasal heroin-assisted treatment: 4-week preliminary findings from a Swiss multicentre observational study. Vogel, M., Meyer, M., Westenberg, J.N. et al. Harm Reduct J 20, 2 (2023). doi.org/10.1186/s12…

Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study.

12. Dezember 2023 | Buprenorphin

Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study. Parkin S, Neale J, Strang J. Int J Drug Policy. 2023 Dec;122:10422…

Invoking a Medical Axiom for Buprenorphine Initiation-See One, Do One, Teach One.

12. Dezember 2023 | Buprenorphin

Invoking a Medical Axiom for Buprenorphine Initiation-See One, Do One, Teach One. Weiner SG. JAMA Netw Open. 2023 Nov 1;6(11):e2342980. doi: 10.1001/jamanetworkopen.2023.42980. PMID: 37948086. https://jamanetwork.com/journals/jamanetw…

The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC.

06. Dezember 2023 | Diamorphin

The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC. Dobischok S, Guh D, Marchand K, MacDonald S, Lock K, Harrison S, Lajeunesse J, Sc…

Cytochrome P450-2D6 activity in people with codeine use disorder.

06. Dezember 2023 | Codein

Cytochrome P450-2D6 activity in people with codeine use disorder. Daglish MRC, Reilly SR, Mostafa S, Edwards C, O'Gorman TM, Hayllar JS. Pharmacogenomics J. 2023 Nov;23(6):195-200. doi: 10.1038/s41397-023-00319-6. Epub 2023 Nov 9. PMID…

Methadone maintenance treatment is more effective than compulsory detoxification in addressing gut microbiota dysbiosis caused by heroin abuse.

06. Dezember 2023 | Methadon zur Substitution

Methadone maintenance treatment is more effective than compulsory detoxification in addressing gut microbiota dysbiosis caused by heroin abuse. Yan P, Ma H, Tian W, Liu J, Yan X, Ma L, Wei S, Zhu J, Zhu Y, Lai J. Front Microbiol. 2023…

Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism.

06. Dezember 2023 | Methadon zur Substitution

Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism. Ferri N, De Martin S, Stuart J, Traversa S, Folli F, Pappagallo M, O'Gorman C, Guidetti C, Mattarei A, Inturrisi CE, Manfredi PL. …

Metabolic and functional substrates of impulsive decision-making in individuals with heroin addiction after prolonged methadone maintenance treatment.

06. Dezember 2023 | Methadon zur Substitution

Metabolic and functional substrates of impulsive decision-making in individuals with heroin addiction after prolonged methadone maintenance treatment. Lv Q, Zhang M, Jiang H, Liu Y, Zhao S, Xu X, Zhang W, Chen T, Su H, Zhang J, Wang H, Zhang…

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial

06. Dezember 2023 | Buprenorphin

Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial John Marsden, Mike Kelleher, Eil…

CHARACTERISTICS, TREATMENT PATTERNS AND RETENTION WITH EXTENDED-RELEASE SUBCUTANEOUS BUPRENORPHINE FOR OPIOID USE DISORDER: A POPULATION-BASED COHORT STUDY IN ONTARIO, CANADA

06. Dezember 2023 | Buprenorphin

CHARACTERISTICS, TREATMENT PATTERNS AND RETENTION WITH EXTENDED-RELEASE SUBCUTANEOUS BUPRENORPHINE FOR OPIOID USE DISORDER: A POPULATION-BASED COHORT STUDY IN ONTARIO, CANADA Iacono A, Wang T, Tadrous M, Campbell 1, Kolla 8, Leece P, Sproule B, Kl…

A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder.

06. Dezember 2023 | Buprenorphin

A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder. Miller JC, Brooks MA, Wurzel KE, Cox EJ, Wurzel JF 3rd. Drugs R D. 2023 Dec;23(4):339-362. doi: 10.1007/s40268-023-00443-5. Epub 2023 No…

Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder.

06. Dezember 2023 | Buprenorphin

Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder. Wipper B, Cooke MP, Winkelman JW. Nat Sci Sleep. 2023 Oct 21;15:851-859. doi: 10.2147/NSS.S427403. PMID…

An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results,

06. Dezember 2023 | Buprenorphin

An Opioid Hiding in Plain Sight: Loperamide-Induced False-Positive Fentanyl and Buprenorphine Immunoassay Results, K Aaron Geno, Adina Badea, Kara L Lynch, Paul Jannetto, Jacqueline A Hubbard, Robert D Nerenz, Mark A Cervinski, The Jou…

Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.

04. Dezember 2023 | Buprenorphin

Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs. Mariani, JJ, Dobbins, RL, Heath, A, Gray, F, Hassman, H. Am J Addict. 2023; 1…

Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities.

10. November 2023 | Diamorphin

Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities. Friedmann, Z., Kinkel, HT., Kühner, C. et al. Harm Reduct J 2…

Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder.

06. November 2023 | Buprenorphin

Weight change in a national cohort of U.S. Military Veterans engaged in medication treatment for opioid use disorder. J

06. November 2023 | Substitutionsmittel Verschiedenes

Weight change in a national cohort of U.S. Military Veterans engaged in medication treatment for opioid use disorder. J Carr MM, Wolkowicz NR, Cave S, Martino S, Masheb R, Midboe AM. Psychiatr Res. 2023 Oct 13;168:204-212. doi: 10.1016/j.jpsyc…

Increases in body mass index following initiation of methadone treatment.

06. November 2023 | Substitutionsmittel Verschiedenes

Increases in body mass index following initiation of methadone treatment. Fenn JM, Laurent JS, Sigmon SC. J Subst Abuse Treat. 2015 Apr;51:59-63. doi: 10.1016/j.jsat.2014.10.007. Epub 2014 Nov 5. PMID: 25441923; PMCID: PMC4346498. https…

Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.

06. November 2023 | Substitutionsmittel Verschiedenes

Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder. Thakrar AP, Uritsky TJ, Christopher C, Winston A, Ronning K, Sigueza AL, Caputo A, McFadden R, Olenik JM, Perro…

An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine.

06. November 2023 | Buprenorphin

An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine. Pande LJ, Arnet RE, Piper BJ. Pharmaceuticals (Basel). 2023 Oct 2;16(10):1397. doi: 10.3390/ph16101397. PMID: 37895868; PMCID…

Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study.

06. November 2023 | Buprenorphin

Drogenkurier 133 – März 2023 - Schwerpunkt: Opioidsubstitution mit Diamorphin

06. November 2023 | Diamorphin

Drogenkurier 133 – März 2023 - Schwerpunkt: Opioidsubstitution mit Diamorphin https://www.jes-bundesverband.de/wp-content/uploads/2023/03/Kurier-133-internet.pdf

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder.

08. Oktober 2023 | Buprenorphin

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. Flam-Ross JM, Marsh E, Weitz M, Savinkina A, Schackman BR, Wang J, Madushani RWMA, Morgan JR, Barocas JA, Walley AY, Chrysanthopoulou SA, Linas BP, Ass…

The experience of buprenorphine implant in patients with opioid use disorder: a series of narrative interviews.

08. Oktober 2023 | Buprenorphin

The experience of buprenorphine implant in patients with opioid use disorder: a series of narrative interviews. Scurti P, Nunzi M, Leonardi C, Pierlorenzi C, Marenzi R, Lamartora V. Front Psychiatry. 2023 Aug 31;14:1205285. doi: 10.3389/…

Challenges of Estimating the Value of Buprenorphine Injectables.

08. Oktober 2023 | Buprenorphin

Challenges of Estimating the Value of Buprenorphine Injectables. Nelson LS, Perrone J. JAMA Netw Open. 2023 Sep 5;6(9):e2329677. doi: 10.1001/jamanetworkopen.2023.29677. PMID: 37703021. https://jamanetwork.com/journals/jamanetworkopen/fu…

Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use.

08. Oktober 2023 | Buprenorphin

Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use. Pytell JD, Fojo AT, Keruly JC, Snow LN, Falade-Nwulia O, Moore R…

Glymphatic-System Function Is Associated with Addiction and Relapse in Heroin Dependents Undergoing Methadone Maintenance Treatment.

08. Oktober 2023 | Methadon zur Substitution

Glymphatic-System Function Is Associated with Addiction and Relapse in Heroin Dependents Undergoing Methadone Maintenance Treatment. Wang L, Qin Y, Li X, Li X, Liu Y, Li W, Wang Y. Brain Sci. 2023 Sep 7;13(9):1292. doi: 10.3390/brainsci1…

Methadone dose escalation in patients with opioid use disorder and cancer as a strategy for controlling cancer-related pain: A case series.

08. Oktober 2023 | Methadon zur Substitution

Methadone dose escalation in patients with opioid use disorder and cancer as a strategy for controlling cancer-related pain: A case series. Carli M, Fini E, De Luca G, Scarselli M, Lamanna F, Vico T, Bocci G. Palliat Support Care. 2023 O…

Opioid relapse and its predictors among methadone maintenance patients: a multicenter, cross-sectional study in Vietnam.

08. Oktober 2023 | Methadon zur Substitution

Opioid relapse and its predictors among methadone maintenance patients: a multicenter, cross-sectional study in Vietnam. Nguyen HTT, Dinh DX. Harm Reduct J. 2023 Sep 16;20(1):136. doi: 10.1186/s12954-023-00872-0. PMID: 37717002; PMCID: P…

Correctiv. David Schraven auf X: „Wie sinnvoll ist die Behandlung mit legalem Heroin? - Interview mit Dr. Martin Burger (DSÄ)

04. Oktober 2023 | Diamorphin

Correctiv. David Schraven auf X: „Wie sinnvoll ist die Behandlung mit legalem Heroin? - Interview mit Dr. Martin Burger (DSÄ) (Correctiv, 04.10.2023, Video, 19:08) https://twitter.com/David_Schraven/status/1709538817252708594

Case Report: Buprenorphine-precipitated fentanyl withdrawal treated with high-dose buprenorphine.

04. Oktober 2023 | Buprenorphin

Case Report: Buprenorphine-precipitated fentanyl withdrawal treated with high-dose buprenorphine. Bormann NL, Gout A, Kijewski V, Lynch A. F1000Res. 2023 Aug 10;11:487. doi: 10.12688/f1000research.120821.2. PMID: 37767082; PMCID: PMC1052…

Long -Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder.

04. Oktober 2023 | Buprenorphin

Long -Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder. Maremmani I, Dematteis M, Gorzelanczyk EJ, Mugelli A, Walcher S, Torrens M. J Clin Med. 2023 Aug 26;12(17):5575. doi: 10.3390/jcm12175575…

Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl. (2)

24. September 2023 | Buprenorphin

Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl. Chambers LC, Hallowell BD, Zullo AR, et al. JAMA Netw Open. 2023;6(9):e2334540. doi:10.1001/jamanetworkopen.202…

Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl.

24. September 2023 | Buprenorphin

Weißes Gold – Profite mit legalem Heroin

16. September 2023 | Diamorphin

Weißes Gold – Profite mit legalem Heroin In Nordrhein-Westfalen gibt es eine Firmengruppe, deren Geschäftsmodell es ist, Drogenabhängigen Drogen zu beschaffen: die Medikus-Gruppe. Medikus, so beschreibt es ihr Gründer, gibt es, weil eine Menge Mensc…

Diamorphingestützte Behandlung: MAGS NRW regelt Einbindung in das örtliche Suchthilfesystem verbindlich

14. September 2023 | Diamorphin

Diamorphingestützte Behandlung: MAGS NRW regelt Einbindung in das örtliche Suchthilfesystem verbindlich Um eine einheitliche Anwendung beim Vollzug der bundesgesetzlichen Vorgaben in allen Regierungsbezirken in Nordrhein-Westfalen zu gewährleisten…

Involvement of the Opioid Peptide Family in Cancer Progression.

14. September 2023 | Methadon in der Krebsmedizin

Involvement of the Opioid Peptide Family in Cancer Progression. Sánchez ML, Rodríguez FD, Coveñas R. Biomedicines. 2023; 11(7):1993. doi.org/10.3390/biomedicines11071993 https://www.mdpi.com/2227-9059/11/7/1993

The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.

14. September 2023 | Methadon zur Substitution

The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users. Shram, M.J., Henningfield, J.E., Apseloff, G. et al. Transl Psychiatry 13, 192 (2023). doi.org/10.1038/…

Levomethadone Therapeutic Drug Monitoring to Aid Opioid Withdrawal Therapy: A Short Communication.

14. September 2023 | Opioidsubstitution

Levomethadone Therapeutic Drug Monitoring to Aid Opioid Withdrawal Therapy: A Short Communication. Pfeifer P, Hildebrand K, Angelov A, Havemann-Reinecke U, Böttcher M, Hiemke C, Prentice T, Roll SC. Ther Drug Monit. 2023 Aug 29. doi: 10…

Psychometric evaluation of two patients monitored for 12 weeks after switching from racemic methadone to levomethadone agonist therapy

14. September 2023 | Opioidsubstitution

Psychometric evaluation of two patients monitored for 12 weeks after switching from racemic methadone to levomethadone agonist therapy Authors: De Luca G.P., Anibaldi G., Paolucci D., Motta P., and De Persis S. Heroin Addiction and Related Clinical…

Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids.

14. September 2023 | Buprenorphin

Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids. Weimer, Melissa B. DO, MCR, DFASAM; Herring, Andrew A. MD; Kawasaki, Sarah S. MD, FASAM; Meyer, Marjorie MD; Kleykamp…

18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.

14. September 2023 | Buprenorphin

18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies. Rutrick D, Learned SM, Boyett B, Hassman D, Shinde S, Zhao Y. J Subst Use Addict Treat…

Retrospective Comparison of the Effectiveness of Buprenorphine Versus Baclofen for Acute Opioid Withdrawal.

14. September 2023 | Buprenorphin

Retrospective Comparison of the Effectiveness of Buprenorphine Versus Baclofen for Acute Opioid Withdrawal. Hermenau M, Stamper B, Leung K, Pomm R, Guerrier C, Cammilleri J, Johnson B. A HCA Healthc J Med. 2023 Apr 28;4(2):139-149. doi…

Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study.

14. September 2023 | Buprenorphin

Evaluating the feasibility of prolonged-release buprenorphine formulations as an alternative to daily opioid agonist therapy regardless of prior treatment adherence: a pilot study. Hard B, DeSilva M. Pilot Feasibility Stud. 2023 Jul 4;9(…

Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.

14. September 2023 | Buprenorphin

Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder. Wang L, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. J Clin Psychol. 2023 Aug 16. doi…

Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.

14. September 2023 | Methadon zur Substitution

The effect of sustainable low-dose sildenafil and cognitive-behavioral training on sexual function in methadone-treated men-a randomized controlled trial.

14. September 2023 | Methadon zur Substitution

The effect of sustainable low-dose sildenafil and cognitive-behavioral training on sexual function in methadone-treated men-a randomized controlled trial. Tavakolifard N, Amini Z. J Addict Dis. 2023 Jul 18:1-8. doi: 10.1080/10550887.2023…

Methadone Potentiates the Cytotoxicity of Temozolomide by Impairing Calcium Homeostasis and Dysregulation of PARP in Glioblastoma Cells.

14. September 2023 | Methadon in der Krebsmedizin

Methadone Potentiates the Cytotoxicity of Temozolomide by Impairing Calcium Homeostasis and Dysregulation of PARP in Glioblastoma Cells. Honc O, Novotny J. Cancers (Basel). 2023 Jul 11;15(14):3567. doi: 10.3390/cancers15143567. PMID: 37509230;…

Postoperative buprenorphine continuation in stabilized buprenorphine patients: A population cohort study.

30. Juni 2023 | Buprenorphin

Postoperative buprenorphine continuation in stabilized buprenorphine patients: A population cohort study. Hauck, TS, Ladha, KS, Le Foll, B, Wijeysundera, DN, Kurdyak, P. Addiction. 2023. doi.org/10.1111/add.16223 ht…

Ulmer Uniklinik steigt in den Ring gegen Krebs und setzt auf Methadon

17. Juni 2023 | Methadon in der Krebsmedizin

Ulmer Uniklinik steigt in den Ring gegen Krebs und setzt auf Methadon Am Universitätsklinikum Ulm hat die lange erwartete klinische Studie zur Frage begonnen, ob Methadon bei der Bekämpfung von Krebs hilft. Derzeit werden weitere Patienten mit Dick…

USA. FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

08. Juni 2023 | Buprenorphin

USA. FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe…

Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study.

06. Juni 2023 | Diamorphin

Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study. Oviedo-Joekes E, Dobischok S, Carvajal J, MacDonald S, McDermid C, Klakowicz P, Harrison S, LaJeunesse J, Chow N…

'This is hardcore': a qualitative study exploring service users' experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England.

06. Juni 2023 | Diamorphin

'This is hardcore': a qualitative study exploring service users' experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England. Riley F, Harris M, Poulter HL, Moore HJ, Ahmed D, Towl G, Walker T. Harm Reduct J. 2023 May 12;2…

Optimally Choosing Medication Type for Patients With Opioid Use Disorder

06. Juni 2023 | Substitutionsmittel Verschiedenes

Optimally Choosing Medication Type for Patients With Opioid Use Disorder Kara E. Rudolph; Nicholas T. Williams; Iván Díaz; Sean X. Luo; John Rotrosen; Edward V. Nunes Am J Epidemiol. 2023;192(5):748-756. https://www.medscape.com/viewar…

Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety.

06. Juni 2023 | Substitutionsmittel Verschiedenes

Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety. Saloner B, Whitley P, Dawson E, Passik S, Gordon AJ, Stein BD. Addiction. 2023 May 9. doi: 10.1111/add.16180. Epu…

Weight change among patients engaged in medication treatment for opioid use disorder: a scoping review.

06. Juni 2023 | Substitutionsmittel Verschiedenes

Weight change among patients engaged in medication treatment for opioid use disorder: a scoping review. Carr MM, Lou R, Macdonald-Gagnon G, Peltier MR, Funaro MC, Martino S, Masheb RM. Am J Drug Alcohol Abuse. 2023 May 18:1-15. doi: 10…

Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series.

06. Juni 2023 | Buprenorphin

Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series. Murray, J.P., Pucci, G., Weyer, G. et al. Addict Sci Clin Pract 18, 38 (2023). doi.org/10.1186/s13722-023-…

Wissenschaftspreis für die Mikrobiologin Heidelinde Fiegl

06. Juni 2023 | Methadon in der Krebsmedizin

Wissenschaftspreis für die Mikrobiologin Heidelinde Fiegl Die Krebsforscherin Heidelinde Fiegl wurde mit dem Wissenschaftspreis der Brigitta Zollner-Stiftung ausgezeichnet. Der für „herausragende wissenschaftliche Arbeiten im Bereich der Frauenheil…

Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review.

06. Juni 2023 | Methadon in der Krebsmedizin

Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review. Constance JE, McFarland MM, Casucci T, Deininger MW, Enioutina EY, Job K, Lemons RS, Lim CS, Ward RM, Yellepeddi V, W…

Intravenöse Opioidagonisten-Therapie (OAT) mit Hydromorphon (Hydagelan®) in Wien

24. Mai 2023 | Diamorphin

Intravenöse Opioidagonisten-Therapie (OAT) mit Hydromorphon (Hydagelan®) in Wien Hans Haltmayer, Ärztlicher Leiter – Suchthilfe Wien gGmbH 25. Substitutions-Forum, 6.Mai 2023, Mondsee Präsentation https://oegabs.at/userfiles/files/substitut…

Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies

16. Mai 2023 | Substitutionsmittel Verschiedenes

Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies Degenhardt, Louisa et al. The Lancet Psychiatry, Volume 0, Issue 0 Abstract https://www.th…

Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies

16. Mai 2023 | Buprenorphin

Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies

16. Mai 2023 | Methadon zur Substitution

Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety.

14. Mai 2023 | Methadon zur Substitution

Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety. Saloner, B, Whitley, P, Dawson, E, Passik, S, Gordon, AJ, Stein, BD. Addiction. 2023. doi…

mefox-studie: Eine klinische Studie zur Kombination von Methadonhydrochlorid und FOLFOX zur Therapie des fortgeschrittenen Darmkrebses

13. Mai 2023 | Methadon in der Krebsmedizin

MEFOX-Studie: Eine klinische Studie zur Kombination von Methadonhydrochlorid und FOLFOX zur Therapie des fortgeschrittenen Darmkrebses MEFOX: a prospective, randomized, controlled phase I/II trial of D,L-Methadone and mFOLFOX6 in treatment of advan…

Methadon in der Krebstherapie: Klinische Studie ist angelaufen

13. Mai 2023 | Methadon in der Krebsmedizin

Methadon in der Krebstherapie: Klinische Studie ist angelaufen 50.000 Menschen unterschrieben für klinische Forschung zur Frage, ob Methadon bei der Bekämpfung von Krebs hilft. An der Uni Ulm hat jetzt eine Studie begonnen, zu der noch passende Tes…

Hexal Suchtmedizin übernimmt L-Polamidon® von Sanofi und sichert die Versorgung Ihrer L-Polamidon®-Patienten

09. Mai 2023 | Opioidsubstitution

Hexal Suchtmedizin übernimmt L-Polamidon® von Sanofi und sichert die Versorgung Ihrer L-Polamidon®-Patienten Sehr geehrte Damen und Herren, Hexal, einer der erfahrensten Versorger in der Drogensubstitution i…

Hexal Suchtmedizin übernimmt L-Polamidon® von Sanofi und sichert die Versorgung Ihrer L-Polamidon®-Patienten

09. Mai 2023 | Schmerzbehandlung

Diamorphinbehandlung – was hat sich getan, was muss getan werden? (Präsentation)

08. Mai 2023 | Diamorphin

Diamorphinbehandlung – was hat sich getan, was muss getan werden? (Präsentation) Dr. Thomas Peschel Patrida - Praxis für Psychiatrie, Psychotherapie und diamorphingestützte Behandlung 14. Internationaler Akzept Kongress Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein. Di…

Intravenous misuse of slow-release oral morphine capsules: how much morphine is injected?

08. Mai 2023 | Morphin ret.

Intravenous misuse of slow-release oral morphine capsules: how much morphine is injected? Bertin C, Montigne E, Teixeira S, Ferrer F, Lauwerie L, Richard D, Authier N. Harm Reduct J. 2023 Apr 27;20(1):59. doi: 10.1186/s12954-023-00781-…

A method of diamorphine (heroin) administration for harm reduction.

08. Mai 2023 | Diamorphin

A method of diamorphine (heroin) administration for harm reduction. Kavanagh ON, Machado TC. Harm Reduct J. 2023 Mar 30;20(1):44. doi: 10.1186/s12954-023-00758-1. PMID: 36998076; PMCID: PMC10061844. https://www.ncbi.nlm.nih.gov/pmc/ar…

Heroin and its metabolites: relevance to heroin use disorder.

08. Mai 2023 | Diamorphin

Heroin and its metabolites: relevance to heroin use disorder. Milella MS, D'Ottavio G, De Pirro S, Barra M, Caprioli D, Badiani A. Transl Psychiatry. 2023 Apr 8;13(1):120. doi: 10.1038/s41398-023-02406-5. PMID: 37031205; PMCID: PMC1008…

Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA).

08. Mai 2023 | Diamorphin

Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA). Allen ST, Schneider KE, Rouhani S, White RH, Morris M, Owczarzak J, Sherman SG. Ann Med. 2023 Dec;55(1):2196435. doi…

Changes in daily dose in open-label compared to double-blind: The role of clients' expectations in injectable opioid agonist treatment.

08. Mai 2023 | Diamorphin

Changes in daily dose in open-label compared to double-blind: The role of clients' expectations in injectable opioid agonist treatment. Blawatt S, Arreola LAG, Magel T, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Addict Beh…

More than just 'free heroin': Caring whilst navigating constraint in the delivery of diamorphine assisted treatment.

08. Mai 2023 | Diamorphin

More than just 'free heroin': Caring whilst navigating constraint in the delivery of diamorphine assisted treatment. Poulter HL, Walker T, Ahmed D, Moore HJ, Riley F, Towl G, Harris M. Int J Drug Policy. 2023 Apr 14;116:104025. doi: 10…

Heroin assisted treatment for key health outcomes in people with chronic heroin addictions: A context-focused systematic review.

08. Mai 2023 | Diamorphin

Heroin assisted treatment for key health outcomes in people with chronic heroin addictions: A context-focused systematic review. McNair R, Monaghan M, Montgomery P. Drug Alcohol Depend. 2023 Apr 6;247:109869. doi: 10.1016/j.drugalcdep…

Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder: A Randomized Clinical Trial.

08. Mai 2023 | Methadon zur Substitution

Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder: A Randomized Clinical Trial. Belcher AM, Cole TO, Massey E, Billing AS, Wagner M, Wooten W, Epstein DH, Hoag SW, Wickwire EM, Greenblatt AD, C…

Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder.

08. Mai 2023 | Methadon zur Substitution

Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder. Thakrar AP, Pytell JD, Stoller KB, Walters V, Weiss RD, Chander G. J Subst Use Addict Treat. 2023 Apr 23;1…

Influence of CYP2B6 Genotype on Methadone Dosage in Patients from the Methadone Maintenance Treatment (MMT) Program in Pereira, Colombia.

08. Mai 2023 | Methadon zur Substitution

Influence of CYP2B6 Genotype on Methadone Dosage in Patients from the Methadone Maintenance Treatment (MMT) Program in Pereira, Colombia. Isaza C, Castaño-Ramírez OM, Vélez JP, Henao J, Beltrán-Angarita L, Sepúlveda-Arias JC. …

Methadone maintenance treatment alters couplings of default mode and salience networks in individuals with heroin use disorder: A longitudinal self-controlled resting-state fMRI study.

08. Mai 2023 | Methadon zur Substitution

Methadone maintenance treatment alters couplings of default mode and salience networks in individuals with heroin use disorder: A longitudinal self-controlled resting-state fMRI study. Chen J, Li Y, Wang S, Li W, Liu Y, Jin L, Li Z, Zhu J, Wa…

'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.

08. Mai 2023 | Buprenorphin

'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue. Clay S, Treloar C, Degenhardt L, Grebely J, Christmass M, Gough C, Hayllar J, Mc…

Rapid induction onto extended-release injectable buprenorphine following opioid overdose: A case series.

05. Mai 2023 | Buprenorphin

Rapid induction onto extended-release injectable buprenorphine following opioid overdose: A case series. Ochalek TA, Ringwood KJ, Davis TT, Gal TS, Wills BK, Sabo RT, Keyser-Marcus L, Martin CE, Polak K, Cumpston KL, Moeller FG. Drug A…

METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES

05. Mai 2023 | Methadon zur Substitution

METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES Huo, Samantha et al. Journal of Emergency Medicine, Volume 64, Issue 3, 391 - 396 https://www.jem-journal.com/article/S0736-4679(23)00010-0/fulltext

Neu. Subutex Depot-Injektionslösungen

30. April 2023 | Buprenorphin

Neu. Subutex Depot-Injektionslösungen Ab 15. Mai wird die INDIVIOR Europe Ltd. folgendes Produkt im deutschen Markt anbieten: Subutex 100 mg Depot-Injektionslösung in einer Fertigspritze / PZN 16512630 Subutex 300 mg Depot-Injektionslösung in ein…

Safety of rapid inpatient methadone initiation protocol: A retrospective cohort study.

09. April 2023 | Methadon zur Substitution

Safety of rapid inpatient methadone initiation protocol: A retrospective cohort study. Racha S, Patel SM, Bou Harfouch LT, Berger O, Buresh ME. J Subst Use Addict Treat. 2023 Mar 15;148:209004. doi: 10.1016/j.josat.2023.209004. Epub ahead of…

Risk of motor vehicle collisions after methadone use: A systematic review and meta-analysis.

09. April 2023 | Methadon zur Substitution

Risk of motor vehicle collisions after methadone use: A systematic review and meta-analysis. Tsai TY, Tu SY, Wu CC, Ho PS, Tung CL, Tsai JH, Yang YH, Wu KF, Chuang HY. Drug Alcohol Depend. 2023 Mar 11;246:109832. doi: 10.1016/j.dr…

A comparative study of sexual behavior, dysfunction, satisfaction, relationship, and sexual quality of life amongst treatment-naïve and abstinent men (buprenorphine-maintained) with Opioid (heroin) dependence syndrome.

09. April 2023 | Buprenorphin

A comparative study of sexual behavior, dysfunction, satisfaction, relationship, and sexual quality of life amongst treatment-naïve and abstinent men (buprenorphine-maintained) with Opioid (heroin) dependence syndrome. Sen MS, Chattopadhyay A…

High-Dose Buprenorphine Initiation in the Emergency Department Among Patients Using Fentanyl and Other Opioids.

09. April 2023 | Buprenorphin

High-Dose Buprenorphine Initiation in the Emergency Department Among Patients Using Fentanyl and Other Opioids. Snyder H, Chau B, Kalmin MM, Speener M, Campbell A, Moulin A, Herring AA. JAMA Netw Open. 2023 Mar 1;6(3):e231572. doi: 10…

A Case Series of Spouses Undergoing Rapid Micro-Induction Technique of Buprenorphine Initiation from Methadone.

09. April 2023 | Buprenorphin

A Case Series of Spouses Undergoing Rapid Micro-Induction Technique of Buprenorphine Initiation from Methadone. Rampetsreiter KR, Salapenka I, Konakanchi JS, Anders J, Sethi R. Kans J Med. 2023 Mar 15;16:74-78. doi: 10.17161/kjm.vol16.18433…

Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl.

09. April 2023 | Buprenorphin

Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl. D’Onofrio G, Hawk KF, Perrone J, et al. JAMA Netw Open. 2023;6(3):e236108. doi:10.1001/jam…

Diamorphingestützte Behandlung Opiatabhängiger in Deutschland – Stellungnahme zur Weiterentwicklung

09. April 2023 | Diamorphin

Diamorphingestützte Behandlung Opiatabhängiger in Deutschland – Stellungnahme zur Weiterentwicklung Die Kampagne „100.000 Substituierte bis 2022“ hat in den letzten 18 Monaten mit verschiedenen Maßnahmen und Interventionen einen Beitrag gelei…

Feasibility, safety, and acceptability of intranasal heroin-assisted treatment in Switzerland: protocol for a prospective multicentre observational cohort study.

09. April 2023 | Diamorphin

Feasibility, safety, and acceptability of intranasal heroin-assisted treatment in Switzerland: protocol for a prospective multicentre observational cohort study. Westenberg JN, Meyer M, Strasser J, Krausz M, Dürsteler KM, Falcato L, Vogel M. …

Spülen nicht Putzen: Sublinguales Buprenorphin schlägt auf die Zähne

12. März 2023 | Buprenorphin

Spülen nicht Putzen: Sublinguales Buprenorphin schlägt auf die Zähne Bereits 2022 hatte die FDA auf Grundlage von Fallmeldungen Alarm geschlagen, nun hat eine kanadisch/US-amerikanische Studie die Vermutungen bestätigt: Sublinguales Buprenorphin ka…

FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain

12. März 2023 | Buprenorphin

FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain Benefits for use outweigh these risks and oral care can help. (FDA – Food and Drugs Administration, USA, 21.01.2023) ht…

Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease.

12. März 2023 | Buprenorphin

Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease. Etminan M, Rezaeianzadeh R, Kezouh A, Aminzadeh K. JAMA. 2022;328(22):2269–2271. doi:10.1001/jama.2022.17485 Abstract https://jamanetwork.com/jou…

ADHD Prevalence among Outpatients with Severe Opioid Use Disorder on Daily Intravenous Diamorphine and/or Oral Opioid Maintenance Treatment.

05. März 2023 | Diamorphin

ADHD Prevalence among Outpatients with Severe Opioid Use Disorder on Daily Intravenous Diamorphine and/or Oral Opioid Maintenance Treatment. Rohner H, Gaspar N, Rosen H, Ebert T, Kilarski LL, Schrader F, Al Istwani M, Lenz AJ, Dilg C, Welskop…

Effects of Methadone on the Toll-like Receptor 4 Expression in Human Non-Small Cell Lung Carcinoma A549 Cell Line Using In-silicoand In vitro Techniques.

05. März 2023 | Methadon in der Krebsmedizin

Effects of Methadone on the Toll-like Receptor 4 Expression in Human Non-Small Cell Lung Carcinoma A549 Cell Line Using In-silicoand In vitro Techniques. Vaseghi G, Rashidi N, Zare N, Ghasemi F, Pourhadi M, Rafiee L, Javanmard…

Crystal methamphetamine use and methadone maintenance treatment dissatisfaction: A prospective cohort study in Vancouver, Canada.

05. März 2023 | Methadon zur Substitution

Crystal methamphetamine use and methadone maintenance treatment dissatisfaction: A prospective cohort study in Vancouver, Canada. Cui Z, Hayashi K, Bach P, Milloy MJ, Kerr T. J Subst Use Addict Treat. 2023 Jan 18:208956. doi: 10.1016/j…

Buprenorphine Maintenance in the Fentanyl Era: Challenges and Opportunities.

05. März 2023 | Buprenorphin

Buprenorphine Maintenance in the Fentanyl Era: Challenges and Opportunities. Modesto-Lowe V, Jain L. Prim Care Companion CNS Disord. 2023 Feb 14;25(1):22l03336. doi: 10.4088/PCC.22l03336. PMID: 36821774. https://www.psychiatrist.com/p…

Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021.

05. März 2023 | Buprenorphin

Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021. Del Pozo B, Atkins D, Andraka-Christou B, Wightman R, Clark MH, Huynh P, Ray B. Drug Alcohol D…

Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature.

05. März 2023 | Buprenorphin

Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature. Ordean A, Tubman-Broeren M. Pathophysiology. 2023 Feb 11;30(1):27-36. doi: 10.3390/pathophysiology30010004. PMID: 36810423; PMCID: PMC99…

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization.

05. März 2023 | Buprenorphin

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization. Gu M, Li A, Mak W, Dong F, Xu N, Zhang J, Shi Y, Zheng N, Tan…

Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States.

05. März 2023 | Buprenorphin

Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States. Sun T, Katenka N, Kogut S, Bratberg J, Rich J, Buchanan A. Pharmacoepidemiolog…

A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder.

05. März 2023 | Buprenorphin

A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder. Ito M, Walzer M, Beth Blauwet M, Spence A, Heo N, Kelsh D, Blahunka P, Erdman J, Nour Alsharif M, Mare…

Adapting low-dose buprenorphine induction to meet patient needs: A pilot study.

05. März 2023 | Buprenorphin

Adapting low-dose buprenorphine induction to meet patient needs: A pilot study. Karavolis ZA, Roy PJ. Drug Alcohol Depend Rep. 2022 Oct 7;5:100104. doi: 10.1016/j.dadr.2022.100104. PMID: 36844162; PMCID: PMC9948859. https://www.ncbi.n…

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations.

05. März 2023 | Buprenorphin

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. Cook RR, Foot C, Arah OA, Humphreys K, Rudolph KE, Luo SX, Tsui JI, Levander XA, Korthuis…

HOW DO PATIENTS FEEL DURING THE FIRST 72 HOURS AFTER INITIATING LONG-ACTING INJECTABLE BUPRENORPHINE? AN EMBODIED QUALITATIVE ANALYSIS.

02. März 2023 | Buprenorphin

HOW DO PATIENTS FEEL DURING THE FIRST 72 HOURS AFTER INITIATING LONG-ACTING INJECTABLE BUPRENORPHINE? AN EMBODIED QUALITATIVE ANALYSIS. Neale, J, Parkin, S, Strang, J. Addiction. 2023; 000– 0., doi.org/10.1111/…

Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment.

07. Februar 2023 | Substitutionsmittel Verschiedenes

Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment. Pan Y, Feaster DJ, Odom G, Brandt L, Hu MC, Weiss RD, Rotrosen J, Saxon AJ, Luo SX, Balise RR. Drug Alcohol Depend Rep. 2022 Dec…

Extended-release monthly buprenorphine injection.

07. Februar 2023 | Buprenorphin

Extended-release monthly buprenorphine injection. Cuperfain AB, Costa T, Chopra N. CMAJ. 2023 Jan 9;195(1):E14. doi: 10.1503/cmaj.220730. PMID: 36623857; PMCID: PMC9829071. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829071/

Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial.

07. Februar 2023 | Buprenorphin

Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. Seval, Nikhil MD; Nunez, Johnathan MD; Roth, Prerana MD; Schade, Meredith MD; Strong…

A Novel Inpatient Buprenorphine Induction Program for Adolescents With Opioid Use Disorder.

07. Februar 2023 | Buprenorphin

A Novel Inpatient Buprenorphine Induction Program for Adolescents With Opioid Use Disorder. Trope LA, Stemmle M, Chang A, Bashiri N, Bazazi AR, Lightfoot M, Congdon JL. Hosp Pediatr. 2023 Feb 1;13(2):e23-e28. doi: 10.1542/hpeds.20…

Precipitated opioid withdrawal after buprenorphine administration in patients presenting to the emergency department: A case series.

07. Februar 2023 | Buprenorphin

Precipitated opioid withdrawal after buprenorphine administration in patients presenting to the emergency department: A case series. Spadaro A, Faude S, Perrone J, Thakrar AP, Lowenstein M, Delgado MK, Kilaru AS. J Am Coll Emerg Physic…

Preliminary attitudes on medications for opioid use disorders (MOUDs) in Southeastern Switzerland and New York City.

07. Februar 2023 | Diamorphin

Preliminary attitudes on medications for opioid use disorders (MOUDs) in Southeastern Switzerland and New York City. Castillo F, Scalise D, Hernandez D, Gupta R, Basaraba CN, Corbeil T, Comer SD, Schneeberger AR. J Addict Dis. 2023 Jan…

Preliminary attitudes on medications for opioid use disorders (MOUDs) in Southeastern Switzerland and New York City.

07. Februar 2023 | Substitutionsmittel Verschiedenes

Schweiz. Substitutionsgestützte Behandlung mit Diacetylmorphin (Heroin)

07. Februar 2023 | Diamorphin

Schweiz. Substitutionsgestützte Behandlung mit Diacetylmorphin (Heroin) Die substitutionsgestützte Behandlung mit Diacetylmorphin (pharmazeutisch hergestelltes Heroin) richtet sich an Personen mit schwerer Heroinabhängigkeit und erfolgt in Fachzent…

The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment.

07. Februar 2023 | Buprenorphin

The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment. McGee M, Chiu K, Moineddin R, Sud A. Appl Health Econ Health Policy. 2023 Jan 18. doi: 10.1007/s40258-022-00787-0. Epub ahead of print. PMID: 36…

Safety and feasibility of intranasal heroin-assisted treatment: 4-week preliminary findings from a Swiss multicentre observational study.

10. Januar 2023 | Diamorphin

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study.

09. Januar 2023 | Diamorphin

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study. Dobischok S, Metcalfe RK, Matzinger EA, Lock K, Harrison S, MacDonald S, Amara S, Schechter MT, Bansback N, Oviedo-Joekes E.&nb…

Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).

08. Januar 2023 | Diamorphin

Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling). Dobischok S, Metcalfe R, Matzinger E, Palis H, Marchand K, Harrison S, MacDonald S, Byres D, Schecht…

Using machine learning to study the effect of medication adherence in Opioid Use Disorder.

08. Januar 2023 | Substitutionsmittel Verschiedenes

Using machine learning to study the effect of medication adherence in Opioid Use Disorder. Warren D, Marashi A, Siddiqui A, Eijaz AA, Pradhan P, Lim D, et al. (2022) PLoS ONE 17(12): e0278988. doi.org/10.1371/journal.pone.0278988 http…

Analysis of Methadone and EDDP in Addicted Patients under Methadone Substitution Treatment: Comparison of Urine and Plasma as Biological Samples.

08. Januar 2023 | Methadon zur Substitution

Analysis of Methadone and EDDP in Addicted Patients under Methadone Substitution Treatment: Comparison of Urine and Plasma as Biological Samples. Ciucă Anghel DM, Ciobanu AM, Guțu CM, Stan M, Tudor G, Baconi DL. GC-MS Molecules. 2022 N…

Psychosocial combined with methadone maintenance treatments versus methadone maintenance treatments alone for treatment of opioid use disorder: A meta-analysis.

08. Januar 2023 | Methadon zur Substitution

Psychosocial combined with methadone maintenance treatments versus methadone maintenance treatments alone for treatment of opioid use disorder: A meta-analysis. Liu C, Li Y. J Addict Dis. 2023 Jan 6:1-10. doi: 10.1080/10550887.2022.215…

Outpatient Rapid Microinduction of Sublingual Buprenorphine in 3 Days From Methadone for Opioid Use Disorder.

08. Januar 2023 | Buprenorphin

Outpatient Rapid Microinduction of Sublingual Buprenorphine in 3 Days From Methadone for Opioid Use Disorder. Salapenka I, Konakanchi JS, Sethi R. Prim Care Companion CNS Disord. 2022 Dec 27;24(6):21cr03150. doi: 10.4088/PCC.21cr03150…

Buprenorphine Microdosing Cross Tapers: A Time for Change.

08. Januar 2023 | Buprenorphin

Buprenorphine Microdosing Cross Tapers: A Time for Change. Raheemullah A, Benhamou OM, Kuo J, Lembke A. Int J Environ Res Public Health. 2022 Dec 8;19(24):16436. doi: 10.3390/ijerph192416436. PMID: 36554317; PMCID: PMC9778657. https:/…

Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.

08. Januar 2023 | Buprenorphin

Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials. Baxley C, Borsari B, Reavis JV, Manuel JK, Herbst E, Becker W, Pennington D, Batki SL…

Transferring patients from high-dose methadone to buprenorphine: A retrospective case series.

08. Januar 2023 | Buprenorphin

Transferring patients from high-dose methadone to buprenorphine: A retrospective case series. Foran A, Tremonti C, Balgobind V, Sakr H, Murnion B. J Opioid Manag. 2022 Nov-Dec;18(6):557-566. doi: 10.5055/jom.2022.0752. PMID: 36523…

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder.

06. Januar 2023 | Buprenorphin

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder. Laffont CM, Ngaimisi E, Gopalakrishnan M, Ivaturi V, Young M, Greenwald MK, Heidbreder C. Front Pharmacol. 2022 Nov 18;13:1052113. doi: 10.3389/fphar…

Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory

25. Dezember 2022 | Substitutionsmittel Verschiedenes

Key implementation factors in telemedicine-delivered medications for opioid use disorder: a scoping review informed by normalisation process theory Teck, Joseph Tay Wee et al. The Lancet Psychiatry, Volume 10, Issue 1, 50 - 64 Abstract htt…

New insights from Observational Retrospective Study on Tolerability of Levomethadone in Patients with Opioid Use Disorder

25. Dezember 2022 | Opioidsubstitution

New insights from Observational Retrospective Study on Tolerability of Levomethadone in Patients with Opioid Use Disorder Sacco S., Barciocco D., Mussi D., and Bartoletti L. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, Vol. 24 • No. N6 • Decemb…

Suboptimal dosing of opioid agonist treatments - a Literature Review

25. Dezember 2022 | Substitutionsmittel Verschiedenes

Suboptimal dosing of opioid agonist treatments - a Literature Review Al-Dewaissan F.B.A.A., Hill D., Evans L., and Luz T.C.B. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, Vol. 24 • No. N5 • October 2022 https://www.heroinaddictionrelated…

Suboxone: History, controversy, and open questions.

11. Dezember 2022 | Buprenorphin

Suboxone: History, controversy, and open questions. Sivils A, Lyell P, Wang JQ, Chu XP. Front Psychiatry. 2022 Oct 28;13:1046648. doi: 10.3389/fpsyt.2022.1046648. PMID: 36386988; PMCID: PMC9664560. https://www.ncbi.nlm.nih.gov/pmc/art…

Schweiz. Die Finanzierung und der Betrieb der HeGeBe in der Schweiz ist in Frage gestellt - Offener Brief an die Krankenversicherer, das BAG und die kantonalen Gesundheitsdirektionen

11. Dezember 2022 | Diamorphin

Schweiz. Die Finanzierung und der Betrieb der HeGeBe in der Schweiz ist in Frage gestellt - Offener Brief an die Krankenversicherer, das BAG und die kantonalen Gesundheitsdirektionen SSAM – Schweizerische Gesellschaft für Suchtmedizin, 08.12.2…

CYP genetic polymorphism, pharmacokinetics of methadone, and the biggest risks

11. Dezember 2022 | Methadon zur Substitution

CYP genetic polymorphism, pharmacokinetics of methadone, and the biggest risks Jovanovic M., Bozovic N., Rancic N., Pjevac A., Rascanin S., and Stojkovic M. Heroin Addiction and Related Clinical Problems, Published Ahead of Print, December 3, 2022…

The effect of a methadone-initiated memory reconsolidation updating procedure in opioid use disorder: A translational study.

11. Dezember 2022 | Methadon zur Substitution

The effect of a methadone-initiated memory reconsolidation updating procedure in opioid use disorder: A translational study. Yue JL, Yuan K, Bao YP, Meng SQ, Shi L, Fang Q, Guo XJ, Cao L, Sun YK, Lu TS, Zeng N, Yan W, Han Y, Sun J, Shi J, Kos…

Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response.

11. Dezember 2022 | Methadon zur Substitution

Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response. Xie X, Gu J, Zhuang D, Zhou Y, Chen X, Shen W, Li L, Liu Y, Xu W, Hong Q, Xu Z, Chen W, Zhou W, Liu H. J Clin Lab Anal. 2022 Nov…

The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial.

11. Dezember 2022 | Methadon zur Substitution

The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial. Padoei F, Mamsharifi P, Hazegh P…

NRW. Medikus-Gruppe: Medizin für Körper und Seele – Die Philosophie der Heroinbehandlung

08. November 2022 | Diamorphin

NRW. Medikus-Gruppe: Medizin für Körper und Seele – Die Philosophie der Heroinbehandlung https://diamorphin.com/

In Essen gibt es neuer Ärger um Diamorphin-Ambulanz

08. November 2022 | Diamorphin

In Essen gibt es neuer Ärger um Diamorphin-Ambulanz In Essen gibt es weiter viel Diskussion um die geplante Diamorphin-Ambulanz. Drei Parteien haben sich zu Wort gemeldet. (Radio Essen, 04.11.2022) https://www.radioessen.de/artikel/in-essen-gibt-e…

Essen: Neue Anlaufstelle für Drogenabhängige geplant

08. November 2022 | Diamorphin

Essen: Neue Anlaufstelle für Drogenabhängige geplant In Essen ist eine neue Anlaufstelle für drogenabhängige Menschen geplant. Die Abteilungen "Soziales" und "Ordnung" der Stadt Essen sehen darin gleich mehrere Chancen. (Radio Essen, 28…

Essen Hbf. Widerstand gegen geplante Heroinambulanz wächst.

08. November 2022 | Diamorphin

Essen Hbf. Widerstand gegen geplante Heroinambulanz wächst. Essen. Die Fraktionen von CDU und Grünen wollen keine privat betriebene Heroin-Ambulanz für Schwerstabhängige. Sie schlagen einen anderen Weg vor. Der Widerstand gegen eine ge…

Schweiz. Erleichterte Heroinabgabe für Süchtige auch nach der Pandemie

08. November 2022 | Diamorphin

Schweiz. Erleichterte Heroinabgabe für Süchtige auch nach der Pandemie Menschen mit einer Sucht hatten während der Coronazeit besondere Regelungen bei der Abgabe des Heroins. Damit seien gute Erfahrungen gemacht worden, heisst es bei den…

Treatment History and Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among People Who Inject Drugs.

08. November 2022 | Substitutionsmittel Verschiedenes

Treatment History and Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among People Who Inject Drugs. Ohlendorf E, Perez-Correa A, Riback L, Ghiroli M, Lopez-Castro T, Fox AD. J Addict Med. 2022 Oct 18. doi: 10.1097/A…

Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.

08. November 2022 | Methadon zur Substitution

Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Kharasch ED, Regina KJ, Blood J, Friedel C. Anesthesiology. 2015 Nov;123(5):1142-53. doi: 10.1097/ALN.0000000000000867. PMID…

Methadone-induced hypoglycemia: A case report.

08. November 2022 | Methadon zur Substitution

Methadone-induced hypoglycemia: A case report. Malboosbaf R, Hatami N, Maghsoomi Z. J Diabetes Investig. 2022 Oct 6. doi: 10.1111/jdi.13919. Epub ahead of print. PMID: 36201002. https://onlinelibrary.wiley.com/doi/10.1111/jd…

Decision tree model based prediction of the efficacy of acupuncture in methadone maintenance treatment.

08. November 2022 | Methadon zur Substitution

Decision tree model based prediction of the efficacy of acupuncture in methadone maintenance treatment. Dong Y, Fan B, Yan E, Chen R, Wei X, Zhan J, Zeng J, Wen H, Lu L. Front Neurol. 2022 Oct 6;13:956255. doi: 10.3389/fneur.2022.95625…

Neurological Manifestations of Chronic Methadone Maintenance Therapy: A Case Report and Literature Review.

08. November 2022 | Methadon zur Substitution

Neurological Manifestations of Chronic Methadone Maintenance Therapy: A Case Report and Literature Review. Gasimova U, Afzal KM, Acharya AB. Cureus. 2022 Sep 24;14(9):e29534. doi: 10.7759/cureus.29534. PMID: 36312663; PMCID: PMC9595224…

UK. MPs call for funding for axed Middlesbrough heroin addiction clinic

08. November 2022 | Diamorphin

UK. MPs call for funding for axed Middlesbrough heroin addiction clinic A ground-breaking clinic for people with heroin addiction should be funded for the rest of the financial year, a prominent committee of MPs has said. Middlesbrough's Heroin As…

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.

08. November 2022 | Buprenorphin

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation. Lowry N…

Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.

08. November 2022 | Buprenorphin

Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review. Bozinoff N, Tardelli V, Rubin-Kahana DS, Le Foll B. Harm Reduct J. 2022 Oct 13;19(1):113. doi: 10.1186/s12954-022-00695-…

Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis.

08. November 2022 | Buprenorphin

Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis. K K A, E J M, D M S. Addict Sci Clin Pract. 2022 Oct 4;17(1):55. doi: 10.1186/s13722-022-00336-z. PMID: 36195895; P…

How do I interpret and use quantitative buprenorphine and norbuprenorphine urine levels?

08. November 2022 | Buprenorphin

How do I interpret and use quantitative buprenorphine and norbuprenorphine urine levels? Waters RC, Perez M. Cleve Clin J Med. 2022 Oct 3;89(10):557-560. doi: 10.3949/ccjm.89a.21019. PMID: 36192022. https://www.ccjm.org/content/89/10/…

Psychological pain and suicidal behavior: A review.

08. November 2022 | Buprenorphin

Psychological pain and suicidal behavior: A review. Baryshnikov I, Isometsä E. Front Psychiatry. 2022 Aug 22;13:981353. doi: 10.3389/fpsyt.2022.981353. PMID: 36203837; PMCID: PMC9531162. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC95…

A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence.

01. November 2022 | Substitutionsmittel Verschiedenes

A randomized, sham-controlled, quintuple-blinded trial to evaluate the NET device as an alternative to medication for promoting opioid abstinence. Greenwald MK, Ghosh S, Winston JR. Contemp Clin Trials Commun. 2022 Oct 18;30:101018. do…

Association between Prescribers' Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability.

11. Oktober 2022 | Substitutionsmittel Verschiedenes

Association between Prescribers' Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability. Adzrago D, Paola AD, Zhu J, Betancur A, Wilkerson JM. Healthcare (Basel). 2022 Sep 9;10(9):1733…

UK. Pioneering Middlesbrough heroin addiction clinic to close

11. Oktober 2022 | Diamorphin

UK. Pioneering Middlesbrough heroin addiction clinic to close A ground-breaking clinic for people tackling heroin addiction is set to close because funding has run out. The Heroin Assisted Treatment (HAT) programme in Middlesbrough was the first o…

Opioid Dose Trajectories and Associations With Mortality, Opioid Use Disorder, Continued Opioid Therapy, and Health Plan Disenrollment.

11. Oktober 2022 | Substitutionsmittel Verschiedenes

Opioid Dose Trajectories and Associations With Mortality, Opioid Use Disorder, Continued Opioid Therapy, and Health Plan Disenrollment. Binswanger IA, Shetterly SM, Xu S, et al. JAMA Netw Open. 2022;5(10):e2234671. doi:10.1001/jam…

Opioid agonist treatment for people who are dependent on pharmaceutical opioids.

11. Oktober 2022 | Substitutionsmittel Verschiedenes

Opioid agonist treatment for people who are dependent on pharmaceutical opioids. Nielsen S, Tse WC, Larance B. Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD011117. doi: 10.1002/14651858.CD011117.pub3. PMID: 36063082; PMCID: PMC9443668…

Managing Opioid Withdrawal in an Outpatient Setting With Lofexidine or Clonidine.

11. Oktober 2022 | Substitutionsmittel Verschiedenes

Managing Opioid Withdrawal in an Outpatient Setting With Lofexidine or Clonidine. Gripshover J, Kosten T. Cureus. 2022 Aug 3;14(8):e27639. doi: 10.7759/cureus.27639. PMID: 36072176; PMCID: PMC9437420. https://www.ncbi.nlm.nih.gov/pmc/…

USA. Opioid Addiction Treatment – A Guide for Patients, Families and Friends

11. Oktober 2022 | Substitutionsmittel Verschiedenes

USA. Opioid Addiction Treatment – A Guide for Patients, Families and Friends ASAM – American Society of Addiction Medicine, 2016 http://eguideline.guidelinecentral.com/i/706017-asam-opioid-patient-piece/0?

MOUD saves lives, especially after 60 days, and the longer the better.

11. Oktober 2022 | Substitutionsmittel Verschiedenes

MOUD saves lives, especially after 60 days, and the longer the better. Williams, AR. Addiction. 2022. doi.org/10.1111/add.16043 https://onlinelibrary.wiley.com/doi/full/10.1111/add.16043

The subjective experience of heroin effects among individuals with chronic opioid use: Revisiting reinforcement in an exploratory study.

11. Oktober 2022 | Diamorphin

The subjective experience of heroin effects among individuals with chronic opioid use: Revisiting reinforcement in an exploratory study. Martinez S, Brandt L, Comer SD, Levin FR, Jones JD. Addict Neurosci. 2022 Dec;4:100034. doi: 10.10…

UK. Commissioning Cracks: The Costs of Defunding Heroin Assisted Treatment

11. Oktober 2022 | Diamorphin

UK. Commissioning Cracks: The Costs of Defunding Heroin Assisted Treatment (…) The DAT program in Middlesbrough provides synthetic medical grade heroin (as diacetylmorphine) for supervised self-injection twice daily, under medical superv…

UK. Heroin Assisted Treatment: James' story (Audio)

11. Oktober 2022 | Diamorphin

UK. Heroin Assisted Treatment: James' story (Audio) Middlesbrough's Heroin Assisted Treatment clinic is set to close. Adam Clarkson meets a former patient to hear about the life-changing effect of treatment. (BBC, UK, 30.09.2022, Audio, 08:00) htt…

Do buprenorphine doses and ratios matter in medication assisted treatment adherence.

11. Oktober 2022 | Buprenorphin

Do buprenorphine doses and ratios matter in medication assisted treatment adherence. Kavanagh K, Tallian K, Sepulveda JA, Rojas S, Martin S, Sikand H. Ment Health Clin. 2022 Aug 23;12(4):241-246. doi: 10.9740/mhc.2022.08.241. PMID: 360…

Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder. Adv Drug

11. Oktober 2022 | Buprenorphin

Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder. Adv Drug Namchuk AB, Lucki I, Browne CA. Alcohol Res. 2022;2:10254. doi: 10.3389/adar.2022.10254. Epub 2022 Feb 21. PMID: 36177442; PMCID: PMC9518754. https://…

Transitioning From High-dose Methadone to Buprenorphine Using a Microdosing Approach: Unique Considerations at ASAM Level 3 Facilities.

11. Oktober 2022 | Buprenorphin

Transitioning From High-dose Methadone to Buprenorphine Using a Microdosing Approach: Unique Considerations at ASAM Level 3 Facilities. Anderson C, Cooley R, Patil D. J Addict Med. 2022 Sep 26. doi: 10.1097/ADM.0000000000001085. Epub a…

Transitioning From High-dose Methadone to Buprenorphine Using a Microdosing Approach: Unique Considerations at ASAM Level 3 Facilities.

11. Oktober 2022 | Methadon zur Substitution

Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.

11. Oktober 2022 | Buprenorphin

Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper. Bozinoff N, Men S, Kurdyak P, Selby P, Gomes T. JAMA Netw Open. 2022 Sep 1;5(9):e2234168. doi: 10.1001/jamanetworkopen.2022.34168. PMID: 3617362…

Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation.

11. Oktober 2022 | Buprenorphin

Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation. Randall A, Hull I, Martin SA. J Addict Med. 2022 Sep 23. doi: 10.1097/ADM.0000000000001073. Epub ahead of print. PMID: 3614…

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings.

11. Oktober 2022 | Buprenorphin

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings. Boyett B, Nadipelli VR, Solem CT, Chilcoat H, Bickel WK, Ling W. J Addict Med. 2022 Sep 16. doi: 10.1097/ADM.0000000000001070. Epub ahead of print…

Buprenorphine and its formulations: a comprehensive review.

11. Oktober 2022 | Buprenorphin

Buprenorphine and its formulations: a comprehensive review. Poliwoda S, Noor N, Jenkins JS, Stark CW, Steib M, Hasoon J, Varrassi G, Urits I, Viswanath O, Kaye AM, Kaye AD. Health Psychol Res. 2022 Aug 20;10(3):37517. doi: 10.52965/001…

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadon

11. Oktober 2022 | Buprenorphin

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid me…

Thirty-day Treatment Continuation After Audio-only Buprenorphine Telehealth Initiation.

10. Oktober 2022 | Buprenorphin

Thirty-day Treatment Continuation After Audio-only Buprenorphine Telehealth Initiation. Wunsch C, Wightman R, Pratty C, Jacka B, Hallowell BD, Clark S, Davis CS, Samuels EA. J Addict Med. 2022 Sep 14. doi: 10.1097/ADM.0000000000001077…

Intrathecal diamorphine for perioperative analgesia during colorectal surgery: a cross-sectional survey of current UK practice.

06. Oktober 2022 | Diamorphin

Intrathecal diamorphine for perioperative analgesia during colorectal surgery: a cross-sectional survey of current UK practice. Alderman J, Sharma A, Patel J, Gao-Smith F, Morgese C. BMJ Open. 2022 Aug 18;12(8):e057407. doi: 10.1136/bm…

2-Minute Neuroscience: Methadone (Video)

23. August 2022 | Methadon zur Substitution

2-Minute Neuroscience: Methadone (Video) Methadone is commonly used to treat opioid use disorder even though its pharmacological action is very similar to that of other opioids like morphine. In this video, I discuss the qualities that make methado…

Opium tincture versus methadone for opioid agonist treatment: A randomized controlled trial,

23. August 2022 | Substitutionsmittel Verschiedenes

Opium tincture versus methadone for opioid agonist treatment: A randomized controlled trial, Nikoo, M., Kianpoor, K., Nikoo, N., Javidanbardan, S., Kazemi, A., Choi, F., Vogel, M., Gholami, A., Tavakoli…

Comparison of Lapse Rate in Drug Dependent Patients in 2 Methods of Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment.

14. August 2022 | Substitutionsmittel Verschiedenes

Comparison of Lapse Rate in Drug Dependent Patients in 2 Methods of Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment. Vafaeinasab M, Zare H, Dehghani A, Malek S, Dehghani-Tafti M, Sarebanhassanabadi M. Subst Abus…

REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats.

14. August 2022 | Methadon zur Substitution

REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats. Henningfield J, Gauvin D, Bifari F, Fant R, Shram M, Buchhalter A, Ashworth J, Lanier R, Pappagallo M, Int…

A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder.

14. August 2022 | Substitutionsmittel Verschiedenes

A highly D3R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D3R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder. Galaj E, Bi GH, Klein B, Hempel B, Shaik AB, Gogarnoiu ES…

How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis.

09. August 2022 | Buprenorphin

How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis. Sud A, Strang M, Buchman DZ, Spithoff S, Upshur REG, Webster F, Grundy Q. BMJ Open. 2022 Jul 12;12(7):e…

Outpatient Microdose Induction with Transdermal Buprenorphine: A Case Series.

09. August 2022 | Buprenorphin

Outpatient Microdose Induction with Transdermal Buprenorphine: A Case Series. Menard S, Jhawar A. Healthcare (Basel). 2022 Jul 14;10(7):1307. doi: 10.3390/healthcare10071307. PMID: 35885833; PMCID: PMC9317019. https://www.ncbi.nlm.nih…

The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost?

09. August 2022 | Buprenorphin

The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost? Gregg J, Hartley J, Lawrence D, Risser A, Blazes C. J Addict Med. 2022 Aug 1. doi: 10.1097/ADM.0000000000001030. Epub ahead of print. PMID: 359139…

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.

09. August 2022 | Substitutionsmittel Verschiedenes

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province. Sadek J, Saunders J. BMC Psychiatry. 2022 Jul 30;22(1):516. doi…

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.

09. August 2022 | Buprenorphin

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.

09. August 2022 | Methadon zur Substitution

Sex differences in weight gain during medication-based treatment for opioid use disorder: A meta-analysis and retrospective analysis of clinical trial data.

09. August 2022 | Methadon zur Substitution

Sex differences in weight gain during medication-based treatment for opioid use disorder: A meta-analysis and retrospective analysis of clinical trial data. Manza P, Kroll D, McPherson KL, Johnson A, Dennis E, Hu L, Tai B, Volkow ND. D…

Does slow release oral morphine have impact on craving and impulsivity in heroin dependent individuals?

09. August 2022 | Morphin ret.

Does slow release oral morphine have impact on craving and impulsivity in heroin dependent individuals? Giustiniani J, Rothen S, Penzenstadler L, Colombo L, Calzada G, Thorens G, Zullino D. Int Clin Psychopharmacol. 2022 Jul 14. doi: 1…

Oral Morphine as an Alternative Substitution Treatment for Opioid Use Disorder, a Rare but Non-risk-free Use.

02. August 2022 | Morphin ret.

Oral Morphine as an Alternative Substitution Treatment for Opioid Use Disorder, a Rare but Non-risk-free Use. Bertin C, Bezin J, Chenaf C, Delorme J, Kerckhove N, Pariente A, Tournier M, Authier N. Front Psychiatry. 2022 Jun 30;13:8935…

Development of an intravenous low-dose buprenorphine initiation protocol.

02. August 2022 | Buprenorphin

Development of an intravenous low-dose buprenorphine initiation protocol. Jablonski LA, Bodnar AR, Stewart RW. Drug Alcohol Depend. 2022 Aug 1;237:109541. doi: 10.1016/j.drugalcdep.2022.109541. Epub 2022 Jun 20. PMID: 35753281. Abstra…

Depot buprenorphine: Safe and effective for clients in jails and prisons?

02. August 2022 | Buprenorphin

Depot buprenorphine: Safe and effective for clients in jails and prisons? There are barriers to receiving opioid use disorder medications, such as buprenorphine, for individuals in criminal justice settings like jails and prisons. These include lim…

Treatment Choices: Buprenorphine

28. Juli 2022 | Buprenorphin

Treatment Choices: Buprenorphine Exchange Supplies, UK. Third edition. oD https://www.exchangesupplies.org/pdf/P802.pdf

Treatment Choices: Suboxone

28. Juli 2022 | Buprenorphin

Treatment Choices: Suboxone Exchange Supplies, UK. Third edition. oD https://www.exchangesupplies.org/pdf/P805.pdf

A Review of Novel Methods To Support The Transition From Methadone and Other Full Agonist Opioids To Buprenorphine/Naloxone Sublingual In Both Community and Acute Care Settings,

28. Juli 2022 | Methadon zur Substitution

A Review of Novel Methods To Support The Transition From Methadone and Other Full Agonist Opioids To Buprenorphine/Naloxone Sublingual In Both Community and Acute Care Settings, Ghosh, Sumantra Monty MD, MSc, FRCPC, ISAM1; Klaire, Sukhpreet MD, CCF…

A Review of Novel Methods To Support The Transition From Methadone and Other Full Agonist Opioids To Buprenorphine/Naloxone Sublingual In Both Community and Acute Care Settings,

28. Juli 2022 | Buprenorphin

Treatment Choices: Methadone

28. Juli 2022 | Methadon zur Substitution

Treatment Choices: Methadone Exchange Supplies, UK. Third edition. oD https://www.exchangesupplies.org/pdf/P801_1.pdf

The Methadone Handbook - Thirteenth edition

28. Juli 2022 | Methadon zur Substitution

The Methadone Handbook - Thirteenth edition Written by: Andrew Preston Published by: Exchange Supplies, Illustrations: Michael Linnell © Exchange Supplies. ISBN 0 9520600 5 1 https://www.exchangesupplies.org/pdf/P301_13_2021.pdf

The Association between Buprenorphine Treatment Duration and Mortality: A Multi-site Cohort Study of People who Discontinued Treatment.

18. Juli 2022 | Buprenorphin

The Association between Buprenorphine Treatment Duration and Mortality: A Multi-site Cohort Study of People who Discontinued Treatment. Glanz JM, Binswanger IA, Clarke CL, Nguyen AP, Ford MA, Ray GT, Xu S, Hechter RC, Yarborough BJH, Roblin D…

Diamorphine-Assisted Treatment (module)

14. Juli 2022 | Diamorphin

Diamorphine-Assisted Treatment (module) Diamorphine-assisted treatment is the prescription and provision of hygienic, medical-grade diamorphine to patients in a clinical set-up – patients attend a clinic and are dosed by a clinician once or twice a…

The Effects of Probiotic Supplementation on Opioid-Related Disorder in Patients under Methadone Maintenance Treatment Programs.

12. Juli 2022 | Methadon zur Substitution

The Effects of Probiotic Supplementation on Opioid-Related Disorder in Patients under Methadone Maintenance Treatment Programs. Molavi N, Rasouli-Azad M, Mirzaei H, Matini AH, Banafshe HR, Valiollahzadeh M, Hassanzadeh M, Saghazade AR, Abbasz…

Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment.

11. Juli 2022 | Diamorphin

Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment. Meyer M, Westenberg JN, Strasser J, Dürsteler KM, Lang UE, Krausz M, Vogel M. Harm Reduct J. 2022 Jun 7;19(1):63. doi: 10…

Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.

21. Juni 2022 | Buprenorphin

Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. Jutras-Aswad D, Le Foll B, Ahamad K, Lim R…

UK. Drug workers warn heroin treatment shortage will cost lives

21. Juni 2022 | Diamorphin

UK. Drug workers warn heroin treatment shortage will cost lives An "unprecedented shortage" of a substitute for illegal heroin in England is putting hundreds of lives at risk, say drug workers. (BBC, UK, 11.06.2022) https://www.bbc.com/news/health…

Schweiz. Heroin made in Switzerland.

06. Juni 2022 | Diamorphin

Schweiz. Heroin made in Switzerland. Reines Heroin aus der Schweiz. Das gibt es ganz legal. Schon seit fast 30 Jahren. Der Produktionsort ist höchst geheim. Der Hersteller will anonym bleiben. Input Redaktor Samuel Emch hat den Schweizer Hero…

Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014-2020.

06. Juni 2022 | Buprenorphin

Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014-2020. Stevens MA, Tsai J, Savitz ST, Nath B, Melnick ER, D'Onofrio G, Jeffery MM. JAMA Net…

The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance.

05. Juni 2022 | Substitutionsmittel Verschiedenes

The influence of poly-drug use patterns on the association between opioid agonist treatment engagement and injecting initiation assistance. Meyers-Pantele SA, Mittal ML, Jain S, Sun S, Rammohan I, Fairbairn N, Milloy MJ, DeBeck K, Hayashi K…

Identifying and Characterizing Medical Advice-Seekers on a Social Media Forum for Buprenorphine Use.

05. Juni 2022 | Buprenorphin

Identifying and Characterizing Medical Advice-Seekers on a Social Media Forum for Buprenorphine Use. Garcia GP, Dehghanpoor R, Stringfellow EJ, Gupta M, Rochelle J, Mason E, Pujol TA, Jalali MS. Int J Environ Res Public Health. 2022 Ma…

Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study.

05. Juni 2022 | Buprenorphin

Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study. Johnson B, Flensburg OL, Capusan AJ. Subst Abuse Treat Prev Policy. 2022 May 25;17(1):40. doi: 10.1186/s13011-022-00474-2. PMID…

Retention rates with monthly depot buprenorphine in general practice in Melbourne, Australia.

05. Juni 2022 | Buprenorphin

Retention rates with monthly depot buprenorphine in general practice in Melbourne, Australia. Andrada E, Rodriguez M, Bandalan JH, Dangelo-Kemp D, Johnston L, Wilson H. Aust J Gen Pract. 2022 Jun;51(6):447-451. doi: 10.31128/AJGP-07-21…

The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review.

05. Juni 2022 | Substitutionsmittel Verschiedenes

The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review. Jordan CG, Kennalley AL, Roberts AL, Nemes KM, Dolma T, Piper BJ. Pharmacy (Basel). 2022 Apr 19;10(3):48. doi: 10.3390/pharmacy10030048…

What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings.

05. Juni 2022 | Substitutionsmittel Verschiedenes

What is success in treatment for opioid use disorder? Perspectives of physicians and patients in primary care settings. Hooker SA, Sherman MD, Lonergan-Cullum M, Nissly T, Levy R. J Subst Abuse Treat. 2022 May 20:108804. doi: 10.1016/j…

Laser meridian massage decreased craving in men with opioid use disorder on methadone maintenance treatment.

05. Juni 2022 | Methadon zur Substitution

Laser meridian massage decreased craving in men with opioid use disorder on methadone maintenance treatment. Hu WL, Tsai MC, Kuo CE, Liu CT, Wu SY, Wu TC, Hung YC. Biomed J. 2021 May 1:S2319-4170(21)00042-1. doi: 10.1016/j.bj.2021.04.0…

Investigating Cognitive Functions in Methadone Users in Comparison with Methadone and Methamphetamine Users and Control Group.

05. Juni 2022 | Methadon zur Substitution

Investigating Cognitive Functions in Methadone Users in Comparison with Methadone and Methamphetamine Users and Control Group. Eslami-Shahrbabaki M, Barfehee D, Parvaresh N, Zamani E, Soltaninejad A, Ahmadi A. Addict Health. 2022 Jan;1…

Side Effects from Chronic Methadone Use in Opioid Addiction: A Scoping Review on Hematological Derangements.

05. Juni 2022 | Methadon zur Substitution

Side Effects from Chronic Methadone Use in Opioid Addiction: A Scoping Review on Hematological Derangements. Khalid K, Anuar A, Ang WC, Jamaluddin R. Curr Drug Saf. 2022 May 14. doi: 10.2174/1574886317666220514154931. Epub ahead of pri…

Switzerland's Dependence on a Diamorphine Monopoly.

04. Juni 2022 | Diamorphin

Switzerland's Dependence on a Diamorphine Monopoly. Schmitt-Koopmann C, Baud CA, Junod V, Simon O. Front Psychiatry. 2022 May 9;13:882299. doi: 10.3389/fpsyt.2022.882299. PMID: 35615450; PMCID: PMC9125182. https://www.ncbi.nlm.nih.gov…

Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study.

26. Mai 2022 | Buprenorphin

Association Between Receipt of Antidepressants and Retention in Buprenorphine Treatment for Opioid Use Disorder: A Population-Based Retrospective Cohort Study. Zhang K, Jones CM, Compton WM, Guy GP, Evans ME, Volkow ND. J Clin Psychiat…

Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials.

26. Mai 2022 | Buprenorphin

Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials. Bergen AW, Baurley JW, Ervin CM, McMahan CS, Bible J, Stafford RS, Mudumbai SC, Saxon AJ. International Journal of…

Prehospital Buprenorphine Treatment for Opioid Use Disorder by Paramedics: First Year Results of the EMS Buprenorphine Use Pilot,

26. Mai 2022 | Buprenorphin

Prehospital Buprenorphine Treatment for Opioid Use Disorder by Paramedics: First Year Results of the EMS Buprenorphine Use Pilot, H. Gene Hern, Vanessa Lara, David Goldstein, M. Kalmin, S. Kidane, S. Shoptaw, Ori Tzvieli & Andrew A. Herring&nbs…

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.

26. Mai 2022 | Buprenorphin

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use. Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA. JAMA Netw Open. 2022;5(5):e2211363. doi:10.1001/ja…

UK. Pushed to the Brink

26. Mai 2022 | Diamorphin

UK. Pushed to the Brink Three years ago, nine people in the South West of England were going about their daily lives, just as anyone else might, juggling jobs and family life with all the everyday ups and downs. Each of them was in regular r…

Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice-Identifying Group Differences and Predictors.

08. Mai 2022 | Diamorphin

Sexual Dysfunctions in Patients Receiving Opioid Agonist Treatment and Heroin-Assisted Treatment Compared to Patients in Private Practice-Identifying Group Differences and Predictors. Meyer M, Brunner P, Geissmann L, Gürtler M, Schwager F, Wa…

Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence.

08. Mai 2022 | Buprenorphin

Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence. Ghosh A, Mahintamani T, Rana DK, Basu D, Mattoo SK. Indian J Psychiatry. 2022 Mar-Apr;64(2):199-208. doi: 10.4103/i…

Non–prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder

28. April 2022 | Buprenorphin

Non–prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder Williams, Arthur Robin et al. Journal of Substance Abuse Treatment, Volume 0, Issue 0, 108770 https://www.journalofsubstanceabusetreatment…

What factors influence retention in buprenorphine and methadone treatment?

28. April 2022 | Substitutionsmittel Verschiedenes

What factors influence retention in buprenorphine and methadone treatment? Medication treatments for opioid use disorder are effective lifesaving therapies, and studies suggest that longer treatment durations result in better patient outcomes (e.g…

Diamorphingestützte Behandlung in Deutschland

22. April 2022 | Diamorphin

Diamorphingestützte Behandlung in Deutschland Gemeinsame Website der Ambulanzen und Praxen in Deutschland, die Diamorphin zur Opioidsubstitution anbieten. (Stand April 2022) http://www.diamorphin-behandlung.de/

Schweiz. Situationsanalyse der heroingestützten Behandlung (HeGeBe).

22. April 2022 | Diamorphin

Schweiz. Situationsanalyse der heroingestützten Behandlung (HeGeBe). Frey, Kathrin; Pestoni, Amélie; Häusermann, Marina (2021) Zürich: KEK – CDC. https://www.bag.admin.ch/dam/bag/en/dokumente/e-f/evalber-ncd-sucht/2021-situationsanalyse-heg…

Schweiz. Substitutionsgestützte Behandlung mit Diacetylmorphin (Heroin)

22. April 2022 | Diamorphin

Exploring why patients in heroin-assisted treatment are getting incarcerated-a qualitative study.

09. April 2022 | Diamorphin

Exploring why patients in heroin-assisted treatment are getting incarcerated-a qualitative study. Meyer M, Rist B, Strasser J, Lang UE, Vogel M, Dürsteler KM, Walter M. BMC Psychiatry. 2022 Mar 7;22(1):169. doi: 10.1186/s12888-022-0381…

Identifying relative strength of methadone versus health and social services in comprehensive substance use disorder treatment using a variance decomposition approach.

05. April 2022 | Methadon zur Substitution

Identifying relative strength of methadone versus health and social services in comprehensive substance use disorder treatment using a variance decomposition approach. Shin HC, Marsh JC. Eval Program Plann. 2022 Feb 23;92:102060. doi…

Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials.

05. April 2022 | Substitutionsmittel Verschiedenes

Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. Lim J, Farhat I, Douros A, Panagiotoglou D (2022) PLoS ONE 17(3): e0266142. doi.org/10.1…

Review of medication-assisted treatment for opioid use disorder.

05. April 2022 | Substitutionsmittel Verschiedenes

Review of medication-assisted treatment for opioid use disorder. Ghanem N, Dromgoole D, Hussein A, Jermyn RT. J Osteopath Med. 2022 Mar 14. doi: 10.1515/jom-2021-0163. Epub ahead of print. PMID: 35285220. https://www.degruyter.com/doc…

Buprenorphine for High-dose Tramadol Dependence: A Case Report of Successful Outpatient Treatment.

09. März 2022 | Buprenorphin

D,L-Methadone enhances the cytotoxic activity of standard chemotherapeutic agents on pediatric rhabdomyosarcoma.

09. März 2022 | Methadon in der Krebsmedizin

D,L-Methadone enhances the cytotoxic activity of standard chemotherapeutic agents on pediatric rhabdomyosarcoma. Urla, C., Corteletti, I., Raible, AS. et al. J Cancer Res Clin Oncol (2022). doi.org/10.1007/s00432-022-03945-y https…

N Diacetylmorphine Hydrochloride: PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

23. Februar 2022 | Diamorphin

N Diacetylmorphine Hydrochloride: PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Diamorphine hydrochloride for injection, Powder, 200 mg per vial, 5 g per vial, intramuscular and intravenous injection. British Pharmacopoeia. Opioid agon…

USA. Methadone: An American Way of Dealing (Video)

15. Februar 2022 | Methadon zur Substitution

USA. Methadone: An American Way of Dealing (Video) Klein and Richert’s camera contrasts a state-operated methadone clinic in Dayton, Ohio, with Washington, DC’s Afrocentric RAP therapeutic community, founded in 1970 by Ron Clark, a vetera…

USA. The Points Methadone Marathon

15. Februar 2022 | Methadon zur Substitution

USA. The Points Methadone Marathon Welcome to the home page for the Points Methadone Marathon! (pointshistory.com, USA, 01.02.2022) https://pointshistory.com/2022/02/01/methadone-marathon-intro/

Update Suchtmedizin: Neue Optionen in der Substitution

08. Februar 2022 | Substitutionsmittel Verschiedenes

Update Suchtmedizin: Neue Optionen in der Substitution Zu Substitution stehen heute zahlreiche Substanzen und Darreichungsformen zur Verfügung. In den letzten Jahren sind insbesondere retardierte Präparate hinzu gekommen, so dass mittlerweile eine…

Integrating Buprenorphine Treatment for Opioid Use with Primary Care is Associated with Greater Retention in Treatment.

08. Februar 2022 | Buprenorphin

Integrating Buprenorphine Treatment for Opioid Use with Primary Care is Associated with Greater Retention in Treatment. Mirer AG, Tiemstra JD, Hammes NE, Cloum HM, LaFavor KJ. J Am Board Fam Med. 2022 Jan-Feb;35(1):206-208. doi: 10.312…

The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013-14.

08. Februar 2022 | Methadon zur Substitution

The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013-14. Krebs E, Hongdilokkul N, Dale LM, Min JE, Schnepel KT, Shigeoka H, Nosyk B. J Subst Abuse Trea…

Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids.

08. Februar 2022 | Methadon in der Krebsmedizin

Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids. Fiegl H, Hagenbuchner J, Kyvelidou C, Seeber B, Sopper S, Tsibulak I, Wieser V, Reiser E, Roessler J, Huhtinen K, Carpén O…

Interim opioid agonist treatment for opioid addiction: a systematic review.

08. Februar 2022 | Substitutionsmittel Verschiedenes

Interim opioid agonist treatment for opioid addiction: a systematic review. Samsó Jofra L, Puig T, Solà I, Trujols J. Harm Reduct J. 2022 Jan 29;19(1):7. doi: 10.1186/s12954-022-00592-x. PMID: 35090475; PMCID: PMC8800211. https://www…

Experiences and Preferences of Opioid-Use-Disorder Patients Who Switched from Brand to Generic Buprenorphine/Naloxone Films: A Case Series.

08. Februar 2022 | Buprenorphin

Experiences and Preferences of Opioid-Use-Disorder Patients Who Switched from Brand to Generic Buprenorphine/Naloxone Films: A Case Series. Cedeño E, Cruz A, Cortés J, Melin K, Roman L, Gonzalez A, Duconge J, Santiago D. Patient Prefer…

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients.

08. Februar 2022 | Buprenorphin

Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. Moss LM, Algera MH, Dobbins R, Gray F, Strafford…

Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency.

08. Februar 2022 | Buprenorphin

Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency. Gornalusse GG, Vojtech LN, Levy CN, Hughes SM, Kim Y, Valdez R, Pandey U, Ochsenbauer C, Astronomo R, McElrath J, Hladik F. Viruses. 2021 Jul…

Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.

08. Februar 2022 | Buprenorphin

Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Petrakis I, Springer SA, Davis C, Ralevski E, Gu L, Lew R, Hermos J…

Opioid agonist treatment for self-harm and suicide prevention

02. Februar 2022 | Substitutionsmittel Verschiedenes

Opioid agonist treatment for self-harm and suicide prevention Nestadt, Paul S et al. The Lancet Psychiatry, Volume 9, Issue 2, 100 - 101 Abstract https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(21)00448-X/fulltext

Buprenorphin. Filling the prescription

02. Februar 2022 | Buprenorphin

Buprenorphin. Filling the prescription This article is the first in a series examining the past, present and future of buprenorphine in the treatment of opioid dependence. Buprenorphine is a medication used in opioid substitution treatment (OST), a…

Low- and very low-dose buprenorphine induction: new(ish) uses for an old(ish) medication?.

02. Februar 2022 | Buprenorphin

Low- and very low-dose buprenorphine induction: new(ish) uses for an old(ish) medication?. Weimer, M.B. and Fiellin, D.A. (2022), Addiction. https://doi.org/10.1111/add.15799 https://onlinelibrary.wiley.com/doi/full/10.1111/add.15799

Statement from SAMHSA Leader on FDA’s Drug Safety Alert on Buprenorphine and Risk for Tooth Decay

02. Februar 2022 | Buprenorphin

Statement from SAMHSA Leader on FDA’s Drug Safety Alert on Buprenorphine and Risk for Tooth Decay Today, Miriam Delphin-Rittmon, Ph.D., Assistant Secretary for Mental Health and Substance Use and the leader of the Substance Abuse and Mental Health…

«One prick and then it´s done»: a mixed-methods exploratory study on intramuscular injection in heroin-assisted treatment.

17. Januar 2022 | Diamorphin

«One prick and then it´s done»: a mixed-methods exploratory study on intramuscular injection in heroin-assisted treatment. Meyer M, Eichenberger R, Strasser J, Dürsteler KM, Vogel M. Harm Reduct J. 2021 Dec 18;18(1):134. doi: 10.1186/s…

Kanada. B.C. doctors upset their ‘safe supply' of heroin going unprescribed during overdose crisis

17. Januar 2022 | Diamorphin

Kanada. B.C. doctors upset their ‘safe supply' of heroin going unprescribed during overdose crisis The doctors are asking the Ministry of Health to fund heroin-assisted treatment for 200 British Columbians at an average cost of $25 a day. (Va…

Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation.

17. Januar 2022 | Buprenorphin

Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation. Brogdon H, Facer KL, Cox EJ, Carlson RH Jr, Wurzel JF 3rd. J Addict Med. 2021 Dec 3. doi: 10.1097/ADM.0000000000000935. Epub ahead of prin…

Opioid use disorder from poppy seed tea successfully treated with buprenorphine in primary care: a case report.

17. Januar 2022 | Buprenorphin

Opioid use disorder from poppy seed tea successfully treated with buprenorphine in primary care: a case report. Hagan S, Achtmeyer CE, Hood C, Hawkins EJ, Williams EC. Addict Sci Clin Pract. 2021 Dec 3;16(1):71. doi: 10.1186/s13722-021…

Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program.

17. Januar 2022 | Buprenorphin

Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program. Furo H, Schwartz DG, Sullivan RW, Elkin PL. Subst Abuse. 2021 Dec 6;15:11782218211061749. d…

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review.

17. Januar 2022 | Buprenorphin

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients-A Critical Review. Soyka M. Front Pharmacol. 2021 Nov 23;12:718811. doi: 10.3389/fphar.2021.718811. PMID: 34887748; PMCID: PMC8650116. https://www.n…

"I don't want to take buprenorphine for the rest of my life": Acceptance and Commitment Therapy for a Client Struggling to Reduce Low-Dose Buprenorphine (a Hermeneutic Single-Case Efficacy Design).

17. Januar 2022 | Buprenorphin

"I don't want to take buprenorphine for the rest of my life": Acceptance and Commitment Therapy for a Client Struggling to Reduce Low-Dose Buprenorphine (a Hermeneutic Single-Case Efficacy Design). Shepherd K, Pritty B, Tickle A, Moghaddam N…

Buprenorphine: Drug Safety Communication - FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain

17. Januar 2022 | Buprenorphin

Buprenorphine: Drug Safety Communication - FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder and pain AUDIENCE: Dentistry, Anesthesiology, Patient, Health Professional…

Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences.

17. Januar 2022 | Methadon zur Substitution

Implications of OPRM1 and CYP2B6 variants on treatment outcomes in methadone-maintained patients in Ontario: Exploring sex differences. Chawar C, Hillmer A, Lamri A, Kapczinski F, Thabane L, Pare G, et al. (2021) PL…

A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder.

07. Dezember 2021 | Substitutionsmittel Verschiedenes

A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder. Chawar C, Hillmer A, Sanger S, D'Elia A, Panesar B, Guan L, Xie DX, Bansal N, Abdullah A, Kapczinski F, Pare G, Thabane L, Samaan Z.&…

Different drugs come with different motives: Examining motives for substance use among people who engage in polysubstance use undergoing methadone maintenance therapy (MMT).

07. Dezember 2021 | Methadon zur Substitution

Different drugs come with different motives: Examining motives for substance use among people who engage in polysubstance use undergoing methadone maintenance therapy (MMT). Mahu IT, Barrett SP, Conrod PJ, Bartel SJ, Stewart SH. Drug A…

Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life.

07. Dezember 2021 | Buprenorphin

Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life. Somaini L, Vecchio S, Corte C, Coppola C, Mahony A, Pitts A, Cutuli M, Orso R, Littlewood R. Cureus. 2021 Oct 5;13(1…

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report.

07. Dezember 2021 | Buprenorphin

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report. Menard S, Jhawar A. Ment Health Clin. 2021 Nov 8;11(6):369-372. doi: 10.9740/mhc.2021.11.369. PMID: 34824962; PMCID: PMC8582770. http…

Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine.

07. Dezember 2021 | Buprenorphin

Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine. Stein MD, VanNoppen D, Herman DS, Anderson BJ, Conti M, Bailey GL. J Subst Abuse Treat. 2021 Nov 14:108661. doi: 10.1016/…

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

07. Dezember 2021 | Buprenorphin

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. Farrell M, Shahbazi J, Byrne M, Grebely J, Lintzeris N, Chambers M, Larance B, Ali R, Nielsen S, D…

Cost-effectiveness of Treatments for Opioid Use Disorder.

05. Dezember 2021 | Substitutionsmittel Verschiedenes

Cost-effectiveness of Treatments for Opioid Use Disorder. Fairley M, Humphreys K, Joyce VR, et al. JAMA Psychiatry. 2021;78(7):767–777. doi:10.1001/jamapsychiatry.2021.0247 https://jamanetwork.com/journals/jamapsychiatry/article-abstr…

Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.

12. November 2021 | Buprenorphin

Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. Roache, J.D., Pavlicova, M., Campbell, A., Choo…

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

12. November 2021 | Buprenorphin

The influence of methadone on cerebral gray matter and functional connectivity.

09. November 2021 | Methadon zur Substitution

The influence of methadone on cerebral gray matter and functional connectivity. Zhu J, Wang S, Liu Y, Wang F, Li Q, Li Z, Sun Y, Li W, Wang W. Ann Palliat Med. 2021 Sep;10(9):9497-9507. doi: 10.21037/apm-21-2012. PMID: 34628875. https…

Fifteen years of heroin-assisted treatment in a Swiss prison-a retrospective cohort study.

09. November 2021 | Diamorphin

Fifteen years of heroin-assisted treatment in a Swiss prison-a retrospective cohort study. Liebrenz M, Gamma A, Buadze A, Schleifer R, Baggio S, Schwartz B, Schneeberger A, Uchtenhagen A. Harm Reduct J. 2020 Oct 13;17(1):67. doi: 10.11…

Australien. The case for an Australian heroin trial: strong then, even stronger now

09. November 2021 | Diamorphin

Australien. The case for an Australian heroin trial: strong then, even stronger now By Alex Wodak, Bob Douglas and David McDonald Pearls and Irritations, 08.11.2021 https://johnmenadue.com/the-case-for-an-australian-heroin-trial-strong-then-even-…

Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations.

09. November 2021 | Buprenorphin

Recent advances in the treatment of opioid use disorders-focus on long-acting buprenorphine formulations. Soyka M, Franke AG. World J Psychiatry. 2021 Sep 19;11(9):543-552. doi: 10.5498/wjp.v11.i9.543. PMID: 34631459; PMCID: PMC8474991…

Köln. Tagesthemen-Reportage aus der Kölner Diamorphin-Ambulanz

21. Oktober 2021 | Diamorphin

Köln. Tagesthemen-Reportage aus der Kölner Diamorphin-Ambulanz (Tagesthemen, Mittendrin-Reportage, ARD, 11.10.2021, Video, 25:52 – 31:07) https://www.ardmediathek.de/video/tagesthemen/das-erste/Y3JpZDovL2Rhc2Vyc3RlLmRlL3RhZ2VzdGhlbWVuLzNjOGE2ODY4L…

Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US.

21. Oktober 2021 | Buprenorphin

Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US. Han B, Jones CM, Einstein EB, Compton WM. JAMA Netw Open. 2021;4(10):e2129409. doi:10.1001/jamanetworkopen.2021.29409 https://jamanetwork.com/journals/…

Recovery capital among people receiving treatment for opioid use disorder with buprenorphine.

21. Oktober 2021 | Buprenorphin

Recovery capital among people receiving treatment for opioid use disorder with buprenorphine. Parlier-Ahmad, A.B., Terplan, M., Svikis, D.S. et al. Harm Reduct J 18, 103 (2021). doi.org/10.1186/s12954-021-00553-w https://harm…

The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review.

08. Oktober 2021 | Diamorphin

The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. F Martins ML, Wilthagen EA, Oviedo-Joekes E, Beijnen JH, de Grave N, Uchtenhagen A, Beck T, Van den Brink W, Schinkel AH. …

Methadone vs. Buprenorphine for In-Hospital Initiation: Which Is Better for Outpatient Care Retention in Patients with Opioid Use Disorder?

08. Oktober 2021 | Buprenorphin

Methadone vs. Buprenorphine for In-Hospital Initiation: Which Is Better for Outpatient Care Retention in Patients with Opioid Use Disorder? Kessler SH, Schwarz ES, Liss DB. J Med Toxicol. 2021 Sep 23. doi: 10.1007/s13181-021-00858-z. E…

Methadone vs. Buprenorphine for In-Hospital Initiation: Which Is Better for Outpatient Care Retention in Patients with Opioid Use Disorder?

08. Oktober 2021 | Methadon zur Substitution

A review of the evidence to explain pharmacological basis of injection (ab)use of buprenorphine-naloxone tablets.

08. Oktober 2021 | Buprenorphin

A review of the evidence to explain pharmacological basis of injection (ab)use of buprenorphine-naloxone tablets. Modak T, Sarkar S, Balhara YPS. J Opioid Manag. 2021;17(7):141-152. doi: 10.5055/jom.2021.0651. PMID: 34520035. Abstract…

A cross-sectional survey on buprenorphine-naloxone practice and attitudes in 22 Canadian emergency physician groups: a cross-sectional survey.

08. Oktober 2021 | Buprenorphin

A cross-sectional survey on buprenorphine-naloxone practice and attitudes in 22 Canadian emergency physician groups: a cross-sectional survey. Kestler A, Kaczorowski J, Dong K, Orkin AM, Daoust R, Moe J, Van Pelt K, Andolfatto G, Klaiman M, Y…

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail.

08. Oktober 2021 | Buprenorphin

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail. Lee JD, Malone M, McDonald R, Cheng A, Vasudevan K, Tofighi…

Retrospective analysis of heroin detoxification with buprenorphine in a psychiatric hospital in Japan.

08. Oktober 2021 | Buprenorphin

Retrospective analysis of heroin detoxification with buprenorphine in a psychiatric hospital in Japan. Nagano T, Kimoto S, Aso K, Komori T, Yamaguchi Y, Okamura K, Yamamoto N, Kishimoto T. Neuropsychopharmacol Rep. 2020 Dec;40(4):376-3…

Kanada. Vancouver clinic revokes 11 patients’ access to take-home heroin doses

06. Oktober 2021 | Diamorphin

Kanada. Vancouver clinic revokes 11 patients’ access to take-home heroin doses Eleven patients who were permitted to take home doses of medical-grade heroin from a Vancouver clinic have had the permission abruptly revoked. The patients were told l…

Kanada/British Columbia. Vancouver clinic first in North America to offer take-home medical-grade heroin

06. Oktober 2021 | Diamorphin

Kanada/British Columbia. Vancouver clinic first in North America to offer take-home medical-grade heroin A safe supply of medical-grade heroin can be a lifeline for those battling opioid addiction. (CBC Canada, Kanada, 16.09.2021) https://www.cbc…

Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel

06. Oktober 2021 | Buprenorphin

Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel Kohan L, Potru S, Barreveld AM, et al Regional Anesthesia & Pain Medicine 2021;46:840-859. https://rapm.bmj.com/cont…

Kanada. Prescription Inhalable Heroin Is Coming to BC. Will the Province Embrace It?

24. September 2021 | Diamorphin

Kanada. Prescription Inhalable Heroin Is Coming to BC. Will the Province Embrace It? Experts say it’s past time to expand life-saving therapy for drug users. (The Tyee, Kanada, 17.09.2021) https://thetyee.ca/News/2021/09/17/Prescription-Inhalable-…

Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database.

24. September 2021 | Buprenorphin

Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database. Saloner B, Whitley P, LaRue L, Dawson E, Huskey A. JAMA Netw Open. 2021;4(9):e2123019. doi:10.1001/jamanetworkopen.2021.23019 h…

Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence.

24. September 2021 | Buprenorphin

Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. Lintzeris N, Dunlop A, Masters D (2019) NSW Ministry of Health, Sydney Australia https://www.health.nsw.gov.au/aod/Pub…

Risk of motor vehicle collisions after methadone use.

20. September 2021 | Methadon zur Substitution

Risk of motor vehicle collisions after methadone use. Yang YH, Ho PS, Wu TN, Wang PW, Lin CR, Tsai JH, Guo YL, Chuang HY. Elife. 2021 Aug 5;10:e63954. doi: 10.7554/eLife.63954. PMID: 34351275; PMCID: PMC8341976. https://www.ncbi.nlm.n…

Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment.

06. September 2021 | Methadon zur Substitution

Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment. Huang CL, Chiang YC, Chang WC, Su YT, Yang JC, Cheng WC, Lane HY, Ho IK, Ma WL. Front Endocrinol (Lausanne). 2021 Aug 5;12:638884. doi: 10.3389/fendo.20…

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.

06. September 2021 | Buprenorphin

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series. Soyka M, Groß G. Am J Drug Alcohol Abuse. 2021 Aug 18:1-6. doi: 10.1080/00952990.2021.1963757. Epub ahead…

Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder.

06. September 2021 | Buprenorphin

Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder. Schellekens AFA, Veldman SE, Suranto ESD, van Rijswijk SM…

Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.

06. September 2021 | Buprenorphin

Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia. Barnett A, Savic M, Lintzeris N, Bathish R, Arunogiri S, Dunlop AJ, Haber P, Graham R, Hayes V, Lubman DI. Drug…

Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone.

17. August 2021 | Substitutionsmittel Verschiedenes

Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone. Agin-Liebes G, Huhn AS, Strain EC, Bigelow GE, Smith MT, Edwards RR, Gruber VA, Tompkins DA. Drug Alcohol Depend. 2021 Sep 1;2…

High-dose intravenous hydromorphone for patients who use opioids in the hospital setting: time to reduce the barriers.

17. August 2021 | Substitutionsmittel Verschiedenes

High-dose intravenous hydromorphone for patients who use opioids in the hospital setting: time to reduce the barriers. Labonté, L.E., Young, S. Harm Reduct J 18, 87 (2021). doi.org/10.1186/s12954-021-00533-0 https://harmreductionj…

ÄZQ veröffentlicht drei aktualisierte Gesundheitsinformationen für Patienten

17. August 2021 | Methadon in der Krebsmedizin

ÄZQ veröffentlicht drei aktualisierte Gesundheitsinformationen für Patienten Berlin – Das Ärztliche Zentrum für Qualität in der Medizin (ÄZQ) hat drei seiner Kurzinformationen für Patienten auf den neuesten Stand gebracht: Testosteron bei älteren M…

Hydromorphone and codeine concentrations in oral fluid specimens from patients receiving substitution therapy with Substitol™ (morphine sulphate).

17. August 2021 | Morphin ret.

Hydromorphone and codeine concentrations in oral fluid specimens from patients receiving substitution therapy with Substitol™ (morphine sulphate). Lierheimer S, Beck O, Keller T, Monticelli FC, Böttcher M. Drug Test Anal. 2021 Jul 11…

Nasal Opioid Agonist Treatment in Patients with Severe Opioid Dependence: A Case Series.

17. August 2021 | Diamorphin

Nasal Opioid Agonist Treatment in Patients with Severe Opioid Dependence: A Case Series. Vogel M, Köck P, Strasser J, Kalbermatten C, Binder H, Dürsteler KM, Walter M, Falcato L, Krausz M, Kormann A. Eur Addict Res. 2021 Jul 26:1-6. do…

Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder.

17. August 2021 | Morphin ret.

Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder. Brothers TD, Fraser J, MacAdam E, Morgan B, Webster D. Drug Alcohol Rev. 2021 Aug 4. doi: 10.1111/dar.13365. Epub ah…

Treatment of opium addiction in persian medicine: A review study.

14. August 2021 | Substitutionsmittel Verschiedenes

Treatment of opium addiction in persian medicine: A review study. Kamali M, Kamali H, Doustmohammadi M, Sheikhbardsiri H, Moghadari M. J Educ Health Promot. 2021 May 20;10:157. doi: 10.4103/jehp.jehp_5_21. PMID: 34222532; PMCID: PMC822…

BISLANG KEIN NUTZEN BELEGT: METHADON GEGEN KREBS

14. August 2021 | Methadon in der Krebsmedizin

BISLANG KEIN NUTZEN BELEGT: METHADON GEGEN KREBS Liebe Leserin, lieber Leser, Sie haben fortgeschrittenen Krebs und fragen sich, ob Methadon Ihnen helfen kann? In dieser Information lesen Sie, was man über die Wirkung von Methadon und mögliche Ris…

USA. TIP 63: Medications for Opioid Use Disorder - Executive Summary

14. August 2021 | Substitutionsmittel Verschiedenes

USA. TIP 63: Medications for Opioid Use Disorder - Executive Summary The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid us…

USA. TIP 63: Medications for Opioid Use Disorder - For Healthcare and Addiction Professionals, Policymakers, Patients, and Families - Full Document

14. August 2021 | Substitutionsmittel Verschiedenes

USA. TIP 63: Medications for Opioid Use Disorder - For Healthcare and Addiction Professionals, Policymakers, Patients, and Families - Full Document This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration…

High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder.

24. Juli 2021 | Buprenorphin

High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. Herring AA, Vosooghi AA, Luftig J, et al. JAMA Netw Open. 2021;4(7):e2117128. doi:10.1001/jamanetworkopen.2021.17128 https://jama…

Heroin-Assisted Treatment and the United Nations international drug control apparatus

24. Juli 2021 | Diamorphin

Heroin-Assisted Treatment and the United Nations international drug control apparatus GDPO Working Paper Series Working Paper No. 7 (July 2021) - Christopher Hallam https://www.swansea.ac.uk/media/GDPO_Working_Paper_on-HAT_FINAL.pdf

Heroin auf Rezept (Audio)

24. Juli 2021 | Diamorphin

Heroin auf Rezept (Audio) (WDR 5 Quarks - Topthemen aus der Wissenschaft. 18.09.2019. 06:32, verfügbar bis 17.09.2024.) https://wdrmedien-a.akamaihd.net/medp/podcast/weltweit/fsk0/200/2005599/wdr5quarkstopthemenausderwissenschaft_2019-09-18_heroin…

UK. Middlesbrough heroin addiction clinic secures funding until March

15. Juli 2021 | Diamorphin

UK. Middlesbrough heroin addiction clinic secures funding until March A scheme which gives supervised diamorphine injections to heroin addicts is to be extended after securing new funding. (BBC, UK, 08.2021) https://www.bbc.com/news/uk-scotland-57…

Gender disparities in opioid treatment progress in methadone versus counseling.

15. Juli 2021 | Methadon zur Substitution

Gender disparities in opioid treatment progress in methadone versus counseling. Guerrero E, Amaro H, Kong Y, Khachikian T, Marsh JC. Subst Abuse Treat Prev Policy. 2021 Jun 23;16(1):52. doi: 10.1186/s13011-021-00389-4. PMID: 34162420;…

Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review.

15. Juli 2021 | Buprenorphin

Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review. Adams KK, Machnicz M, Sobieraj DM. Addict Sci Clin Pract. 2021 Jun 8;16(1):36. doi: 10.1186/s13722-021-00244-8. PMID: 34103087;…

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder.

15. Juli 2021 | Buprenorphin

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder. Chappuy M, Meroueh F, Trojak B, Bachellier J, Bendimerad P, Kosim M, Hjelmström P, Nubukpo P, Brou…

Advancing emergency department-initiated buprenorphine.

15. Juli 2021 | Buprenorphin

Advancing emergency department-initiated buprenorphine. Huntley K, Einstein E, Postma T, Thomas A, Ling S, Compton W. J Am Coll Emerg Physicians Open. 2021 Jun 16;2(3):e12451. doi: 10.1002/emp2.12451. PMID: 34179878; PMCID: PMC8208651…

Schottland. Methadone alternative rolled out after Scottish prisons trial

15. Juli 2021 | Buprenorphin

Schottland. Methadone alternative rolled out after Scottish prisons trial A drug used in a pilot scheme to help prisoners affected by heroin addiction is to be rolled out across Scotland. Buvidal acts as a replacement treatment for methadone, with…

Opium tincture-assisted treatment for opioid use disorder: A systematic review.

15. Juli 2021 | Substitutionsmittel Verschiedenes

Opium tincture-assisted treatment for opioid use disorder: A systematic review. Noroozi A, Kebriaeezadeh A, Mirrahimi B, Armoon B, Ahounbar E, Narenjiha H, Salehi M, Karamouzian M. J Subst Abuse Treat. 2021 Jun 4;129:108519. doi: 10.10…

Webinar. Long-acting buprenorphine in the treatment of opioid dependence: striking the balance between greater freedom and strong engagement

03. Juli 2021 | Buprenorphin

Webinar. Long-acting buprenorphine in the treatment of opioid dependence: striking the balance between greater freedom and strong engagement Watch the summer educational session led by Dr Julia Lewis, and joined by Dr Steve Brinksman that dis…

Schottland. Developing Heroin Assisted Treatment in Scotland – learning from current practice - SDF Webinar (Video)

03. Juli 2021 | Diamorphin

Schottland. Developing Heroin Assisted Treatment in Scotland – learning from current practice - SDF Webinar (Video) The Scottish Government has made its intentions clear regarding the provision of Heroin Assisted Treatment across Scotland. This wil…

'Apprentissage de l’élargissement des modalités de prescription de l’héroïne médicale avec le Covid-19',

21. Juni 2021 | Diamorphin

'Apprentissage de l’élargissement des modalités de prescription de l’héroïne médicale avec le Covid-19', Calzada, G., Giustiniani, J., Gois, T., Kuntz, A., Khazaal, Y., Zullino, D. (2021). Rev Med Suisse 2021; volume 7. no. 742, 1111 -…

Australien. New heroin treatment option yielding positive results among patients at Melbourne injecting rooms

18. Juni 2021 | Buprenorphin

Australien. New heroin treatment option yielding positive results among patients at Melbourne injecting rooms (…) The injectable is a slow-release version of buprenorphine available for patients to take once a week, once a month, or in Summer's cas…

Does Heroin-Assisted Treatment Reduce Crime? A Review of Randomized-Controlled Trials.

18. Juni 2021 | Diamorphin

Does Heroin-Assisted Treatment Reduce Crime? A Review of Randomized-Controlled Trials. Smart, R., and Reuter, P. (2021) Addiction, doi.org/10.1111/add.15601 Abstract https://onlinelibrary.wiley.com/doi/abs/10.1111/add…

Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway.

08. Juni 2021 | Methadon zur Substitution

Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway. Chalabianloo F, Fadnes LT, Høiseth G, Ohldieck C, Vold JH, Aas C, Løberg EM, Joh…

Differences in cue-induced brain activation between long-term methadone maintenance treatment and protracted abstinence in heroin use disorder patients: a functional magnetic resonance imaging study.

08. Juni 2021 | Methadon zur Substitution

Differences in cue-induced brain activation between long-term methadone maintenance treatment and protracted abstinence in heroin use disorder patients: a functional magnetic resonance imaging study. Wei X, Li Q, Chen J, Shen B, Wang W, Li W…

Advocating for diamorphine: Cosmopolitical care and collective action in the ruins of the 'old British system'.

08. Juni 2021 | Diamorphin

Advocating for diamorphine: Cosmopolitical care and collective action in the ruins of the 'old British system'. Dennis F. Crit Public Health. 2021;31(2):144-155. doi: 10.1080/09581596.2020.1772463. Epub 2020 Jun 4. PMID: 34079177; PMCI…

Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.

08. Juni 2021 | Buprenorphin

Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. Kosten T, Aharonovich E…

Emergency physician perspectives on initiating buprenorphine/naloxone in the emergency department: A qualitative study.

08. Juni 2021 | Buprenorphin

Emergency physician perspectives on initiating buprenorphine/naloxone in the emergency department: A qualitative study. Dong KA, Lavergne KJ, Salvalaggio G, Weber SM, Xue CJ, Kestler A, Kaczorowski J, Orkin AM, Pugh A, Hyshka E. J Am C…

Buprenorphine: Far Beyond the "Ceiling".

08. Juni 2021 | Buprenorphin

Buprenorphine: Far Beyond the "Ceiling". Infantino R, Mattia C, Locarini P, Pastore AL, Maione S, Luongo L. Biomolecules. 2021 May 31;11(6):816. doi: 10.3390/biom11060816. PMID: 34072706. https://www.mdpi.com/2218-273X/11/6/816

Extended-Release Buprenorphine and Its Evaluation With Patient-Reported Outcomes.

08. Juni 2021 | Buprenorphin

Extended-Release Buprenorphine and Its Evaluation With Patient-Reported Outcomes. Compton WM, Volkow ND. JAMA Netw Open. 2021 May 3;4(5):e219708. doi: 10.1001/jamanetworkopen.2021.9708. PMID: 33970262. https://jamanetwork.com/journals…

A novel maintenance therapeutic for Opioid Use Disorder.

08. Juni 2021 | Substitutionsmittel Verschiedenes

A novel maintenance therapeutic for Opioid Use Disorder. Youngblood B, Li K, Gehlert DR, Medina JC, Schwartz N. J Pharmacol Exp Ther. 2021 May 19:JPET-AR-2020-000214. doi: 10.1124/jpet.120.000214. Epub ahead of print. PMID: 34011529. https…

Prevalence and Characteristics of Chronic Pain in Buprenorphine and Methadone-Maintained Patients.

07. Juni 2021 | Methadon zur Substitution

Prevalence and Characteristics of Chronic Pain in Buprenorphine and Methadone-Maintained Patients. Delorme J, Pennel L, Brousse G, Daulouède JP, Delile JM, Lack P, Gérard A, Dematteis M, Kabore JL, Authier N, Chenaf C; TOXIDOL Study group.&nb…

Prevalence and Characteristics of Chronic Pain in Buprenorphine and Methadone-Maintained Patients.

07. Juni 2021 | Buprenorphin

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis.

07. Juni 2021 | Substitutionsmittel Verschiedenes

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. Santo T, Clark B, Hickman M, et al. JAMA Psychiatry. Publish…

Opioid Agonist Therapy reduces mortality risk among people with opioid dependence

07. Juni 2021 | Substitutionsmittel Verschiedenes

Opioid Agonist Therapy reduces mortality risk among people with opioid dependence A new global review has found that receiving Opioid Agonist Therapy (OAT) is associated with lower risk of multiple causes of death among people with opioid dependenc…

Opioid Agonist Therapy (OAT) associated with lower risk of multiple causes of death for people with opioid dependence

07. Juni 2021 | Substitutionsmittel Verschiedenes

Opioid Agonist Therapy (OAT) associated with lower risk of multiple causes of death for people with opioid dependence A new global review has found that receiving Opioid Agonist Therapy (OAT) is associated with lower risk of multiple causes of deat…

New Approaches in Drug Dependence: Opioids.

07. Juni 2021 | Substitutionsmittel Verschiedenes

New Approaches in Drug Dependence: Opioids. Mielau J, Vogel M, Gutwinski S, Mick I. Curr Addict Rep. 2021 May 26:1-8. doi: 10.1007/s40429-021-00373-9. Epub ahead of print. PMID: 34055568; PMCID: PMC8149259. https://www.ncbi.nlm.nih.go…

Methadon in der Krebsbehandlung - Das Forum für den fachlichen Austausch zu Methadon in der Medizin

07. Juni 2021 | Methadon in der Krebsmedizin

Methadon in der Krebsbehandlung - Das Forum für den fachlichen Austausch zu Methadon in der Medizin https://forum.methadon-krebsbehandlung-verein.de/

UK. Cleveland's new Police and Crime Commissioner says he won't continue funding Middlesbrough's Heroin Assisted Treatment

24. Mai 2021 | Diamorphin

UK. Cleveland's new Police and Crime Commissioner says he won't continue funding Middlesbrough's Heroin Assisted Treatment Cleveland's new Police and Crime Commissioner Steve Turner has been told he is "making a mistake" by ending funding from his…

ANDOPIO Study Group. Evaluation of functional status among patients undergoing maintenance treatments for opioid use disorders.

18. Mai 2021 | Methadon zur Substitution

ANDOPIO Study Group. Evaluation of functional status among patients undergoing maintenance treatments for opioid use disorders. Ruíz Ruíz JJ, Martinez Delgado JM, García-Marchena N; Harm Reduct J. 2021 Apr 13;18(1):41. doi: 10.1186/s12…

Influence of DRD2 Polymorphisms on the Clinical Outcomes of Opioiddependent Patients on Methadone Maintenance Therapy.

18. Mai 2021 | Methadon zur Substitution

Influence of DRD2 Polymorphisms on the Clinical Outcomes of Opioiddependent Patients on Methadone Maintenance Therapy. Zahari Z, Lee CS, Ibrahim MA, Musa N, Mohd Yasin MA, Lee YY, Tan SC, Mohamad N, Ismail R. J Pharm Bioallied Sci. 202…

Gender Differences on Methadone Maintenance Treatment Outcome among Patients with Opioid use Disorder: A Systematic Review.

18. Mai 2021 | Methadon zur Substitution

Gender Differences on Methadone Maintenance Treatment Outcome among Patients with Opioid use Disorder: A Systematic Review. Mohemmad Rizal MR, Hayat Khan A, Noor Harun S, Saleh Z. J Pharm Bioallied Sci. 2020 Nov;12(Suppl 2):S657-S662…

Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study.

18. Mai 2021 | Buprenorphin

Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study. Tay Wee Teck J, Baldacchino A, Gibson L, Lafferty C. Front Pharmacol. 2021 Mar 23;12:6…

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder.

18. Mai 2021 | Buprenorphin

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. De Aquino JP, Parida S, Sofuoglu M. Clin Drug Investig. 2021 Apr 5:1–12. doi: 10.1007/s40261-021-01032-7. Epub ahead of print. PMID: 33818748; PMCID: PMC8020374…

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.

13. Mai 2021 | Buprenorphin

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. Lintzeris N, Dunlop AJ, Haber PS, et al. JAMA Netw Open. 2021;4(5):e…

Australien. ‘Game changer’ treatment cuts heroin use

12. Mai 2021 | Buprenorphin

Australien. ‘Game changer’ treatment cuts heroin use An opioid treatment being introduced around Australia has been dubbed a game changer after dozens of users at Melbourne’s safe injecting room stopped taking heroin. The Richmond site was among t…

Poisoning Deaths Associated With Buprenorphine Almost Always Involve Sedatives or Other Opioids

09. Mai 2021 | Buprenorphin

Poisoning Deaths Associated With Buprenorphine Almost Always Involve Sedatives or Other Opioids Buprenorphine has a favorable safety profile because of its partial agonist and ceiling respiratory depression effects. However, there are poisoning dea…

Sixmo: Buprenorphin-6-Monatsimplantat erhält Zulassungsempfehlung

22. April 2021 | Buprenorphin

Sixmo: Buprenorphin-6-Monatsimplantat erhält Zulassungsempfehlung Das Buprenorphin-haltige 6-Monatsimplantat Sixmo hat eine Zulassungsempfehlung für die Substitutionstherapie von stabilen Opiatabhängigen mit einem maximalen Buprenorphin-Bedar…

EMA. Sixmo (Buprenorphin) - Übersicht über Sixmo und warum es in der EU zugelassen ist

22. April 2021 | Buprenorphin

EMA. Sixmo (Buprenorphin) - Übersicht über Sixmo und warum es in der EU zugelassen ist Was ist Sixmo und wofür wird es angewendet? Sixmo ist ein Implantat, das zur Behandlung einer Abhängigkeit von Opioiden wie Heroin oder Morphin angewendet wird…

Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.

11. April 2021 | Buprenorphin

Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Larance B, Degenhardt L, Grebely J, Nielsen S, Bruno R, Dietze P, Lancaster K, Larney S, Santo T Jr, Shanaha…

Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence.

11. April 2021 | Buprenorphin

Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence. Hard B. Case Rep Psychiatry. 2021 Feb 27;2021:6657350. doi: 10.1155/2021/6657350. PMID: 33728083;…

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.

11. April 2021 | Buprenorphin

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. Fava M, Thase ME, Trivedi MH, Ehrich E, Martin WF, Memisoglu A, Nangia N, Stanford AD, Yu M, Pathak S. …

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route.

11. April 2021 | Buprenorphin

Evaluation of Drug‐Drug Interaction Liability for Buprenorphine Extended‐Release Monthly Injection Administered by Subcutaneous Route. Kharidia, J., Howgate, E.M., Laffont, C.M., Liu, Y. and Young, M.A. (2021), Clinical Pharmacology in…

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis.

11. April 2021 | Buprenorphin

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis. McCormack L, Ponce J, Chatterjee A, Tan JK. JAAD Case Rep. 2021 Jan 11;10:22-24. doi: 10.1016/j.jdcr.2020.12.031. PMID: 33732840; PMCID: PMC7941000. https://www.nc…

Micro-dosing Intravenous Buprenorphine to Rapidly Transition From Full Opioid Agonists.

11. April 2021 | Buprenorphin

Micro-dosing Intravenous Buprenorphine to Rapidly Transition From Full Opioid Agonists. Thakrar AP, Jablonski L, Ratner J, Rastegar DA. J Addict Med. 2021 Mar 19. doi: 10.1097/ADM.0000000000000838. Epub ahead of print. PMID: 33758112…

Quality of Life in Opioid Replacement Therapy: A Naturalistic Cross-Sectional Comparison of Methadone/Levomethadone, Buprenorphine, and Diamorphine Patients.

02. April 2021 | Substitutionsmittel Verschiedenes

Quality of Life in Opioid Replacement Therapy: A Naturalistic Cross-Sectional Comparison of Methadone/Levomethadone, Buprenorphine, and Diamorphine Patients. Guillery SPE, Hellweg R, Kronenberg G, Bohr U, Kunte H, Enge S. Eur Addict Re…

SUBOXONE® Sublingualfilm ist jetzt für die Behandlung der Opioidabhängigkeit verfügbar

27. März 2021 | Buprenorphin

SUBOXONE® Sublingualfilm ist jetzt für die Behandlung der Opioidabhängigkeit verfügbar Mannheim - Indivior (INDV) gab heute bekannt, dass Suboxone® Sublingualfilm (Buprenorphin und Naloxon) jetzt in Deutschland für die Substitutionstherapie bei Opi…

The administration of the opioid buprenorphine decreases motivational error signals

27. März 2021 | Buprenorphin

The administration of the opioid buprenorphine decreases motivational error signals D.M. Pfabigan, M. Rütgen, S.L. Kroll, I. Riečanský, C. Lamm, Psychoneuroendocrinology, 2021, 105199, ISSN 0306-4530, doi.org/10.1016/j.psyneuen.2021.105199. In Pre…

Berlin. 15 Jahre Erhebungen zum sogenannten „Beikonsum“ - Was und wieviel konsumieren unsere Klienten* neben ihrem verschriebenen Substitutionsmedikament?

23. März 2021 | Substitutionsmittel Verschiedenes

Berlin. 15 Jahre Erhebungen zum sogenannten „Beikonsum“ - Was und wieviel konsumieren unsere Klienten* neben ihrem verschriebenen Substitutionsmedikament? 2005 ging es los – erstmals fragten wir das „Handlungswissen“ derjenigen ab, die im Notdienst…

UK. Guidance: Injectable opioid treatment: commissioning and providing services (2)

23. März 2021 | Diamorphin

UK. Guidance: Injectable opioid treatment: commissioning and providing services Guidance on commissioning and providing injectable opioid treatment for people with opioid dependence who have not responded to oral treatment. (Government UK, Pu…

RBP-6000: a rationally designed prolonged-release buprenorphine formulation

21. März 2021 | Buprenorphin

RBP-6000: a rationally designed prolonged-release buprenorphine formulation Authors: Wiest K., Shaya G., Somaini L., and Greenwald M. Summary: Background. RBP-6000 (Sublocade®; Subutex Prolonged Release Solution for Injection®) is a monthly prolon…

Substitution treatment for opioid dependence with slow-release oral morphine: Retention rate, health status, and substance use after switching to morphine,

21. März 2021 | Morphin ret.

Substitution treatment for opioid dependence with slow-release oral morphine: Retention rate, health status, and substance use after switching to morphine, Kirsten Lehmann, Silke Kuhn, Cinzia Baschirotto, Britta Jacobsen, Stephan Walcher, Herbert G…

Different formulations of methadone and levomethadone in the management of Opioid Use Disorder.

21. März 2021 | Methadon zur Substitution

Different formulations of methadone and levomethadone in the management of Opioid Use Disorder. Somaini L., Vecchio S., Salvatore D.F., Ercolini A., and Leonardi C. Heroin Addiction and Related Clinical Problems, Published Ahead of Print, March 18…

Different formulations of methadone and levomethadone in the management of Opioid Use Disorder.

21. März 2021 | Opioidsubstitution

Microdosing Case Study Series – Transferring from Methadone to Oral Buprenorphine

21. März 2021 | Methadon zur Substitution

Microdosing Case Study Series – Transferring from Methadone to Oral Buprenorphine Cassells N., Hill D.R., Marr E., and Stewart E. Heroin Addiction and Related Clinical Problems, Published Ahead of Print, December 4, 2020 Conclusions: The case stu…

A case study of methadone-induced delayed post-hypoxic leukoencephalopathy with improvement by antioxidant therapy.

21. März 2021 | Methadon zur Substitution

A case study of methadone-induced delayed post-hypoxic leukoencephalopathy with improvement by antioxidant therapy. Hakamifard A, Hajiahmadi S, Khorvash F, Azish S. North Clin Istanb. 2020 Aug 31;8(1):106-108. doi: 10.14744/nci.2020.29…

Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial.

14. März 2021 | Buprenorphin

Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. Wong JSH, Nikoo M, Westenberg JN, Sue…

Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence.

14. März 2021 | Buprenorphin

Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence. Robbins JL, Englander H, Gregg J. J Am Board Fam Med. 2021 Feb;34(Suppl):S141-S146. doi: 10.3122/jabfm.2021.S1.200236. PMID: 33622829. https://www…

Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans.

14. März 2021 | Diamorphin

Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans. Eydt E, Glegg S, Sutherland C, Meador K, Trew M, Perreault M, Goyer MÈ, Le Foll B, Turnbull J, Fairbairn N. CMAJ Open. 2021 Fe…

Are people with opioid use disorder interested in an innovative treatment option?

05. März 2021 | Diamorphin

Are people with opioid use disorder interested in an innovative treatment option? Opioid-involved overdose deaths are continuing to rise. A substantial proportion of individuals with opioid use disorder do not receive treatment and, for those that…

Opioid overdose reduced in patients taking buprenorphine

05. März 2021 | Buprenorphin

Opioid overdose reduced in patients taking buprenorphine Study indicates the drug is effective in opioid users who also take benzodiazepines for anxiety, other conditions. (Washington University School of Medicine, 02.03.2021) https://medicine.wus…

Suchtrehabilitation von Opioidabhängigen in Behandlung mit injizierbarem, subkutanem Depot-Buprenorphin (ARIDE) - Addiction recovery of opioid dependent patients treated with injectable subcutaneous depot buprenorphine (ARIDE)

01. März 2021 | Buprenorphin

Suchtrehabilitation von Opioidabhängigen in Behandlung mit injizierbarem, subkutanem Depot-Buprenorphin (ARIDE) - Addiction recovery of opioid dependent patients treated with injectable subcutaneous depot buprenorphine (ARIDE) Wir freuen uns ü…

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.

27. Februar 2021 | Buprenorphin

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone. Rolland B, Trojak B, Nourredine M, Bachellier J, Chappuy M, Bendimerad P, Kosim M, Hjelmström P, Meroueh…

Intravenous Buprenorphine Micro-dosing Induction in a Patient on Methadone Treatment: A Case Report.

27. Februar 2021 | Buprenorphin

Intravenous Buprenorphine Micro-dosing Induction in a Patient on Methadone Treatment: A Case Report. Crane K, Snead J, Stanley R, Avery J, Ghosh SM, Mints G. Psychosomatics. 2020 Jul 25:S0033-3182(20)30213-9. doi: 10.1016/j.psym.2020.0…

Microdosing and standard-dosing take-home buprenorphine from the emergency department: A feasibility study.

27. Februar 2021 | Buprenorphin

Microdosing and standard-dosing take-home buprenorphine from the emergency department: A feasibility study. Moe J, Badke K, Pratt M, Cho RY, Azar P, Flemming H, Sutherland KA, Harvey B, Gurney L, Lockington J, Brasher P, Gill S, Garrod E, Bat…

Schweiz. Grünes Licht für Studie mit Diaphin zur intranasalen Anwendung

27. Februar 2021 | Diamorphin

Schweiz. Grünes Licht für Studie mit Diaphin zur intranasalen Anwendung https://arud.ch/newsletter/newsletter-februar-2021

Reasons for Increasing Daily Methadone Maintenance Dosage among Deceptive Patients: A Qualitative Study.

04. Februar 2021 | Methadon zur Substitution

Reasons for Increasing Daily Methadone Maintenance Dosage among Deceptive Patients: A Qualitative Study. Khosravi M, Kasaeiyan R. J Med Life. 2020 Oct-Dec;13(4):572-579. doi: 10.25122/jml-2020-0038. PMID: 33456609; PMCID: PMC7803314…

UK. John Marks, heroin prescribing and HAT (Audio)

03. Februar 2021 | Diamorphin

UK. John Marks, heroin prescribing and HAT (Audio) This episode explores the issue of prescribing heroin to people with heroin problems, a practice with a long history and usually today termed Heroin Assisted Treatment or HAT. The episode draws on…

Effectiveness of incentivised adherence and abstinence monitoring in buprenorphine maintenance: a pragmatic, randomised controlled trial.

03. Februar 2021 | Buprenorphin

Effectiveness of incentivised adherence and abstinence monitoring in buprenorphine maintenance: a pragmatic, randomised controlled trial. Elarabi, H. F., Shawky, M., Mustafa, N., Radwan, D., Elarasheed, A., Yousif Ali, A., Osman, M., Kashmar…

Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France.

03. Februar 2021 | Buprenorphin

Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France. Mezaache, S., Carrieri, P., Briand-Madrid, L. et al Harm Reduct J 18, 11…

When Physical and Social Pain Coexist: Insights Into Opioid Therapy

22. Januar 2021 | Substitutionsmittel Verschiedenes

When Physical and Social Pain Coexist: Insights Into Opioid Therapy Mark D. Sullivan, Jane C. Ballantyne The Annals of Family Medicine Jan 2021, 19 (1) 79-82; DOI: 10.1370/afm.2591 https://www.annfammed.org/content/19/1/79

d,l-Methadone causes leukemic cell apoptosis via an OPRM1-triggered increase in IP3R-mediated ER Ca2+ release and decrease in Ca2+ efflux, elevating [Ca2+]i.

22. Januar 2021 | Methadon in der Krebsmedizin

d,l-Methadone causes leukemic cell apoptosis via an OPRM1-triggered increase in IP3R-mediated ER Ca2+ release and decrease in Ca2+ efflux, elevating [Ca2+]i. Lee, J., Rosales, J.L., Byun, HG. et al. Sci Rep 11, 1009 (2021). doi.org/10…

DROGENKURIER - magazin des jes-bundesverbands, dez. 2020 nr. 124 -- Wann wird die Diamorphin-substitution zur gleichwertigen Behandlung?

18. Januar 2021 | Diamorphin

DROGENKURIER - magazin des jes-bundesverbands, dez. 2020 nr. 124 -- Wann wird die Diamorphin-substitution zur gleichwertigen Behandlung? https://www.diamorphin.com/assets/files/Drogenkurier_WDA.pdf

Online Event. Heroin Assisted Treatment

13. Januar 2021 | Diamorphin

Online Event. Heroin Assisted Treatment Wed, 27 January 2021, 14:00 – 15:30 GMT. Middlesbrough has been operating England's only Heroin Assisted Treatment programme for 18mths with some fantastic early findings. The programme has seen dramati…

Diamorphingestützte Substitutionsbehandlung: Die tägliche Spritze

13. Januar 2021 | Diamorphin

Diamorphingestützte Substitutionsbehandlung: Die tägliche Spritze Bühring, Petra Dtsch Arztebl 2020; 117(1-2): A-16 / B-18 / C-18 https://www.aerzteblatt.de/archiv/211759/Diamorphingestuetzte-Substitutionsbehandlung-Die-taegliche-Spritze

Bericht über die Methadon-Behandlung des niedersächsischen Jugendberatungszentrums Hannover des DPWV

09. Januar 2021 | Opioidsubstitution

Bericht über die Methadon-Behandlung des niedersächsischen Jugendberatungszentrums Hannover des DPWV Dr.med. Jürgen Lotze, Marie-Louise Rabe, Hartmut Stichtenoth Niedersächsisches Ärzteblatt, Nr. 11. 46.Jahrgang, 7. Juni 1973, 359-362 Lotze_Polam…

Heroin-assisted treatment of heroin-addicted patients normalizes regulatory T cells but does not restore CD4+ T cell proliferation.

05. Januar 2021 | Diamorphin

Heroin-assisted treatment of heroin-addicted patients normalizes regulatory T cells but does not restore CD4+ T cell proliferation. Hansen W, Luppus S, Barthel R, Chang DI, Broemstrup J, Zwarg T, Shibata J, Westendorf AM, Buer J, Scherbaum N…

Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE).

05. Januar 2021 | Buprenorphin

Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE). Schulte B, Lehmann K, Schmidt CS, Rühling E, Weber B, Sch…

Methadone Suppresses Neuronal Function and Maturation in Human Cortical Organoids.

05. Januar 2021 | Methadon zur Substitution

Methadone Suppresses Neuronal Function and Maturation in Human Cortical Organoids. Wu W, Yao H, Dwivedi I, Negraes PD, Zhao HW, Wang J, Trujillo CA, Muotri AR, Haddad GG. Front Neurosci. 2020 Nov 23;14:593248. doi: 10.3389/fnins.2020.5…

Buprenorphine-naloxone microdosing: Tool for opioid agonist therapy induction.

05. Januar 2021 | Buprenorphin

Buprenorphine-naloxone microdosing: Tool for opioid agonist therapy induction. Marwah R, Coons C, Myers J, Dumont Z. Can Fam Physician. 2020 Dec;66(12):891-894. French. doi: 10.46747/cfp.6612891. Erratum in: Can Fam Physician. 2020 Dec…

Case Series: Rapid Induction Onto Long Acting Buprenorphine Injection for High Potency Synthetic Opioid Users.

05. Januar 2021 | Buprenorphin

Case Series: Rapid Induction Onto Long Acting Buprenorphine Injection for High Potency Synthetic Opioid Users. Mariani JJ, Mahony A, Iqbal MN, Luo SX, Naqvi NH, Levin FR. Am J Addict. 2020 Jul;29(4):345-348. doi: 10.1111/ajad.13018. Epub 202…

Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent.

05. Januar 2021 | Methadon in der Krebsmedizin

Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent. Haas B, Ciftcioglu J, Jermar S, Weickhardt S, Eckstein N, Kaina B. J Cancer Res Clin Oncol. 2020 Dec 14. doi: 10.1007/s00432-020-03485-3. Epub ahea…

Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market.

28. Dezember 2020 | Buprenorphin

Buprenorphine-naloxone "microdosing": an alternative induction approach for the treatment of opioid use disorder in the wake of North America's increasingly potent illicit drug market. Randhawa PA, Brar R, Nolan S. CMAJ. 2020 Jan 20;19…

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach.

28. Dezember 2020 | Buprenorphin

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach. Rozylo J, Mitchell K, Nikoo M, Durante SE, Barbic SP, Lin D, Mathias S, Azar P. Addict Sci Clin Pract. 2020 Jan 15;15(1):2…

From methadone to Methadose: Lessons learned from methadone formulation change in British Columbia.

25. Dezember 2020 | Methadon zur Substitution

From methadone to Methadose: Lessons learned from methadone formulation change in British Columbia. Raski M, Sutherland C, Brar R. Can Fam Physician. 2020 Nov;66(11):797-798. PMID: 33208417. https://www.cfp.ca/content/66/11/797.long

The effect of methadone on depression among addicts: a systematic review and meta-analysis.

25. Dezember 2020 | Methadon zur Substitution

The effect of methadone on depression among addicts: a systematic review and meta-analysis. Mohammadi M, Kazeminia M, Abdoli N, Khaledipaveh B, Shohaimi S, Salari N, Hosseinian-Far M. Health Qual Life Outcomes. 2020 Nov 23;18(1):373. d…

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder.

25. Dezember 2020 | Buprenorphin

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder. Seguí HA, Melin K, Quiñones DS, Duconge J. J Transl Genet Genom. 2020;4:263-277. doi: 10.20517/jtgg.2020.35. Epub 2020 Jul 30. PMID: 33274315;…

Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine.

25. Dezember 2020 | Buprenorphin

Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine. Parsons G, Ragbir C, D'Agnone O, Gibbs A, Littlewood R, Hard B. Subst Abuse Rehabil. 2020 Nov 2;11:41-47. doi…

Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department.

25. Dezember 2020 | Buprenorphin

Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department. Martin A, Butler K, Chavez T, Herring A, Wakeman S, Hayes BD, Raja A. West J Emerg Med. 2020 Nov 2;21(6):257-263. doi: 10.5811/westjem.2020.7.46079…

Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders.

25. Dezember 2020 | Buprenorphin

Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders. Bestepe EE, Tunali N, Sarıdoğan GE. Neuropsychiatr Dis Treat. 2020 Nov 12;16:2695-2705. doi: 10.2147/NDT.S276…

Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment.

25. Dezember 2020 | Substitutionsmittel Verschiedenes

Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment. Gicquelais RE, Bohnert ASB, Thomas L, Foxman B. Sci Rep. 2020 Nov 10;10(1):19471. doi: 10.1038/s41598-020-76570-9. PMID: 331730…

Schweiz. Heroingestützte Behandlung in der Schweiz

07. Dezember 2020 | Diamorphin

Schweiz. Heroingestützte Behandlung in der Schweiz Seit 2001 gibt es ein regelmässiges Monitoring der heroingestützten Behandlung (HeGeBe) in der Schweiz. Dieser Bericht (pdf, 39S.) präsentiert die Ergebnisse der Erhebung 2019. Der Name HeGeBe ist…

The effect of crocin (the main active saffron constituent) on the cognitive functions, craving, and withdrawal syndrome in opioid patients under methadone maintenance treatment.

26. November 2020 | Methadon zur Substitution

The effect of crocin (the main active saffron constituent) on the cognitive functions, craving, and withdrawal syndrome in opioid patients under methadone maintenance treatment. Abbaszadeh-Mashkani S, Hoque SS, Banafshe HR, Ghaderi A. …

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study.

26. November 2020 | Buprenorphin

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study. Ling W, Nadipelli VR, Aldridge AP, Ronquest NA, Solem CT, Chilcoat H, Albright V…

How do individuals fare long-term after receiving long-acting, injectable formulations of buprenorphine for opioid use disorder?

26. November 2020 | Buprenorphin

How do individuals fare long-term after receiving long-acting, injectable formulations of buprenorphine for opioid use disorder? Evidence has mounted regarding the short-term effectiveness of long-acting buprenorphine formulations for opioid use di…

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine.

26. November 2020 | Buprenorphin

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine. Blazes CK, Morrow JD. Front Psychiatry. 2020 Sep 11;11:549272. doi: 10.3389/fpsyt.2020.549272. PMID: 33061915; PMCID: PMC7517938. https://www.ncbi.nlm.nih.gov/pmc/artic…

Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block.

26. November 2020 | Buprenorphin

Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. Tran PN, Sheng J, Randolph AL, Baron CA, Thiebaud N, Ren M, et al. (2020) PLoS ONE 15(11): e0241362. doi.org/10.1371/journal.pone.0241362…

Prescribing Buprenorphine for Opioid Use Disorders in the ED: A Review of Best Practices, Barriers, and Future Directions.

26. November 2020 | Buprenorphin

Prescribing Buprenorphine for Opioid Use Disorders in the ED: A Review of Best Practices, Barriers, and Future Directions. Cao SS, Dunham SI, Simpson SA. Open Access Emerg Med. 2020 Oct 14;12:261-274. doi: 10.2147/OAEM.S267416. PMID: 3…

Trends in the Use of Buprenorphine in US Emergency Departments, 2002-2017.

26. November 2020 | Buprenorphin

Trends in the Use of Buprenorphine in US Emergency Departments, 2002-2017. Rhee TG, D'Onofrio G, Fiellin DA. JAMA Netw Open. 2020 Oct 1;3(10):e2021209. doi: 10.1001/jamanetworkopen.2020.21209. PMID: 33079195; PMCID: PMC7576404. https…

Novel forms of injectable buprenorphine and French model of opioid use disorder treatment.

26. November 2020 | Buprenorphin

Novel forms of injectable buprenorphine and French model of opioid use disorder treatment. Lapeyre-Mestre M. Therapie. 2020 Sep-Oct;75(5):393-395. doi: 10.1016/j.therap.2020.09.007. Epub 2020 Sep 28. PMID: 33039103; PMCID: PMC7521403. https…

NRW/Holzwickede: Kontrollierte Heroinabgabe an Schwerstabhängige

10. November 2020 | Diamorphin

NRW/Holzwickede: Kontrollierte Heroinabgabe an Schwerstabhängige 200 Suchtpatienten sollen künftig in einer Arztpraxis in Holzwickede im Kreis Unna kontrolliert mit Heroin versorgt werden. (WDR, 27.10.2020) https://www1.wdr.de/nachrichten/ru…

UK. Middlesbrough heroin injection scheme hailed a success

10. November 2020 | Diamorphin

UK. Middlesbrough heroin injection scheme hailed a success A pilot scheme which gives supervised diamorphine injections to heroin addicts has been hailed as a success by those behind it, one year on. The programme, based in Middlesbrough, focuses o…

Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study.

09. November 2020 | Diamorphin

Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study. Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, McNeil R. Drug Alcohol Depend. 2020 Nov 1;216:10…

Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study.

09. November 2020 | Substitutionsmittel Verschiedenes

Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.

30. Oktober 2020 | Buprenorphin

Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report. Szczesniak, L.M., Calleo, V.J. & Sullivan, R.W. Harm Reduct J 17, 71 (2020). doi.org/10.1186/s12954-020-00417-9 https://harmred…

'Game-changer' drug to tackle addiction

30. Oktober 2020 | Buprenorphin

'Game-changer' drug to tackle addiction For more than 20 years, Dougie's life was a vicious cycle of drugs, crime and the death of people close to him. But for the past nine months he has been taking a medication that blocks his craving for heroin…

NRW/Unna. Diamorphinambulanz in Holzwickede: Stellungnahme der Aidshilfe im Kreis Unna

30. Oktober 2020 | Diamorphin

NRW/Unna. Diamorphinambulanz in Holzwickede: Stellungnahme der Aidshilfe im Kreis Unna Die Aidshilfe im Kreis Unna begrüßt die Pläne zur Eröffnung einer Diamorphin-Ambulanz in Holzwickede ausdrücklich. Mit dem Angebot wird in der Region eine wichti…

NRW/Unna. Geplante Diamorphin-Ambulanz für Süchtige sorgt für Diskussionen in Howi

30. Oktober 2020 | Diamorphin

NRW/Unna. Geplante Diamorphin-Ambulanz für Süchtige sorgt für Diskussionen in Howi Drogensüchtige sollen in Holzwickede über ein Diamorphin-Programm versorgt werden. Die geplante Praxis war gestern Gegenstand eines Informationsabends. (Rundblick-Un…

NRW/Holzwickede: Pläne für Heroin-Ambulanz

30. Oktober 2020 | Diamorphin

NRW/Holzwickede: Pläne für Heroin-Ambulanz In Holzwickede sind die Pläne für eine so genannte Heroin-Ambulanz vorgestellt worden. Die Gemeinde hatte zu dem Infoabend eingeladen, zu dem rund 40 Leute kamen. Die Ambulanz soll bis…

Fifteen years of heroin-assisted treatment in a Swiss prison—a retrospective cohort study.

30. Oktober 2020 | Diamorphin

Fifteen years of heroin-assisted treatment in a Swiss prison—a retrospective cohort study. Liebrenz, M., Gamma, A., Buadze, A. et al. Harm Reduct J 17, 67 (2020). doi.org/10.1186/s12954-020-00412-0 https://harmreductionjourna…

Diamorphingestützte Behandlung in Deutschland – Stand 2020

11. Oktober 2020 | Diamorphin

Diamorphingestützte Behandlung in Deutschland – Stand 2020 Christian Plattner 7. Alternativer Drogen- und Suchtbericht 2020, Seiten 47-49, Hrsg.: akzept e.V., Deutsche Aidshilfe, Berlin im Oktober 2020 https://alternativer-drogenbericht.de/…

Toward patient-tailored therapy in agonist opioid treatment: the role of psychopathology, craving behavioural covariates, stress reaction and methadone blood concentration. A case series

11. Oktober 2020 | Methadon zur Substitution

Toward patient-tailored therapy in agonist opioid treatment: the role of psychopathology, craving behavioural covariates, stress reaction and methadone blood concentration. A case series Maremmani A.G.I., Bacciardi S., Maremmani I., Della Rocca F…

Effectiveness, tolerability and safety of a long-term therapy with levomethadone in clinical practice: a retrospective observational study

11. Oktober 2020 | Opioidsubstitution

Effectiveness, tolerability and safety of a long-term therapy with levomethadone in clinical practice: a retrospective observational study Consoli A. Heroin Addiction and Related Clinical Problems, Published Ahead of Print, September 17, 2020 htt…

Opioid-Agonisten-Therapie bei Opioidabhängigkeit [Opioid Agonist Therapy (OAT) for opioid dependency

09. Oktober 2020 | Substitutionsmittel Verschiedenes

Opioid-Agonisten-Therapie bei Opioidabhängigkeit [Opioid Agonist Therapy (OAT) for opioid dependency Köck P, Strasser J. Ther Umsch. 2020;77(1):29-36. German. doi: 10.1024/0040-5930/a001148. PMID: 32486990. Abstract https://econtent.hogref…

Betäubungsmittel im Fokus: Sonderfall Substitutionstherapie

09. Oktober 2020 | Substitutionsmittel Verschiedenes

Betäubungsmittel im Fokus: Sonderfall Substitutionstherapie Verordnungen von Substitutionsmitteln sind ein Fall für sich. Bei der Bearbeitung eines solchen Rezepts gilt es zahlreiche Regelungen zu beachten. Der siebte Teil der PZ-Serie »Betäu…

A mixed‐methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community‐based care in England and Wales.

09. Oktober 2020 | Buprenorphin

A mixed‐methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community‐based care in England and Wales. Gibson, R., MacLeod, N., Donaldson, L. J., Williams, H…

A mixed‐methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community‐based care in England and Wales.

09. Oktober 2020 | Methadon zur Substitution

Should Buprenorphine Induction Dosing Be Lower for the Elderly Population With Opioid Use Disorder? A Case of Buprenorphine-Induced Hemodynamic Instability.

09. Oktober 2020 | Buprenorphin

Should Buprenorphine Induction Dosing Be Lower for the Elderly Population With Opioid Use Disorder? A Case of Buprenorphine-Induced Hemodynamic Instability. Chaparro A, Ravishankar DA, Sethi R. Prim Care Companion CNS Disord. 2020 Sep…

Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada

09. Oktober 2020 | Buprenorphin

Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. Piske M, Thomson T, Krebs E, Hongdilokkul N, Bruneau J, Gr…

Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada

09. Oktober 2020 | Methadon zur Substitution

Buprenorphine Implants, Injections Are Underused.

09. Oktober 2020 | Buprenorphin

Buprenorphine Implants, Injections Are Underused. Rubin R. JAMA. 2020 Sep 22;324(12):1128. doi: 10.1001/jama.2020.17587. PMID: 32960225. https://jamanetwork.com/journals/jama/fullarticle/2770828

Buprenorphine for Opioid Use Disorder in the Emergency Department: A Retrospective Chart Review.

09. Oktober 2020 | Buprenorphin

Buprenorphine for Opioid Use Disorder in the Emergency Department: A Retrospective Chart Review. LeSaint KT, Klapthor B, Wang RC, Geier C. West J Emerg Med. 2020 Aug 24;21(5):1175-1181. doi: 10.5811/westjem.2020.6.46452. PMID: 32970572…

Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug‐related poisoning deaths? A retrospective cohort study.

13. September 2020 | Methadon zur Substitution

Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug‐related poisoning deaths? A retrospective cohort study. Durand, L., O'Driscoll, D., Boland, F., Keenan, E., Ryan…

OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis.

13. September 2020 | Buprenorphin

OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis. Wright N, Hard J, Fearns C, Gilman M, Littlewood R, Clegg R, Parimelalagan L, Alam F. Clinicoecon Outcomes Res. 2020;12:499-504, do…

UK. ‘Very promising’: UK’s first full heroin-prescribing scheme extended after reductions in crime and homelessness

13. September 2020 | Diamorphin

UK. ‘Very promising’: UK’s first full heroin-prescribing scheme extended after reductions in crime and homelessness ‘Prison, increased sentencing, police crackdowns and all other efforts to break that cycle have failed,’ says police and crime commi…

Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use

06. September 2020 | Methadon zur Substitution

Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use Ramli FF. [published online ahead of print, 2020 Aug 11]. Bosn J Basic Med Sci. 2020;10.17305/bjbms.2020.4897. doi:1…

Hospital Initiated Injectable Opioid Agonist Therapy for the Treatment of Severe Opioid Use Disorder: A Case Series

06. September 2020 | Diamorphin

Hospital Initiated Injectable Opioid Agonist Therapy for the Treatment of Severe Opioid Use Disorder: A Case Series Brar R, Fairbairn N, Colizza K, Ryan A, Nolan S. [published online ahead of print, 2020, Aug 4]. J Addict Med. 2020…

Hospital Initiated Injectable Opioid Agonist Therapy for the Treatment of Severe Opioid Use Disorder: A Case Series

06. September 2020 | Substitutionsmittel Verschiedenes

Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.

06. September 2020 | Buprenorphin

Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. Tompkins CNE, Neale J, Strang J. J Subst Abuse Treat. 2019;104:64-71. doi:10.1016/j.jsat.2019.06.007 https://www.journalofsub…

Buprenorphine Treatment for Opioid Use Disorder: An Overview.

06. September 2020 | Buprenorphin

Buprenorphine Treatment for Opioid Use Disorder: An Overview. Shulman M, Wai JM, Nunes EV. CNS Drugs. 2019;33(6):567-580. doi:10.1007/s40263-019-00637-z https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585403/

Comparing the Efficacy of Methadone and Tincture of Opium in Controlling Agitation Caused by Withdrawal Syndrome in Opium-Addicted Patients in the Intensive Care Unit: A Randomized Trial Study.

05. September 2020 | Methadon zur Substitution

Comparing the Efficacy of Methadone and Tincture of Opium in Controlling Agitation Caused by Withdrawal Syndrome in Opium-Addicted Patients in the Intensive Care Unit: A Randomized Trial Study. Sohrevardi SM, Pournamdari M, Salimi R, Sarrafza…

Online-Fachtag "Diamorphin, Substitution, Versorgung“ 16.09.2020

05. September 2020 | Diamorphin

Online-Fachtag "Diamorphin, Substitution, Versorgung“ 16.09.2020 Der Online-Fachtag findet über das Videokonferenzsystem ZOOM statt. Uhrzeit: 13:45 Uhr -16.30 Uhr, Veranstalter: Landesverband akzept NRW e.V. in Kooperation mit der Stiftu…

UK. Middlesbrough heroin injection scheme to be extended

30. August 2020 | Diamorphin

UK. Middlesbrough heroin injection scheme to be extended A pilot scheme which gives supervised heroin injections to addicts has been extended for a further year following "promising results". The heroin assisted treatment programme, based in Middl…

Buprenorphine Treatment for Opioid Use Disorder in Community‐Based Settings: Outcome Related to Intensity of Services and Urine Drug Test Results.

30. August 2020 | Buprenorphin

Buprenorphine Treatment for Opioid Use Disorder in Community‐Based Settings: Outcome Related to Intensity of Services and Urine Drug Test Results. Galanter, M., Femino, J., Hunter, B. and Hauser, M. (2020), Am J Addict, 29: 271-278. do…

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy.

23. August 2020 | Buprenorphin

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy. Towers CV, Deisher H. Case Rep Obstet Gynecol. 2020;2020:3127676. Published 2020 Jul 17. doi:10.1155/2020/3127676 Subcutaneous Extended-Release Buprenorphine Use in Pregnan…

Medications for opioid use disorders: clinical and pharmacological considerations.

23. August 2020 | Substitutionsmittel Verschiedenes

Medications for opioid use disorders: clinical and pharmacological considerations. Volkow ND, Blanco C. J Clin Invest. 2020;130(1):10-13. doi:10.1172/JCI134708 Medications for opioid use disorders: clinical and pharmacological conside…

Methadone Inhibits Viral Restriction Factors and Facilitates HIV Infection in Macrophages.

23. August 2020 | Methadon zur Substitution

Methadone Inhibits Viral Restriction Factors and Facilitates HIV Infection in Macrophages. Wang MR, Wu DD, Luo F, et al. Front Immunol. 2020;11:1253. Published 2020 Jul 3. doi:10.3389/fimmu.2020.01253 Methadone Inhibits Viral Restriction Fa…

Atomic-Level Characterization of the Methadone-Stabilized Active Conformation of µ-Opioid Receptor

23. August 2020 | Methadon zur Substitution

Atomic-Level Characterization of the Methadone-Stabilized Active Conformation of µ-Opioid Receptor Kapoor A, Provasi D, Filizola M. [published online ahead of print, 2020 Jul 17]. Mol Pharmacol. 2020;mol.119.119339. doi:10.1124/mo…

Kanada. A Domestic Safe Supply of Injectable Heroin Would Save Lives

23. August 2020 | Diamorphin

Kanada. A Domestic Safe Supply of Injectable Heroin Would Save Lives And a new BC company has just formed to produce it. It’s up to the province now. (The Tyee, Kanada, 10.08.2020) Kanada. A Domestic Safe Supply of Injectable Heroin Would Save Liv…

Vorteile und Chancen von Depot-Buprenorphin in der alltäglichen Praxis

09. August 2020 | Buprenorphin

Vorteile und Chancen von Depot-Buprenorphin in der alltäglichen Praxis Mannheim/Lund, 29.07.2020 – Mit der wachsenden Erfahrung zum Einsatz des Depot-Buprenorphin Buvidal® seit seiner Einführung im Februar 2019 zeichnen sich die Vorteile und Chance…

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study

09. August 2020 | Buprenorphin

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study Larance B, Byrne M, Lintzeris N On behalf of the CoLAB study team, et al BMJ Open 2020;10:e034389…

Reducing harm through the development of good preparation practices for the injection of slow release morphine sulphate capsules.

09. August 2020 | Morphin ret.

Reducing harm through the development of good preparation practices for the injection of slow release morphine sulphate capsules. Keijzer, L. Harm Reduct J 17, 48 (2020). doi.org/10.1186/s12954-020-00389-w Reducing harm thro…

MEFOX-Studie: Eine klinische Studie zur Kombination von Methadonhydrochlorid und FOLFOX zur Therapie des fortgeschrittenen Darmkrebses

09. August 2020 | Methadon in der Krebsmedizin

Ulm. Was eine Forscherin darf - und was nicht

09. August 2020 | Methadon in der Krebsmedizin

Ulm. Was eine Forscherin darf - und was nicht Erschwert die Uni der Chemikerin Claudia Friesen die Arbeit? SPD-Politikerin Hilde Mattheis sieht Anzeichen dafür. Der Medizin-Dekan sagt, das Gegenteil sei der Fall. (Südwestpresse, 27.07.2020) www.pr…

Substitutionsbehandlung und Lebensqualität: Methadon vs. retardiertes Morphinsulfat – eine Vergleichsstudie

09. August 2020 | Morphin ret.

Substitutionsbehandlung und Lebensqualität: Methadon vs. retardiertes Morphinsulfat – eine Vergleichsstudie Salvatore M. Giacomuzzi, Y. Riemer2, M. Ertl, G. Kemmler, R. Richter, H. Rössler, H. Hinterhuber Suchtmed 3 (1) 2001 Diskussio…

„Methadon in der Krebsbehandlung Deutschland e.V.“

05. August 2020 | Methadon in der Krebsmedizin

„Methadon in der Krebsbehandlung Deutschland e.V.“ Methadon in der Krebstherapie sucht den Austausch. Als Verein möchten wir mit fachlichen Informationen und Erfahrungen von Betroffenen und Ärzten lösungsorientiert weiterhelfen. Mit Ihrer Mitglied…

Methadone‐related deaths among youth and young adults in Sweden 2006–15.

18. Juli 2020 | Methadon zur Substitution

Methadone‐related deaths among youth and young adults in Sweden 2006–15. Fugelstad, A., Bremberg, S., Hjelmström, P., and Thiblin, I. (2020) Addiction, doi.org/10.1111/add.15152. https://onlinelibrary.wiley.com/doi/full/…

Kanada. Prof, former public health officer launch company to produce legal heroin for treatment

18. Juli 2020 | Diamorphin

Kanada. Prof, former public health officer launch company to produce legal heroin for treatment Long before fentanyl transformed the illicit drug market, researchers in Vancouver embarked on a study that would open the door in Canada to a new form…

Buprenorphine. Alan Cowan, researcher who helped develop drug used to treat opioid addiction, dies at 77

11. Juli 2020 | Buprenorphin

Buprenorphine. Alan Cowan, researcher who helped develop drug used to treat opioid addiction, dies at 77 Alan Cowan, 77, of Ambler, a Philadelphia pharmacology professor, and before that a researcher who in his first professional job helped develop…

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates.

07. Juli 2020 | Buprenorphin

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. Kovar L, Schräpel C, Selzer D, et al. Pharmaceutics. 2020;12(6):E578. Published 2020 Jun 23. doi:10.3390/pharmaceutics1206…

A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.

07. Juli 2020 | Morphin ret.

A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine. Kinzler ER, Pantaleon C, Iverson M, Aigner S. Ad…

An Efficient and Smooth Methadone-to-Buprenorphine Transition Protocol Utilizing a Transdermal Fentanyl Bridge and a Pharmacokinetic Inducer: The Stanciu Method.

07. Juli 2020 | Methadon zur Substitution

An Efficient and Smooth Methadone-to-Buprenorphine Transition Protocol Utilizing a Transdermal Fentanyl Bridge and a Pharmacokinetic Inducer: The Stanciu Method. Stanciu CN, Gibson S, Teja N, Healey CJ. Cureus. 2020;12(5):e8310. Publis…

An Efficient and Smooth Methadone-to-Buprenorphine Transition Protocol Utilizing a Transdermal Fentanyl Bridge and a Pharmacokinetic Inducer: The Stanciu Method.

07. Juli 2020 | Buprenorphin

Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment

07. Juli 2020 | Methadon zur Substitution

Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment Baldassarri SR, Beitel M, Zinchuk A, et al. [published online ahead of print, 2020 Jun 17]. Sleep Breath…

Contamination in Opium, Opium Tincture, and Methadone Oral Solution, in Iran.

07. Juli 2020 | Methadon zur Substitution

Contamination in Opium, Opium Tincture, and Methadone Oral Solution, in Iran. Rahimi M, Eshraghi MA, Shadnia S. Lead Addict Health. 2020;12(1):34-39. doi:10.22122/ahj.v12i1.258 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291899/

Scotland's 2009-2015 methadone-prescription cohort: quintiles for daily-dose of prescribed methadone and risk of methadone-specific death

07. Juli 2020 | Methadon zur Substitution

Scotland's 2009-2015 methadone-prescription cohort: quintiles for daily-dose of prescribed methadone and risk of methadone-specific death Gao L, Robertson JR, Bird SM. [published online ahead of print, 2020 Jun 12]. Br J Clin Pharmacol…

Precision therapeutic opioid dosing implications from genetic biomarkers and craving score.

07. Juli 2020 | Substitutionsmittel Verschiedenes

Precision therapeutic opioid dosing implications from genetic biomarkers and craving score. Chang HW, Ho WC, Huang CL, Wang RY. Medicine (Baltimore). 2020;99(22):e20429. doi:10.1097/MD.0000000000020429 https://journals.lww.com/md-journal/Fu…

Consequences of Opioid Abuse and their Treatments in Persian Medicine: A Review Study.

07. Juli 2020 | Substitutionsmittel Verschiedenes

Consequences of Opioid Abuse and their Treatments in Persian Medicine: A Review Study. Kamali M, Tajadini H, Mehrabani M, Moghadari M. Addict Health. 2020;12(1):46-57. doi:10.22122/ahj.v12i1.250 https://www.ncbi.nlm.nih.gov/pmc/articl…

Effects of Medication-Assisted Treatment (MAT) for Opioid Use Disorder on Functional Outcomes: A Systematic Review.

07. Juli 2020 | Substitutionsmittel Verschiedenes

Effects of Medication-Assisted Treatment (MAT) for Opioid Use Disorder on Functional Outcomes: A Systematic Review. Maglione MA, Laura R, Christine C, et al. Rand Health Q. 2020;8(4):RR-2108-OSD. Published 2020 Jun 15. https://w…

Ulm. Taser- statt Tumorforschung

07. Juli 2020 | Methadon in der Krebsmedizin

Ulm. Taser- statt Tumorforschung Am Institut für Rechtsmedizin ist für die Methadonforscherin kein Platz mehr. Die Klinikleitung beteuert, sie garantiere der Chemikerin weiterhin „bestmögliche Arbeitsbedingungen.“ Doch es gibt Gründe, daran zu zwei…

Against Repurposing Methadone for Glioblastoma Therapy.

07. Juli 2020 | Methadon in der Krebsmedizin

Against Repurposing Methadone for Glioblastoma Therapy. Vatter T, Klumpp L, Ganser K, et al. Biomolecules. 2020;10(6):E917. Published 2020 Jun 17. doi:10.3390/biom10060917 https://www.mdpi.com/2218-273X/10/6/917

Ulm. Methadon gegen Krebs: Ulmer Methadon-Forscherin Friesen wird versetzt

07. Juli 2020 | Methadon in der Krebsmedizin

Ulm. Methadon gegen Krebs: Ulmer Methadon-Forscherin Friesen wird versetzt Die zum Einsatz von Methadon in der Krebstherapie forschende Chemikerin Dr. Claudia Friesen ist von Mittwoch an nicht mehr im Ulmer Institut für Rechtsmedizin beschäft…

Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care

21. Juni 2020 | Morphin ret.

Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care Cinzia Baschirotto, Kirsten Lehmann, Silke Kuhn…

Kanada. Injectable opioid agonist treatment for patients with opioid dependence: a review of clinical and cost-effectiveness. Ottawa: CADTH; 2020 May.

10. Juni 2020 | Diamorphin

Kanada. Injectable opioid agonist treatment for patients with opioid dependence: a review of clinical and cost-effectiveness. Ottawa: CADTH; 2020 May. (CADTH rapid response report: summary with critical appraisal). https://cadth.ca/sit…

Barriers to Prescribing Buprenorphine in the Emergency Department.

10. Juni 2020 | Buprenorphin

Barriers to Prescribing Buprenorphine in the Emergency Department. Kim HS, Samuels EA. Overcoming JAMA Netw Open. 2020;3(5):e204996. doi:10.1001/jamanetworkopen.2020.4996 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/27…

Tackling the overdose crisis: The role of safe supply

10. Juni 2020 | Substitutionsmittel Verschiedenes

Tackling the overdose crisis: The role of safe supply Ivsins A, Boyd J, Beletsky L, McNeil R. [published online ahead of print, 2020 May 1]. Int J Drug Policy. 2020;80:102769. doi:10.1016/j.drugpo.2020.102769 https://www.ncbi.nlm.nih…

Wuppertal. NEUE DIAMORPHINAMBULANZ IN WUPPERTAL

10. Juni 2020 | Diamorphin

Wuppertal. NEUE DIAMORPHINAMBULANZ IN WUPPERTAL Der JES Bundesverband gratuliert der Elterngruppe Wuppertal sowie den kommunalen Trägern der Drogenhilfe, dass ihre langjährigen Bemühungen für eine Heroinvergabe nun endlich umgesetzt wurden. (JES Bu…

Retention of patients in opioid substitution treatment: A systematic review.

01. Juni 2020 | Substitutionsmittel Verschiedenes

Berlin. „Kombinat Neubau“ - Weiterer Standort für eine diamorphingestützte Behandlung in Berlin

12. Mai 2020 | Diamorphin

Berlin. „Kombinat Neubau“ - Weiterer Standort für eine diamorphingestützte Behandlung in Berlin Am 1. April 2020 eröffnete der Drogennotdienst in Kooperation mit vier Ärzt_innen in der Ru- schestraße 103 eine neue Am- bulanz für Integrierte Drogenh…

Toward precision prescribing for methadone: Determinants of methadone deposition.

09. Mai 2020 | Methadon zur Substitution

Toward precision prescribing for methadone: Determinants of methadone deposition. Talal AH, Ding Y, Venuto CS, Chakan LM, McLeod A, Dharia A, et al. (2020) PLoS ONE 15(4): e0231467. doi.org/10.1371/journal.pone.0231467 https://journals.plos…

USA. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document.

09. Mai 2020 | Buprenorphin

USA. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document. This updated Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to…

USA. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document.

09. Mai 2020 | Methadon zur Substitution

CLINICAL GUIDELINES FOR USE OF DEPOT BUPRENORPHINE (BUVIDAL®) IN THE TREATMENT OF OPIOID DEPENDENCE

09. Mai 2020 | Buprenorphin

CLINICAL GUIDELINES FOR USE OF DEPOT BUPRENORPHINE (BUVIDAL®) IN THE TREATMENT OF OPIOID DEPENDENCE This Clinical Guideline has been developed to inform decision-making by clinicians prescribing and/or patients being treated with Buvidal® long…

EMA. Summary of opinion (post authorisation): Suboxone (buprenorphine / naloxone) sublingual film

09. Mai 2020 | Buprenorphin

EMA. Summary of opinion (post authorisation): Suboxone (buprenorphine / naloxone) sublingual film On 30 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marke…

Two world first studies of depot buprenorphine completed

09. Mai 2020 | Buprenorphin

Two world first studies of depot buprenorphine completed Two world first studies of depot buprenorphine have recently been completed. Both studies are great achievements at the forefront of international research efforts in this field and have sali…

Expanding access to diacetylmorphine and hydromorphone for people who use opioids in Canada.

09. Mai 2020 | Diamorphin

Expanding access to diacetylmorphine and hydromorphone for people who use opioids in Canada. Maghsoudi N, Bowles J, Werb D. Can J Public Health. 2020 Mar 27. doi: 10.17269/s41997-020-00315-4. Abstract https://www.ncbi.nlm.nih.gov/pubmed/32…

Progress Report on EMBED: A Pragmatic Trial of User-Centered Clinical Decision Support to Implement EMergency Department-Initiated BuprenorphinE for Opioid Use Disorder.

26. April 2020 | Buprenorphin

Progress Report on EMBED: A Pragmatic Trial of User-Centered Clinical Decision Support to Implement EMergency Department-Initiated BuprenorphinE for Opioid Use Disorder. Melnick ER, Nath B, Ahmed OM, Brandt C, Chartash D, Dziura JD, Hess EP, Hollan…

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.

26. April 2020 | Buprenorphin

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis. Andorn AC, Haight BR, Shinde S, Fudala PJ, Zhao Y, Heidbreder C, Learned SM, Fox NL, Nadipelli VR, Hassman…

Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.

26. April 2020 | Buprenorphin

Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state. Bogan C, Jennings L, Haynes L, Barth K, Moreland A, Oros M, Goldsby S, Lane S, Funcell C, Brady K. J Subst Abuse Treat. 2020 Mar;112S…

Prescribing heroin: John Marks, the Merseyside clinics, and lessons from history.

25. April 2020 | Diamorphin

Prescribing heroin: John Marks, the Merseyside clinics, and lessons from history. Seddon T. Int J Drug Policy. 2020 Mar 24;78:102730. doi: 10.1016/j.drugpo.2020.102730. Abstract https://www.sciencedirect.com/science/article/abs/pii/S095539592030…

The Use of the Methadone/Metabolite Ratio (MMR) to Identify an Individual Metabolic Phenotype and Assess Risks of Poor Response and Adverse Effects: Towards Scientific Methadone Dosing.

25. April 2020 | Methadon zur Substitution

The Use of the Methadone/Metabolite Ratio (MMR) to Identify an Individual Metabolic Phenotype and Assess Risks of Poor Response and Adverse Effects: Towards Scientific Methadone Dosing. McCarthy JJ, Graas J, Leamon MH, Ward C, Vasti EJ, Fassbender…

Effect of heroin on right ventricular cardiac performance.

25. April 2020 | Diamorphin

Effect of heroin on right ventricular cardiac performance. Selcuk M, Yildirim E, Saylik F, Deniz O, Mutluer FO. Cardiovasc J Afr. 2020 Mar 5;31:1-4. doi: 10.5830/CVJA-2020-002. http://www.cvja.co.za/onlinefirst/DOI-10-5830-CVJA-2020-002.pdf

Injectable buprenorphine for opioid use disorder: Effects on 1-year recovery outcomes

21. April 2020 | Buprenorphin

Injectable buprenorphine for opioid use disorder: Effects on 1-year recovery outcomes An extended release version of buprenorphine was recently approved by the FDA to treat opioid use disorder. Prior research has revealed the short-term benefits of…

Sexual Inactivity in Methadone Maintenance Treatment Patients.

12. April 2020 | Methadon zur Substitution

Sexual Inactivity in Methadone Maintenance Treatment Patients. Ramli FF, Tg Abu Bakar Sidik TMI, Naina Mohamed I. Int J Environ Res Public Health. 2020 Mar 18;17(6). pii: E1993. doi: 10.3390/ijerph17061993. https://www.mdpi.com/1660-4601/17/6/1993

Differences in Gut Microbial Diversity are Driven by Drug Use and Drug Cessation by Either Compulsory Detention or Methadone Maintenance Treatment.

12. April 2020 | Methadon zur Substitution

Differences in Gut Microbial Diversity are Driven by Drug Use and Drug Cessation by Either Compulsory Detention or Methadone Maintenance Treatment. Li Q, Chen S, Liu K, Long D, Liu D, Jing Z, Huang X. Microorganisms. 2020 Mar 13;8(3). pii: E411. d…

Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach.

12. April 2020 | Buprenorphin

Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach. Caulfield MDG, Brar R, Sutherland C, Nolan S. BMJ Case Rep. 2020 Mar 25;13(3…

Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone.

12. April 2020 | Buprenorphin

Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone. Elman I, Howard M, Borodovsky JT, Mysels D, Rott D, Borsook D, Albanese M. Sci Rep. 2020 Mar 27;10(1):5617. d…

Emergency Department Clinicians' Attitudes Toward Opioid Use Disorder and Emergency Department-initiated Buprenorphine Treatment: A Mixed-Methods Study.

12. April 2020 | Buprenorphin

Emergency Department Clinicians' Attitudes Toward Opioid Use Disorder and Emergency Department-initiated Buprenorphine Treatment: A Mixed-Methods Study. Im DD, Chary A, Condella AL, Vongsachang H, Carlson LC, Vogel L, Martin A, Kunzler N, Weiner SG…

Perioperative Management of a Patient Taking Suboxone® at the Time of Ambulatory Surgery.

12. April 2020 | Buprenorphin

Perioperative Management of a Patient Taking Suboxone® at the Time of Ambulatory Surgery. Malan SH, Bailey CH, Khurmi N. Case Rep Anesthesiol. 2020 Mar 9;2020:5628348. doi: 10.1155/2020/5628348. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC…

Traditional Chinese Medicine-facilitated switch from methadone to buprenorphine-naloxone for treatment of heroin dependence: a case report.

12. April 2020 | Buprenorphin

Traditional Chinese Medicine-facilitated switch from methadone to buprenorphine-naloxone for treatment of heroin dependence: a case report. Huang KY, Hsu CH, Yu KC, Yeh YH, Han KC, Wei HT. J Tradit Chin Med. 2019 Apr;39(2):281-284. PMID: 32186053…

Opioid agonist treatment reduces losses in quality of life and quality-adjusted life expectancy in heroin users: Evidence from real world data.

12. April 2020 | Substitutionsmittel Verschiedenes

Opioid agonist treatment reduces losses in quality of life and quality-adjusted life expectancy in heroin users: Evidence from real world data. Chang KC, Lee KY, Lu TH, Hwang JS, Lin CN, Ting SY, Chang CC, Wang JD. Drug Alcohol Depend. 2019 Aug 1;…

Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment.

12. April 2020 | Substitutionsmittel Verschiedenes

Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment. Yedinak JL, Goedel WC, Paull K, Lebeau R, Krieger MS, Thompson C, et al. (2019) PLoS Med 16(11): e1002963. doi.or…

Opioid and Polydrug Use Among Patients in Opioid Maintenance Treatment.

12. April 2020 | Substitutionsmittel Verschiedenes

Opioid and Polydrug Use Among Patients in Opioid Maintenance Treatment. Carlsen SL, Lunde LH, Torsheim T. Subst Abuse Rehabil. 2020 Jan 29;11:9-18. doi: 10.2147/SAR.S221618. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996215/

Rapid Induction Therapy for Opioid-Use Disorder Using Buprenorphine Transdermal Patch: A Case Series.

12. April 2020 | Buprenorphin

Rapid Induction Therapy for Opioid-Use Disorder Using Buprenorphine Transdermal Patch: A Case Series. Saal D, Lee F. Perm J. 2020;24. doi: 10.7812/TPP/19.124. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089594/

Hab-o Shefa, a Persian Medicine Compound for Maintenance Treatment of Opioid Dependence: Randomized Placebo-Controlled Clinical Trial.

12. April 2020 | Substitutionsmittel Verschiedenes

Hab-o Shefa, a Persian Medicine Compound for Maintenance Treatment of Opioid Dependence: Randomized Placebo-Controlled Clinical Trial. Moosavyzadeh A, Mokri A, Ghaffari F, Faghihzadeh S, Azizi H, Jafari Hajati R, Naseri M. J Altern Complement Med…

Cochrane. Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders.

12. April 2020 | Codein

Cochrane. Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders. Carney T, Van Hout MC, Norman I, Dada S, Siegfried N, Parry CD. Cochrane Database Syst Rev. 2020 Feb 18;2:CD012254. doi: 10.1002/146518…

Buprenorphin-Depot: Annäherung an das Äquivalenzprinzip in Haft - Besondere Eignung von Buvidal® zur Substitutionstherapie in der JVA

08. März 2020 | Buprenorphin

Buprenorphin-Depot: Annäherung an das Äquivalenzprinzip in Haft - Besondere Eignung von Buvidal® zur Substitutionstherapie in der JVA Mannheim/Lund, 13.12.2019 – Die 4. Gefängnismedizintage am 5. und 6. Dezember 2019 in Frankfurt stießen auf…

Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study.

06. März 2020 | Buprenorphin

Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study. Ahmadi J, Sarani EM, Jahromi MS. Ci Ji Yi Xue Za Zhi. 2019 Mar 14;32(1):58-64. doi: 10.4103/tcm…

HIV Treatment Initiation and Retention Among Individuals Initiated on Injectable Opioid Agonist Therapy for Severe Opioid Use Disorder: A Case Series.

01. März 2020 | Diamorphin

HIV Treatment Initiation and Retention Among Individuals Initiated on Injectable Opioid Agonist Therapy for Severe Opioid Use Disorder: A Case Series. Giang V, Brar R, Sutherland C, Nolan S. J Addict Med. 2020 Jan 31. doi: 10.1097/ADM.000000000000…

Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial.

01. März 2020 | Buprenorphin

Buprenorphine to reverse respiratory depression from methadone overdose in opioid-dependent patients: a prospective randomized trial. Zamani N, Buckley NA, Hassanian-Moghaddam H. Crit Care. 2020 Feb 7;24(1):44. doi: 10.1186/s13054-020-2740-y. htt…

Sexual dysfunction in men on buprenorphine - naloxone-based substitution therapy.

01. März 2020 | Buprenorphin

Sexual dysfunction in men on buprenorphine - naloxone-based substitution therapy. Mattoo SK, Ghosh A, Subodh BN, Basu D, Satapathy A, Prasad S, Sharma MP. Indian J Psychiatry. 2020 Jan-Feb;62(1):66-72. doi: 10.4103/psychiatry.IndianJPsychiatry_195…

Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management.

01. März 2020 | Buprenorphin

Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management. Osborne V, Davies M, Roy D, Tescione F, Shakir SAW. BMJ Evid Based Med. 2020 Feb 24. pii: bmjebm-2019-111295. doi: 10.1136/bmjebm-2…

Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders.

01. März 2020 | Codein

Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders. Carney T, Van Hout MC, Norman I, Dada S, Siegfried N, Parry CD. Cochrane Database Syst Rev. 2020 Feb 18;2:CD012254. doi: 10.1002/14651858.CD01225…

Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

01. März 2020 | Methadon zur Substitution

Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. JAMA Netw Open. 2020 Feb 5;3(2):e1920622. doi: 10.1001/jamanetworko…

Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

01. März 2020 | Buprenorphin

Increases in body mass index and cardiovascular risk factors during methadone maintenance treatment.

01. März 2020 | Methadon zur Substitution

Increases in body mass index and cardiovascular risk factors during methadone maintenance treatment. Sweeney MM, Antoine DG, Nanda L, Géniaux H, Lofwall MR, Bigelow GE, Umbricht A. J Opioid Manag. 2019 Sep/Oct;15(5):367-374. doi: 10.5055/jom.2019…

Efficacy of Heroin-assisted Treatment In Belgium: A Randomised Controlled Trial.

29. Februar 2020 | Diamorphin

Efficacy of Heroin-assisted Treatment In Belgium: A Randomised Controlled Trial. Demaret I, Quertemont E, Litran G, Magoga C, Deblire C, Dubois N, De Roubaix J, Charlier C, Lemaître A, Ansseau M. Eur Addict Res. 2015;21(4):179-87. doi: 10.1159/000…

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.

29. Februar 2020 | Buprenorphin

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Larance, B., Degenhardt, L., Grebely, J., Nielsen, S., Bruno, R., Dietze, P., Lancaster, K., Larney, S., Santo, T…

Safety aspects of opioid-naïve patients with high-grade glioma treated with D,L-Methadone: an observational case series.

29. Februar 2020 | Methadon in der Krebsmedizin

Safety aspects of opioid-naïve patients with high-grade glioma treated with D,L-Methadone: an observational case series. von der Brelie C, Schatlo B, Bettag C, Rohde V. Neurosurg Rev. 2020 Feb 14. doi: 10.1007/s10143-020-01250-1. Abstract…

Kanada. Observational Prospective Study of Injectable Opioid Agonist Treatment - The iOAT Study (Evaluation)

16. Februar 2020 | Diamorphin

Kanada. Observational Prospective Study of Injectable Opioid Agonist Treatment - The iOAT Study (Evaluation) Baseline Interview Results BC Centre on Substance Use (BCCSU), Kanada, Februar 2020 https://www.bccsu.ca/wp-content/uploads/2020/02/BC-iO…

Abuses of FDA Regulatory Procedures - The Case of Suboxone.

08. Februar 2020 | Buprenorphin

Abuses of FDA Regulatory Procedures - The Case of Suboxone. Haffajee RL, Frank RG. N Engl J Med. 2020 Feb 6;382(6):496-498. doi: 10.1056/NEJMp1906680. The manufacturer of brand-name buprenorphine products exploited various FDA regulatory pr…

Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study.

08. Februar 2020 | Buprenorphin

Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study. Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C. J Subst Abuse Treat. 2020 Mar;110:1-8. doi: 10.10…

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach.

08. Februar 2020 | Buprenorphin

Early-Career and Graduating Physicians More Likely to Prescribe Buprenorphine.

08. Februar 2020 | Buprenorphin

Early-Career and Graduating Physicians More Likely to Prescribe Buprenorphine. Peterson LE, Morgan ZJ, Eden AR. J Am Board Fam Med. 2020 Jan-Feb;33(1):7-8. doi: 10.3122/jabfm.2020.01.190230. https://www.jabfm.org/content/33/1/7.long

ALDH2 Gene: Its Effects on the Neuropsychological Functions in Patients with Opioid Use Disorder Undergoing Methadone Maintenance Treatment.

08. Februar 2020 | Methadon in der Krebsmedizin

ALDH2 Gene: Its Effects on the Neuropsychological Functions in Patients with Opioid Use Disorder Undergoing Methadone Maintenance Treatment. Lee PW, Wang TY, Chang YH, Lee SY, Chen SL, Wang ZC, Chen PS, Chu CH, Huang SY, Tzeng NS, Lee IH, Chen KC…

Transition From Methadone to Buprenorphine Using a Short-acting Agonist Bridge in the Inpatient Setting: A Case Study.

08. Februar 2020 | Methadon zur Substitution

Transition From Methadone to Buprenorphine Using a Short-acting Agonist Bridge in the Inpatient Setting: A Case Study. Callan J, Pytell J, Ross J, Rastegar DA. J Addict Med. 2020 Jan 22. doi: 10.1097/ADM.0000000000000623. Abstract https://…

Factors Related to Relapse in Patients with Substance-related Disorders under Methadone Maintenance Therapy: Decision Tree Analysis.

08. Februar 2020 | Methadon zur Substitution

Factors Related to Relapse in Patients with Substance-related Disorders under Methadone Maintenance Therapy: Decision Tree Analysis. Moradinazar M, Farnia V, Alikhani M, Karyani AK, Rezaei S, Rezaeian S, Matin BK, Najafi F. Oman Med J. 2020 Jan 23…

Outcome of Patients With High Depressive Symptoms on Admission to Methadone Maintenance Treatment.

08. Februar 2020 | Methadon zur Substitution

Outcome of Patients With High Depressive Symptoms on Admission to Methadone Maintenance Treatment. Malik E, Adelson M, Sason A, Schreiber S, Peles E. J Dual Diagn. 2019 Oct-Dec;15(4):281-290. doi: 10.1080/15504263.2019.1656353. Abstract https://…

Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment.

08. Februar 2020 | Diamorphin

Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment. Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Su…

Trauma Severity in Early Childhood Correlates with Stress and Satiety Hormone Levels in a Pilot Cohort Receiving Diamorphine Maintenance Treatment.

08. Februar 2020 | Diamorphin

Trauma Severity in Early Childhood Correlates with Stress and Satiety Hormone Levels in a Pilot Cohort Receiving Diamorphine Maintenance Treatment. Groh A, Rhein M, Roy M, Gessner C, Lichtinghagen R, Heberlein A, Hillemacher T, Bleich S, Walter M…

Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy

19. Januar 2020 | Buprenorphin

Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy Vierke C, Marxen B, Boettcher M, Hiemke C, Havemann-Reinecke U. Eur Arch Psychiatry Clin Neurosci (2020). doi.org/10.1007/s00406-019-01091-0 https://link.springe…

"Die Knochen schmerzen. Ich schwitze Bäche" - Aus dem Alltag eines Schweizer Heroinabhängigen

12. Januar 2020 | Diamorphin

"Die Knochen schmerzen. Ich schwitze Bäche" - Aus dem Alltag eines Schweizer Heroinabhängigen Die progressive Schweizer Drogenpolitik brachte nicht nur die offene Drogenszene zum Verschwinden, sondern rettete zahlreichen Süchtigen das Le…

Initiation of injectable opioid agonist treatment in hospital: A case report.

05. Januar 2020 | Diamorphin

Initiation of injectable opioid agonist treatment in hospital: A case report. McAdam M, Brar R, Young S. Drug Alcohol Rev. 2019 Dec 9. doi: 10.1111/dar.13020. Abstract https://www.ncbi.nlm.nih.gov/pubmed/31814186

Initiation of injectable opioid agonist treatment in hospital: A case report.

05. Januar 2020 | Substitutionsmittel Verschiedenes

Recurrent Use of Implantable Buprenorphine.

05. Januar 2020 | Buprenorphin

Recurrent Use of Implantable Buprenorphine. Campbell MC. Prim Care Companion CNS Disord. 2019 Dec 5;21(6). pii: 19l02434. doi: 10.4088/PCC.19l02434. https://www.psychiatrist.com/pcc/article/pages/2019/v21n06/19l02434.aspx

A Retrospective Survey of Buprenorphine Substitute Treatment With Minimal Dosage in Heroin Use Disorder.

05. Januar 2020 | Buprenorphin

A Retrospective Survey of Buprenorphine Substitute Treatment With Minimal Dosage in Heroin Use Disorder. Shen W, Wang Q, Zhang J, Ping W, Zhang J, Ye W, Hu Q, Cerci D, Zhou W. Front Psychiatry. 2019 Dec 4;10:888. doi: 10.3389/fpsyt.2019.00888.&nbs…

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation.

05. Januar 2020 | Buprenorphin

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation. Ling W, Shoptaw S, Goodman-Meza D. Subst Abuse Rehabil. 2019 Nov 29;10:69-78. doi: 10.2147/SAR.S155843. https://www.ncbi.nlm.nih.gov…

Factors Associated with Sleep Disorders among Methadone-Maintained Drug Users in Vietnam.

05. Januar 2020 | Methadon zur Substitution

Factors Associated with Sleep Disorders among Methadone-Maintained Drug Users in Vietnam. Le TA, Dang AD, Tran AHT, Nguyen LH, Nguyen THT, Phan HT, Latkin CA, Tran BX, Ho CSH, Ho RCM. Int J Environ Res Public Health. 2019 Nov 6;16(22). pii: E4315…

Health-Seeking Behavior for Erectile Dysfunction in Methadone Maintenance Treatment Patients.

05. Januar 2020 | Methadon zur Substitution

Health-Seeking Behavior for Erectile Dysfunction in Methadone Maintenance Treatment Patients. Ramli FF, Shuid AN, Pakri Mohamed RM, Tg Abu Bakar Sidik TMI, Naina Mohamed I. Int J Environ Res Public Health. 2019 Nov 1;16(21). pii: E4249. doi: 10.33…

Schottland. 'Heroin-assisted treatment - New service, new hope' with Danny Ahmed and Dr Carole Hunter (Podcast)

05. Januar 2020 | Diamorphin

Schottland. 'Heroin-assisted treatment - New service, new hope' with Danny Ahmed and Dr Carole Hunter (Podcast) The new 'Enhanced Drug Treatment Service' in Glasgow has opened it's doors and offers Heroin-Assisted Treatment (HAT) - the prescribing…

Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.

05. Januar 2020 | Buprenorphin

Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada. Weicker SA, Hayashi K, Grant C, Milloy MJ, Wood E, Kerr T. Drug Alcohol Depend. 2019 Dec 1;205:107672. doi: 10.1016/j.drugalcdep.2019.107672. Abstract…

Synthetic Urines in a Buprenorphine Clinic.

05. Januar 2020 | Buprenorphin

Synthetic Urines in a Buprenorphine Clinic. Embers DM, Ravishankar DA, Din A, Sethi R. Kans J Med. 2019 Nov 25;12(4):146-147. eCollection 2019 Nov. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884010/

Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine.

25. Dezember 2019 | Buprenorphin

Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine. Chhabra N, Aks SE. Am J Emerg Med. 2019 Nov 16. pii: S0735-6757(19)30627-8. doi: 10.1016/j.ajem.2019.09.014. Abstract https://www.ncbi.nlm.nih.gov/pubmed/317536…

Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine.

25. Dezember 2019 | Buprenorphin

Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine. Blue TR, Gordon MS, Schwartz RP, Couvillion K, Vocci FJ, Fitzgerald TT, O'Grady KE. Addict Sci Clin Pract. 2019 Dec 2;14(1):45. do…

Inhibitory role of Gi-coupled receptors on cAMP-driven cancers with focus on opioid receptors in lung adenocarcinoma and its stem cells.

25. Dezember 2019 | Methadon in der Krebsmedizin

Inhibitory role of Gi-coupled receptors on cAMP-driven cancers with focus on opioid receptors in lung adenocarcinoma and its stem cells. Schuller HM. Vitam Horm. 2019;111:299-311. doi: 10.1016/bs.vh.2019.05.009. Epub 2019 Jun 21. Abstract https…

Methadone hydrochloride and leukemia cells: Effects on cell viability, DNA fragmentation and apoptotic proteins expression level.

25. Dezember 2019 | Methadon in der Krebsmedizin

Methadone hydrochloride and leukemia cells: Effects on cell viability, DNA fragmentation and apoptotic proteins expression level. Kua VMD, Rasul A, Sreenivasan S, Rasool B, Younis T, Lai NS. Pak J Pharm Sci. 2019 Jul;32(4(Supplementary)):1797-1803…

Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. (FINDINGS: Review Analysis)

25. Dezember 2019 | Diamorphin

Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. (FINDINGS: Review Analysis) Strang J., Groshkova T., Uchtenhagen A. et al. The British Journal…

UK. Five drop out of 'free heroin' trial but early success could mean scheme rolled out to Stockton

25. Dezember 2019 | Diamorphin

UK. Five drop out of 'free heroin' trial but early success could mean scheme rolled out to Stockton Efforts to bring Middlesbrough's Heroin Assisted Treatment (HAT) scheme to Stockton have received early backing. (Teessidelive, UK, 21.12.2019) htt…

Opioid use disorder and treatment: challenges and opportunities.

22. Dezember 2019 | Substitutionsmittel Verschiedenes

Opioid use disorder and treatment: challenges and opportunities. Hoffman KA, Ponce Terashima J, McCarty D. BMC Health Serv Res. 2019 Nov 25;19(1):884. doi: 10.1186/s12913-019-4751-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876068/

New…and improved? The latest studies on injectable buprenorphine for opioid use disorder

22. Dezember 2019 | Buprenorphin

New…and improved? The latest studies on injectable buprenorphine for opioid use disorder Suboxone is a first-line treatment for opioid use disorder. The need to take it daily, however, increases the risk that someone will miss a…

Adjunctive memantine for opioid use disorder treatment: A systematic review.

22. Dezember 2019 | Substitutionsmittel Verschiedenes

Adjunctive memantine for opioid use disorder treatment: A systematic review. Elias AM, Pepin MJ, Brown JN. J Subst Abuse Treat. 2019 Dec;107:38-43. doi: 10.1016/j.jsat.2019.10.003. https://www.ncbi.nlm.nih.gov/pubmed/31757263

Camurus. Buprenorphin als Depot – Für stabile und instabile Patienten - Auf Buvidal® einstellen und erfolgreich Rituale aufbrechen

08. Dezember 2019 | Buprenorphin

Buprenorphin als Depot – Für stabile und instabile Patienten - Auf Buvidal® einstellen und erfolgreich Rituale aufbrechen Mannheim/Lund, 4.12.2019 – Seit Februar 2019 können opioidabhängige Patienten*innen in Deutschland mit dem neuen Buprenorphin-…

Opioid Substitution Treatment Using Buprenorphine for Management of Dependence on Natural Opioids: Case Series.

08. Dezember 2019 | Buprenorphin

Opioid Substitution Treatment Using Buprenorphine for Management of Dependence on Natural Opioids: Case Series. Kathiresan P, Ambekar A, Sarkar S. Indian J Psychol Med. 2019 Nov 11;41(6):586-588. doi: 10.4103/IJPSYM.IJPSYM_62_19. https://ww…

Fentanyl assisted treatment: a possible role in the opioid overdose epidemic?

08. Dezember 2019 | Substitutionsmittel Verschiedenes

Fentanyl assisted treatment: a possible role in the opioid overdose epidemic? Bardwell G, Wood E, Brar R. Subst Abuse Treat Prev Policy. 2019 Nov 11;14(1):50. doi: 10.1186/s13011-019-0241-2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849248/

Preparation, Characterization and Dermal Delivery of Methadone.

27. November 2019 | Methadon in der Krebsmedizin

Preparation, Characterization and Dermal Delivery of Methadone. Kung CP, Sil BC, Hadgraft J, Lane ME, Patel B, McCulloch R. Pharmaceutics. 2019 Oct 2;11(10). pii: E509. doi: 10.3390/pharmaceutics11100509. https://www.mdpi.com/1999-4923/11/10/509/…

Preparation, Characterization and Dermal Delivery of Methadone.

27. November 2019 | Methadon zur Substitution

Unusual Drug Test Results for a Patient on Buprenorphine and Naloxone.

27. November 2019 | Buprenorphin

Unusual Drug Test Results for a Patient on Buprenorphine and Naloxone. Gall B, El-Khoury JM. Clin Chem. 2019 Oct;65(10):1332-1333. doi: 10.1373/clinchem.2019.309484. http://clinchem.aaccjnls.org/content/65/10/1332.long

Sustained-release Oral Hydromorphone for the Treatment of Opioid Use Disorder.

27. November 2019 | Substitutionsmittel Verschiedenes

Sustained-release Oral Hydromorphone for the Treatment of Opioid Use Disorder. Braithwaite V, Fairgrieve C, Nolan S. J Addict Med. 2019 Oct 25. doi: 10.1097/ADM.0000000000000585. Abstract https://www.ncbi.nlm.nih.gov/pubmed/31658114

Schottland. Scotland's first heroin treatment clinic for addicts to open

27. November 2019 | Diamorphin

Schottland. Scotland's first heroin treatment clinic for addicts to open Scotland's first scheme for giving drug addicts pharmaceutical grade heroin is to open in Glasgow city centre. The £1.2m Enhanced Drug Treatment Service (EDTS) is the first i…

Buprenorphine poisoning in children: a 10-year-experience of Marseille Poison Center.

27. November 2019 | Buprenorphin

Buprenorphine poisoning in children: a 10-year-experience of Marseille Poison Center. von Fabeck K, Boulamery A, Glaizal M, de Haro L, Simon N. Fundam Clin Pharmacol. 2019 Nov 1. doi: 10.1111/fcp.12518. Abstract https://www.ncbi.nlm.nih.gov/pubm…

Hitting Heroin and Crack Markets: Funding Heroin Assisted Treatment through increased Proceeds of Crime Act Money

23. November 2019 | Diamorphin

Hitting Heroin and Crack Markets: Funding Heroin Assisted Treatment through increased Proceeds of Crime Act Money Senior members of the police up and down the UK would like to introduce Heroin Assisted Treatment, but feel they don't have the funds…

Neue Substitutionsprodukte, neue Chancen? Der Wurm muss dem Fisch schmecken, nicht dem Angler (Präsentation)

19. November 2019 | Substitutionsmittel Verschiedenes

Neue Substitutionsprodukte, neue Chancen? Der Wurm muss dem Fisch schmecken, nicht dem Angler (Präsentation) Dr. Manfred Nowak, Landau NaSuKo – 5.Nationale Substitutionskonferenz, 27.09.2019, Berlin https://www.akzept.eu/wp-content/uploads/2019/1…

Dr. Claudia Friesen im Interview: „Bei Methadon wird grundsätzlich alles infrage gestellt!“

19. November 2019 | Methadon in der Krebsmedizin

Dr. Claudia Friesen im Interview: „Bei Methadon wird grundsätzlich alles infrage gestellt!“ Dr. rer. nat. Claudia Friesen veröffentlichte 2008 In-vitro-Daten zur Wirksamkeit von D,L-Methadonhydrochlorid gegen humane Leukämiezellen (CEM und HL-60)…

Supplement: Perspektiven der Onkologie. Methadon in der Krebstherapie: Erste klinische Multicenterstudie

16. November 2019 | Methadon in der Krebsmedizin

Supplement: Perspektiven der Onkologie. Methadon in der Krebstherapie: Erste klinische Multicenterstudie Dtsch Arztebl 2019; 116(46): [24] Gießelmann, Kathrin https://www.aerzteblatt.de/archiv/210852/Methadon-in-der-Krebstherapie-Erste-klinische-…

The association between health conditions and cannabis use in patients with opioid use disorder receiving methadone maintenance treatment.

10. November 2019 | Methadon zur Substitution

The association between health conditions and cannabis use in patients with opioid use disorder receiving methadone maintenance treatment. Shams I, Sanger N, Bhatt M, Rosic T, Luo C, Shahid H, Mouravska N, Tam SL, Hillmer A, Chawar C, D'Elia A, Hud…

Current status of opioid addiction treatment and related preclinical research.

10. November 2019 | Substitutionsmittel Verschiedenes

Current status of opioid addiction treatment and related preclinical research. Kreek MJ, Reed B, Butelman ER. Sci Adv. 2019 Oct 2;5(10):eaax9140. doi: 10.1126/sciadv.aax9140. eCollection 2019 Oct. Review. https://www.ncbi.nlm.nih.gov/pmc/articles…

A Unique Case Report on Methadone Used for Treatment of Opioid-induced Hyperalgesia in a Cancer Patient at the End of Life.

10. November 2019 | Methadon in der Krebsmedizin

A Unique Case Report on Methadone Used for Treatment of Opioid-induced Hyperalgesia in a Cancer Patient at the End of Life. Bitar HN, Cipta AM, Lee KW, Woo WS. Cureus. 2019 Aug 15;11(8):e5394. doi: 10.7759/cureus.5394. https://www.ncbi.nlm.nih.go…

A comparison of sexual desire in opiate-dependent men receiving methadone and buprenorphine maintenance treatment.

10. November 2019 | Buprenorphin

A comparison of sexual desire in opiate-dependent men receiving methadone and buprenorphine maintenance treatment. Yee A, Loh HS, Loh HH, Riahi S, Ng CG, Sulaiman AHB. Ann Gen Psychiatry. 2019 Oct 22;18:25. doi: 10.1186/s12991-019-0249-z. h…

A comparison of sexual desire in opiate-dependent men receiving methadone and buprenorphine maintenance treatment.

10. November 2019 | Methadon zur Substitution

Schweiz. Heroingestützte Behandlung: Ein Film räumt auf mit Vorurteilen (Video)

09. November 2019 | Diamorphin

Schweiz. Heroingestützte Behandlung: Ein Film räumt auf mit Vorurteilen (Video) Seit 25 Jahren behandeln die UPK Basel im Janus Opioidabhängige. Der Film zum Jubiläum gibt einen doppelten Einblick in die kontrollierte Heroinverschreibung: In die Ar…

Methadon bei Krebs: Der große Game Changer?

09. November 2019 | Methadon in der Krebsmedizin

Methadon bei Krebs: Der große Game Changer? Die „Methadon-Welle“ rollt seit der Veröffentlichung der Zellexperimente von Dr. rer. nat. Claudia Friesen immer wieder durch die Medien. Die Befürworter sehen Hoffnung für bislang hoffnungslose Fälle. Di…

Debatte um Methadon und Krebs Internist aus Ulm: „Methadon kann nur das Sahnehäubchen sein“

04. November 2019 | Methadon in der Krebsmedizin

Debatte um Methadon und Krebs Internist aus Ulm: „Methadon kann nur das Sahnehäubchen sein“ Der Hausarzt Dr. Christian Kröner aus Pfuhl setzt Methadon seit Jahren in der Schmerztherapie ein. Das beschert ihm einen Zulauf von Patienten mit Kre…

Studie in Ulm Hilft Methadon bei Krebs?

04. November 2019 | Methadon in der Krebsmedizin

Studie in Ulm Hilft Methadon bei Krebs? Hoffnung für Krebskranke oder Irrweg? Nach kontroversen Debatten um das Mittel Methadon soll erstmals eine Therapiestudie der Uni Ulm zeigen, ob sich damit Tumore wirksam bekämpfen lassen - oder nicht…

Deutsche Krebshilfe fördert Methadon-Therapiestudie - Wirkstoff soll die Chemotherapie bei Darmkrebs verstärken

04. November 2019 | Methadon in der Krebsmedizin

Deutsche Krebshilfe fördert Methadon-Therapiestudie - Wirkstoff soll die Chemotherapie bei Darmkrebs verstärken Ulm (gwb) –In den letzten Jahren ist das Schmerzmittel Methadon als vermeintlich vielversprechendes Krebsmedikament in den Blickpu…

Middlesbrough Heroin Assisted Treatment (HAT) programme: New approach to tackling drug addiction in Middlesbrough unveiled

10. Oktober 2019 | Diamorphin

Middlesbrough Heroin Assisted Treatment (HAT) programme: New approach to tackling drug addiction in Middlesbrough unveiled A pioneering treatment and recovery programme aimed at freeing the most entrenched heroin users from addiction is launched ne…

Heroin Assisted Treatment (HAT) – A NEW GROUND-BREAKING TREATMENT FOR LONG-TERM HEROIN USERS IN MIDDLESBROUGH

10. Oktober 2019 | Diamorphin

Heroin Assisted Treatment (HAT) – A NEW GROUND-BREAKING TREATMENT FOR LONG-TERM HEROIN USERS IN MIDDLESBROUGH What is Heroin Assisted Treatment? Heroin Assisted Treatment, or HAT, is a medical treatment for people with a long-term dependency on her…

Norwegen. 'The entire pharmaceutical compendium' in the treatment of substance use disorders

06. Oktober 2019 | Substitutionsmittel Verschiedenes

Norwegen. 'The entire pharmaceutical compendium' in the treatment of substance use disorders Jørg Mørland, Helge Waal Tidsskr Nor Legeforen 2019, doi: 10.4045/tidsskr.18.0678 https://tidsskriftet.no/en/2019/02/kronikk/entire-pharmaceutical-compen…

Pharmacoeconomic Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.)

06. Oktober 2019 | Buprenorphin

Pharmacoeconomic Review Report: Buprenorphine extended-release injection (Sublocade): (Indivior Canada, Ltd.) Indication: For the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilize…

CADTH Canadian Drug Expert Committee Recommendation: Buprenorphine (Sublocade — Indivior Canada Ltd.): Indication: Opioid use disorder [Internet].

06. Oktober 2019 | Buprenorphin

CADTH Canadian Drug Expert Committee Recommendation: Buprenorphine (Sublocade — Indivior Canada Ltd.): Indication: Opioid use disorder [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun. https://www.ncbi…

Opioids and their endocrine effects: A systematic review and meta-analysis.

06. Oktober 2019 | Methadon zur Substitution

Opioids and their endocrine effects: A systematic review and meta-analysis. de Vries F, Bruin M, Lobatto DJ, Dekkers OM, Schoones JW, van Furth WR, Pereira AM, Karavitaki N, Biermasz NR, Zamanipoor Najafabadi AH. J Clin Endocrinol Metab. 2019 Sep…

Methadone poisonings: a seven year retrospective study of the French Poison Centers Network focusing on suicide attempts versus misuses.

06. Oktober 2019 | Methadon zur Substitution

Methadone poisonings: a seven year retrospective study of the French Poison Centers Network focusing on suicide attempts versus misuses. Torrents R, Glaizal M, Sinno-Tellier S, Richard N, Nisse P, Vodovar D, Bloch J, Simon N, de Haro L. Fundam Cli…

Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study.

06. Oktober 2019 | Methadon zur Substitution

Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study. Murnion BP, Rivas C, Demirkol A, Hayes V, Lintzeris N, Nielsen S. Pa…

Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study.

06. Oktober 2019 | Buprenorphin

Correlation between interleukin-6 levels and methadone maintenance therapy outcomes.

06. Oktober 2019 | Methadon zur Substitution

Correlation between interleukin-6 levels and methadone maintenance therapy outcomes. Lu RB, Wang TY, Lee SY, Chen SL, Chang YH, See Chen P, Lin SH, Chu CH, Huang SY, Tzeng NS, Lee IH, Chin Chen K, Kuang Yang Y, Chen P, Chen SH, Hong JS. Drug Alcoh…

Testing a Neuro-Evolutionary Theory of Social Bonds and Addiction: Methadone Associated With Lower Attachment Anxiety, Comfort With Closeness, and Proximity Maintenance.

06. Oktober 2019 | Methadon zur Substitution

Testing a Neuro-Evolutionary Theory of Social Bonds and Addiction: Methadone Associated With Lower Attachment Anxiety, Comfort With Closeness, and Proximity Maintenance. Torres N. Front Psychiatry. 2019 Sep 6;10:602. doi: 10.3389/fpsyt.2019.00602…

Kanada. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline

23. September 2019 | Diamorphin

Kanada. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline Nadia Fairbairn, Josey Ross, Michael Trew, Karine Meador, Jeff Turnbull, Scott MacDonald, Eugenia Oviedo-Joekes, Bernard Le Foll, Marie-Ève Goyer, Mi…

Kanada. CRISM National Injectable Opioid Agonist Treatment Guideline

23. September 2019 | Diamorphin

Kanada. CRISM National Injectable Opioid Agonist Treatment Guideline CRISM developed the first national injectable opioid agonist treatment (iOAT) guideline in the world. This guideline includes two companion documents: a clinical guideline and an…

Medication-Assisted Treatment for Opioid-Use Disorder.

21. September 2019 | Substitutionsmittel Verschiedenes

Medication-Assisted Treatment for Opioid-Use Disorder. Tyler S. Oesterle, Nuria J. Thusius, Teresa A. Rummans, Mark S. Gold. Mayo Clinic Proceedings, 2019; DOI: 10.1016/j.mayocp.2019.03.029 https://www.mayoclinicproceedings.org/article/S002…

Anästhesievorbereitung: Welche Medikamente vor einer Narkose abgesetzt werden sollten

21. September 2019 | Substitutionsmittel Verschiedenes

Anästhesievorbereitung: Welche Medikamente vor einer Narkose abgesetzt werden sollten Schreiner, Mathias J.; Kehl, Franz Dtsch Arztebl 2019; 116(31-32): A-1428 / B-1183 / C-1167 https://www.aerzteblatt.de/archiv/209139/Anaesthesievorbereitung-Wel…

Anästhesievorbereitung: Welche Medikamente vor einer Narkose abgesetzt werden sollten

21. September 2019 | Methadon zur Substitution

Anästhesievorbereitung: Welche Medikamente vor einer Narkose abgesetzt werden sollten

21. September 2019 | Buprenorphin

Anästhesievorbereitung: Welche Medikamente vor einer Narkose abgesetzt werden sollten

21. September 2019 | Methadon in der Krebsmedizin

Ulm. Wie wirkungsvoll ist Methadon im Kampf gegen Krebs?

17. September 2019 | Methadon in der Krebsmedizin

Ulm. Wie wirkungsvoll ist Methadon im Kampf gegen Krebs? Claudia Friesen, die Leiterin des Forschungslabors am Institut für Rechtsmedizin am Ulmer Universitätsklinikum, ist weiter heftiger Kritik von Medizinern ausgesetzt. Chemikerin sieht sic…

Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.

08. September 2019 | Morphin ret.

Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients. Bertin C, Delorme J, Riquelme M, Peyrière H, Brousse G, Eschalier A, Ardid D, Chenaf C, Authier N. Br J Clin Pharmacol. 20…

What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.

08. September 2019 | Buprenorphin

What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A, Brousse G, Jama…

Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution

08. September 2019 | Buprenorphin

Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution Soyka, M. & Pogarell, O. Nervenarzt (2019) 90: 932. doi.org/10.1007/s00115-019-0783-6 Abstract https://link.springer.com/article/10.1007%2Fs00115-019-0…

Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines [Internet].

08. September 2019 | Buprenorphin

Buprenorphine for Opioid Use Disorders during Pregnancy: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines [Internet]. Edge R, Butcher R. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2…

Pain management in opioid maintenance treatment.

08. September 2019 | Substitutionsmittel Verschiedenes

Pain management in opioid maintenance treatment. Koller G, Schwarzer A, Halfter K, Soyka M. Expert Opin Pharmacother. 2019 Aug 16:1-13. doi: 10.1080/14656566.2019.1652270. Abstract https://www.ncbi.nlm.nih.gov/pubmed/31418602

Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review.

08. September 2019 | Substitutionsmittel Verschiedenes

Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review. Wang SC, Chen YC, Lee CH, Cheng CM. Int J Mol Sci. 2019 Sep 2;20(17). pii: E4294. doi: 10.3390/ijms20174294. https://www.mdpi.com/1422-0067/20/17/4294/htm

Effects of Parental Opioid Use: Outcomes of Children of Parents in Medication-Assisted Treatment Compared to Healthy Controls.

08. September 2019 | Substitutionsmittel Verschiedenes

Effects of Parental Opioid Use: Outcomes of Children of Parents in Medication-Assisted Treatment Compared to Healthy Controls. Betcher HK, Vande Voort JL, Croarkin PE, Gandhi KD, Shekunov J, Larrabee BR, Limbeck MG, Rummans TA, Romanowicz M. Prim…

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.

08. September 2019 | Substitutionsmittel Verschiedenes

Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Ann Intern Med. 2018 Aug 7;169(3):1…

Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.

08. September 2019 | Substitutionsmittel Verschiedenes

Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime. Molero Y, Zetterqvist J, Binswanger IA, Hellner C, Larsson H, Fazel S. Am J Psychiatry. 2018 Oct 1;175(10):970-978. doi: 10.1176/appi…

Opioid Use Disorders: Perioperative Management of a Special Population.

08. September 2019 | Substitutionsmittel Verschiedenes

Opioid Use Disorders: Perioperative Management of a Special Population. Ward EN, Quaye AN, Wilens TE. Anesth Analg. 2018 Aug;127(2):539-547. doi: 10.1213/ANE.0000000000003477. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523021/

Early Diagnosis of Hearing Loss in Patients Under Methadone Maintenance Treatment.

08. September 2019 | Methadon zur Substitution

Early Diagnosis of Hearing Loss in Patients Under Methadone Maintenance Treatment. Bayat A, Saki N, Mirmomeni G, Yadollahpour A. Front Neurol. 2019 Jul 16;10:749. doi: 10.3389/fneur.2019.00749. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6…

Dose Tapering Strategy for Heroin Abstinence among Methadone Maintenance Treatment Participants: Evidence from A Retrospective Study in Guangdong, China.

08. September 2019 | Methadon zur Substitution

Dose Tapering Strategy for Heroin Abstinence among Methadone Maintenance Treatment Participants: Evidence from A Retrospective Study in Guangdong, China. Lu Q, Zou X, Liu Y, Gong C, Ling L. Int J Environ Res Public Health. 2019 Aug 6;16(15). pii…

Frequent nightmares in Chinese patients undergoing methadone maintenance therapy: prevalence, correlates, and their association with functional impairment.

08. September 2019 | Methadon zur Substitution

Frequent nightmares in Chinese patients undergoing methadone maintenance therapy: prevalence, correlates, and their association with functional impairment. Zhong BL, Xu YM, Xie WX, Lu J. Neuropsychiatr Dis Treat. 2019 Jul 18;15:2063-2072. doi: 10…

Efficacy of Electroacupuncture Combined with Methadone Maintenance Therapy: A Case-Control Study.

08. September 2019 | Methadon zur Substitution

Efficacy of Electroacupuncture Combined with Methadone Maintenance Therapy: A Case-Control Study. Chen YL, Lee TC, Chen YT, Lo LC, Hsu WY, Ouyang WC. Evid Based Complement Alternat Med. 2019 Jul 21;2019:7032581. doi: 10.1155/2019/7032581. h…

Auf der Packungsrückseite: Falsche Wirkstoffgehaltsangabe bei Subutex

05. September 2019 | Buprenorphin

Auf der Packungsrückseite: Falsche Wirkstoffgehaltsangabe bei Subutex Die Firma Indivior ruft eine Charge Subutex 8mg Sublingualtabletten 28 Stück zurück. Der Grund: Auf der Rückseite der Packung ist der falsche Wirkstoffgehalt aufgedruckt. (Deutsc…

Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids.

02. September 2019 | Methadon zur Substitution

Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids. Makunts T, U A, Atayee RS, Abagyan R. Sci Rep. 2019 Aug 28;9(1):12490. doi: 10.1038/s41598-019-48955-y. https://www.n…

Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids.

02. September 2019 | Methadon in der Krebsmedizin

Tramadol könnte Hypoglykämien auslösen

02. September 2019 | Methadon zur Substitution

Tramadol könnte Hypoglykämien auslösen San Diego – Das Schmerzmittel Tramadol, das zunehmend als sichere Alternative zu anderen Opioiden betrachtet wird, kann offenbar schwere Hypoglykämien auslösen. Dies kam in einer Analyse von Datenbanken der US…

Tramadol könnte Hypoglykämien auslösen

02. September 2019 | Methadon in der Krebsmedizin

Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.

02. September 2019 | Buprenorphin

Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment. Withey SL, Spealman RD, Bergman J, Paronis CA. J Pharmacol Exp Ther. 2019 Aug 14. pii: jpet.119.259010. doi: 10.1124/jpet.119.259010 http://jpet.aspetj…

Dortmund. Diskussion um Diamorphin-Ambulanz: Hilfe für Süchtige- aber mit welchem Konzept?

01. September 2019 | Diamorphin

Dortmund. Diskussion um Diamorphin-Ambulanz: Hilfe für Süchtige- aber mit welchem Konzept? Eine kontrollierte Diamorphin-Abgabe für Dortmund bringt die CDU-Sozialfraktion in die Diskussion. Es geht dabei um synthetisch hergestelltes Heroin, w…

UK. ‘Saved from a horrible fate’: Legal heroin prescribed to hundreds of UK drug users, figures reveal

01. September 2019 | Diamorphin

UK. ‘Saved from a horrible fate’: Legal heroin prescribed to hundreds of UK drug users, figures reveal ‘Vital’ treatment threatened by cuts to addiction services, risking ‘untold damage’, expert warns. (The Independent, UK, 17.08.2019) https://www…

UK. 'Heroin assisted treatment scheme a chance to finally turn the tide against drugs'

01. September 2019 | Diamorphin

UK. 'Heroin assisted treatment scheme a chance to finally turn the tide against drugs' AS official figures reveal drugs deaths have soared to record levels, Police and Crime Commissioner for Cleveland, Barry Coppinger, outlines a scheme being pilot…

Berlin. Suchtbehandlung: Stoff vom Staat

18. August 2019 | Diamorphin

Berlin. Suchtbehandlung: Stoff vom Staat Seit zehn Jahren gibt es in Deutschland Heroin als Kassenleistung. Berliner Süchtige erhalten ihre Dosis in der Praxis Patrida. Der Bedarf ist groß. (Zitty, Berlin, 12.08.2019) https://www.zitty.de/stoff-vo…

Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine .

18. August 2019 | Buprenorphin

Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine . Strang J, Knight A, Baillie S, Reed K, Bogdanowicz K, Bell J. Int J Clin Pharmacol Ther. 2018 Feb;56(2):81-85. doi…

SUBOXONE® (buprenorphine and naloxone) sublingualfilm CIII – RISK EVALUATION AND MITIGATION STRATEGY (REMS)

18. August 2019 | Buprenorphin

SUBOXONE® (buprenorphine and naloxone) sublingualfilm CIII – RISK EVALUATION AND MITIGATION STRATEGY (REMS) Buprenorphine (opioid partial agonist‐antagonist) Naloxone (opioidantagonist) Initial REMS approval: 08/2010, Most recent modification: 04/…

Kanada. British Columbia: Injectable opioid treatment comes to Vancouver Island for first time

16. August 2019 | Diamorphin

Kanada. British Columbia: Injectable opioid treatment comes to Vancouver Island for first time The treatment delivers pharmaceutical-grade opioids via a syringe, rather than pills. (CBC News, Kanada, 14.08.2019) https://www.cbc.ca/news/canada/brit…

Methadon soll als Krebsmittel getestet werden

16. August 2019 | Methadon in der Krebsmedizin

Methadon soll als Krebsmittel getestet werden Claudia Friesen will Methadon als Krebsmittel testen. Damit macht sie sich unter den Ärzten viele Feinde. (TagesAnzeiger, Schweiz, 15.08.2019) https://twnews.ch/ch-news/methadon-soll-als-krebsmittel-ge…

Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.

12. August 2019 | Buprenorphin

Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects. Wachman EM, Saia K, Miller M, Valle E, Shrestha H, Carter G, Werler M, Jones H. Clin Ther. 2019 Jul 27. pii: S0149-2918(19)30346…

Buprenorphine in the United States: Motives for abuse, misuse, and diversion.

12. August 2019 | Buprenorphin

Buprenorphine in the United States: Motives for abuse, misuse, and diversion. Chilcoat HD, Amick HR, Sherwood MR, Dunn KE. J Subst Abuse Treat. 2019 Sep;104:148-157. doi: 10.1016/j.jsat.2019.07.005. Abstract https://www.ncbi.nlm.nih.gov/pu…

Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.

12. August 2019 | Methadon zur Substitution

Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol. Terasaki D, Smith C, Calcaterra SL. Pharmacotherapy. 2019 Jul 26. doi: 10.1002/phar.23…

Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol.

12. August 2019 | Buprenorphin

Specificity of personality relationships to particular forms of concurrent substance use among methadone maintenance therapy clients.

12. August 2019 | Methadon zur Substitution

Specificity of personality relationships to particular forms of concurrent substance use among methadone maintenance therapy clients. Mahu IT, Conrod PJ, Barrett SP, Sako A, Swansburg J, Lawrence M, Laroque F, Morin JF, Chinneck A, Nogueira-Arjona…

Decreased Level of Blood MicroRNA-133b in Men with Opioid Use Disorder on Methadone Maintenance Therapy.

12. August 2019 | Methadon zur Substitution

Decreased Level of Blood MicroRNA-133b in Men with Opioid Use Disorder on Methadone Maintenance Therapy. Hsu CW, Huang TL, Tsai MC. J Clin Med. 2019 Jul 25;8(8). pii: E1105. doi: 10.3390/jcm8081105. https://www.mdpi.com/2077-0383/8/8/1105

Supervised injectable opioid agonist therapy in a supported housing setting for the treatment of severe opioid use disorder.

12. August 2019 | Diamorphin

Supervised injectable opioid agonist therapy in a supported housing setting for the treatment of severe opioid use disorder. Brar R, Sutherland C, Nolan S. BMJ Case Rep. 2019 Aug 1;12(7). pii: e229456. doi: 10.1136/bcr-2019-229456. Abstract http…

What is the connection between serum phosphorus, cancer and heroin? A medical hypothesis based on observational studies.

12. August 2019 | Methadon in der Krebsmedizin

What is the connection between serum phosphorus, cancer and heroin? A medical hypothesis based on observational studies. Kouloulias V, Papaloucas CD, Papaloucas A. J BUON. 2017 Sep-Oct;22(5):1303-1306. https://www.jbuon.com/archive/22-5-1303.pdf

Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine.

11. August 2019 | Buprenorphin

Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine. Oscar D’Agnone Case Reports in Psychiatry, vol. 2019, Article ID 9381346, 4 pages, 2019. doi.org/10.1155/2019/9381346. https://www…

Meta-Opinion. What place for prolonged-release buprenorphine depot formulations (Buvidal®) in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.

11. August 2019 | Buprenorphin

Meta-Opinion. What place for prolonged-release buprenorphine depot formulations (Buvidal®) in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A…

Vielversprechend: Suchtexpert*innen präsentieren erste Praxis-Erfahrungen mit Depot Buvidal®

11. August 2019 | Buprenorphin

Vielversprechend: Suchtexpert*innen präsentieren erste Praxis-Erfahrungen mit Depot Buvidal® Mannheim/Lund. Seit Anfang des Jahres in Deutschland verfügbar, liegen nun erste Erfahrungen mit dem neuen Buprenorphin-Depot Buvidal®zur Behandlung der Op…

Comparing the Effects of Methadone, Buprenorphine, and Opium Tincture Maintenance Therapy on Sexual Function.

28. Juli 2019 | Buprenorphin

Comparing the Effects of Methadone, Buprenorphine, and Opium Tincture Maintenance Therapy on Sexual Function. Kheradmand A, Fazeli A, Mazaheri Meybodi A. Addict Health. 2019 Apr;11(2):120-128. doi: 10.22122/ahj.v11i2.232. https://www.ncbi.nlm.nih…

Comparing the Effects of Methadone, Buprenorphine, and Opium Tincture Maintenance Therapy on Sexual Function.

28. Juli 2019 | Methadon zur Substitution

Offering Emergency Buprenorphine Without a Prescription.

28. Juli 2019 | Buprenorphin

Offering Emergency Buprenorphine Without a Prescription. Roy PJ, Stein MD. JAMA.Published online July 08, 2019. doi:10.1001/jama.2019.8309 https://jamanetwork.com/journals/jama/fullarticle/2737850

Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines [Internet].

28. Juli 2019 | Buprenorphin

Buprenorphine for Opioid Use Disorder: A Review of Comparative Clinical Effectiveness, Safety, Cost-Effectiveness, and Guidelines [Internet]. Marchand DK, Young C, Loshak H. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 A…

Epidemiology of severe buprenorphine exposures reported to the U.S. Poison Centers.

28. Juli 2019 | Buprenorphin

Epidemiology of severe buprenorphine exposures reported to the U.S. Poison Centers. Rege SV, Ngo DA, Ait-Daoud N, Holstege CP. Drug Alcohol Depend. 2019 Jul 16;202:115-122. doi: 10.1016/j.drugalcdep.2019.05.015. Abstract https://www.ncbi.nlm.nih…

Petitionsausschuss unterstützt Forderungen nach Forschung bei Methadon in der Krebstherapie

23. Juli 2019 | Methadon in der Krebsmedizin

Petitionsausschuss unterstützt Forderungen nach Forschung bei Methadon in der Krebstherapie Berlin – Der Petitionsausschuss des Bundestags hat sich in der letzten Sitzungswoche des Parlaments einstimmig hinter die Forderung einer Petition nach eine…

USA. In den USA erzielt ein Vergleich über Opioid-Vermarktung einen neuen Rekord

14. Juli 2019 | Buprenorphin

USA. In den USA erzielt ein Vergleich über Opioid-Vermarktung einen neuen Rekord Der britische Konzern Reckitt Benckiser lässt die Abwehr einer Strafklage 1,4 Milliarden Dollar kosten. Es geht um das Medikament Suboxone, das zur Suchtbehandlung ang…

USA. Reckitt Benckiser zahlt Milliardenstrafe in den USA

14. Juli 2019 | Buprenorphin

USA. Reckitt Benckiser zahlt Milliardenstrafe in den USA London – Reckitt Benckiser legt den Streit mit den US-Behörden wegen verbotener Marketingmethoden für sein Kombinationspräparat Suboxone Film mit einer Milliardenzahlung bei. (aerzteblatt.de…

Free Clinical Update Special Edition - Espranor®

14. Juli 2019 | Buprenorphin

Free Clinical Update Special Edition - Espranor® This clinical update focuses on Espranor® (bup-lyo), the lyophilized (rapid-disintegrating) buprenorphine tablet for opioid use disorder (OUD), produced by Ethypharm, which has been available since J…

Erste Behandlungserfahrungen mit wöchentlichem und monatlichem subkutanem Buprenorphin-Depot in Deutschland (Poster)

07. Juli 2019 | Buprenorphin

Erste Behandlungserfahrungen mit wöchentlichem und monatlichem subkutanem Buprenorphin-Depot in Deutschland (Poster) Claus Schubert, Nikolaus Springer, Antje Breske. Das erste wöchentliche/monatliche subkutane Buprenorphin-Depot (Buvidal®) wurde i…

Erfahrungen nach der Zulassung mit dem wöchentlichen und monatlichen subkutanen Buprenorphin-Depot im Praxisalltag: Fragen an Medical Information und Antworten. (Poster)

07. Juli 2019 | Buprenorphin

Erfahrungen nach der Zulassung mit dem wöchentlichen und monatlichen subkutanen Buprenorphin-Depot im Praxisalltag: Fragen an Medical Information und Antworten. (Poster) Anfragen, die Camurus MIS per E-Mail oder Telefon erhielt, wurden nach Themen…

Effectiveness of Mindfulness-based Relapse Prevention on Quality of Life and Craving in Methadone-treated Patients: A Randomized Clinical Trial.

06. Juli 2019 | Methadon zur Substitution

Effectiveness of Mindfulness-based Relapse Prevention on Quality of Life and Craving in Methadone-treated Patients: A Randomized Clinical Trial. Yaghubi M, Zargar F. Addict Health. 2018 Oct;10(4):250-259. doi: 10.22122/ahj.v10i4.573. https://www…

DL-Methadone as an Enhancer of Chemotherapeutic Drugs in Head and Neck Cancer Cell Lines.

06. Juli 2019 | Methadon in der Krebsmedizin

DL-Methadone as an Enhancer of Chemotherapeutic Drugs in Head and Neck Cancer Cell Lines. Landgraf V, Griessmann M, Roller J, Polednik C, Schmidt M. Anticancer Res. 2019 Jul;39(7):3633-3639. doi: 10.21873/anticanres.13511. Abstract https://www.n…

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men.

06. Juli 2019 | Buprenorphin

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men. Ziaaddini H, Heshmati S, Chegeni M, Mousavi-Ramezanzade M, Mazhari S. Addict Health. 2018 Oct;10(4):269-275. doi: 10.22122/ahj.v10i4.679. https://ww…

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.

06. Juli 2019 | Buprenorphin

Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder. Dong R, Wang H, Li D, Lang L, Gray F, Liu Y, Laffont CM, Young M, Jiang J, Liu Z, Learned SM. Dr…

Palliativversorgung von Patienten in Opioidsubstitutionsbehandlung (mit CME)

06. Juli 2019 | Substitutionsmittel Verschiedenes

Palliativversorgung von Patienten in Opioidsubstitutionsbehandlung (mit CME) Hoffmann-Menzel, J.Goldmann, M.Kern, K.Weckbecker, L. Wüllenweber, L. Radbruch Schmerz 2019 · 33:263–280, doi.org/10.1007/s00482-019-0376-0 Abstract (freier Zugang für 1…

Buvidal®Homepage (im Aufbau)

06. Juli 2019 | Buprenorphin

Buvidal®Homepage (im Aufbau) https://www.buvidal.de/

Berlin / Stuttgart. Petitionsausschuss befürwortet klinische Studien: Forschungsunterstützung bei Methadon – jetzt doch!

06. Juli 2019 | Methadon in der Krebsmedizin

Berlin / Stuttgart. Petitionsausschuss befürwortet klinische Studien: Forschungsunterstützung bei Methadon – jetzt doch! Methadon in der Krebstherapie – sinnvoll oder nicht? Diese Zweifel sollen kleiner werden: Der Petitionsausschuss unterstüt…

Exploring the Effects of Vitamin D Supplementation on Cognitive Functions and Mental Health Status in Subjects Under Methadone Maintenance Treatment.

30. Juni 2019 | Methadon zur Substitution

Exploring the Effects of Vitamin D Supplementation on Cognitive Functions and Mental Health Status in Subjects Under Methadone Maintenance Treatment. Ghaderi A, Rasouli-Azad M, Farhadi MH, Mirhosseini N, Motmaen M, Pishyareh E, Omidi A, Asemi Z. J…

Cigarette Smoking Is Significantly Linked to Sexual Dissatisfaction in Chinese Heroin-Dependent Patients Receiving Methadone Maintenance Treatment.

30. Juni 2019 | Methadon zur Substitution

Cigarette Smoking Is Significantly Linked to Sexual Dissatisfaction in Chinese Heroin-Dependent Patients Receiving Methadone Maintenance Treatment. Zhong BL, Xu YM, Xie WX, Lu J. Front Psychiatry. 2019 May 22;10:306. doi: 10.3389/fpsyt.2019.00306…

Loneliness and Illicit Opioid Use Among Methadone Maintenance Treatment Patients.

30. Juni 2019 | Methadon zur Substitution

Loneliness and Illicit Opioid Use Among Methadone Maintenance Treatment Patients. Polenick CA, Cotton BP, Bryson WC, Birditt KS. Subst Use Misuse. 2019 Jun 24:1-10. doi: 10.1080/10826084.2019.1628276. Abstract https://www.ncbi.nlm.nih.gov/…

Functional Correlates of Resting-State Connectivity in the Default Mode Network of Heroin Users on Methadone Treatment and Medication-Free Therapeutic Community Program.

30. Juni 2019 | Methadon zur Substitution

Functional Correlates of Resting-State Connectivity in the Default Mode Network of Heroin Users on Methadone Treatment and Medication-Free Therapeutic Community Program. Kuo LW, Lin PS, Lin SY, Liu MF, Jan H, Lee HC, Wang SC. Front Psychiatry. 201…

Indivior Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for SUBOXONE®(buprenorphine and naloxone) Sublingual Film

24. Juni 2019 | Buprenorphin

Indivior Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for SUBOXONE®(buprenorphine and naloxone) Sublingual Film Slough, UK, 18 June 2019–Indivior PLC (LON: INDV) (the ‘Company’), a global…

Sex differences in high opioid dose escalation among Malaysian patients with long term opioid therapy.

24. Juni 2019 | Substitutionsmittel Verschiedenes

Sex differences in high opioid dose escalation among Malaysian patients with long term opioid therapy. Zin CS, Alias NE, Taufek NH, Ahmad MM. J Pain Res. 2019 Apr 24;12:1251-1257. doi: 10.2147/JPR.S199243. https://www.ncbi.nlm.nih.gov/pmc/article…

Kanada. Free heroin? Unusual clinic offers 'chance at being human again'

21. Juni 2019 | Diamorphin

Kanada. Free heroin? Unusual clinic offers 'chance at being human again' Low-dose drug program provides an alternative to potentially deadly street narcotics. (CBC, Kanada, 09.06.2019) https://www.cbc.ca/news/health/national-heroin-treatment…

Aufgrund von zwei Fallberichten: AkdÄ warnt vor Stürzen unter Methadon

21. Juni 2019 | Methadon in der Krebsmedizin

Aufgrund von zwei Fallberichten: AkdÄ warnt vor Stürzen unter Methadon Methadon ist etabliert in der Substitutionstherapie opioidabhängiger Patienten. In der Tumortherapie ist Methadon derzeit nicht offiziell anerkannt und zugelassen, die antiproli…

Buvidal®. Free Clinical Update: Special Edition

21. Juni 2019 | Buprenorphin

Buvidal®. Free Clinical Update: Special Edition This Clinical Update focuses on the new prolonged release subcutaneous buprenorphine injection for opioid use disorder . The purpose of this update is not to summarise the pharmacological proper…

Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use.

15. Juni 2019 | Methadon zur Substitution

Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. Carroll KM, DeVito EE, Yip SW, Nich C, Sofu…

Methadone enhances the effectiveness of 5-aminolevulinic acid-based photodynamic therapy for squamous cell carcinoma and glioblastoma in vitro.

15. Juni 2019 | Methadon in der Krebsmedizin

Methadone enhances the effectiveness of 5-aminolevulinic acid-based photodynamic therapy for squamous cell carcinoma and glioblastoma in vitro. Shi L, Buchner A, Pohla H, Pongratz T, Rühm A, Zimmermann W, Gederaas OA, Zhang L, Wang X, Stepp H, Srok…

Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.

11. Juni 2019 | Buprenorphin

Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Frost, M., Bailey, G. L., Lintzeris, N., Strang, J., Dunlop, A., Nunes, E. V., Jansen, J. B., Frey…

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.

06. Juni 2019 | Buprenorphin

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences. Neale, J. , Tompkins, C. N. and Strang, J. (2019), Drug Alcohol Rev.. doi:10.1111/dar.12939 https://onlinelibrary.wiley.com/doi/full/10.1111/…

FREE WEBINAR: Long-acting Buprenorphine prescribing in criminal justice settings: implications for services

04. Juni 2019 | Buprenorphin

FREE WEBINAR: Long-acting Buprenorphine prescribing in criminal justice settings: implications for services Presenters: Dr Jake Hard, GP, Chair, RCGP Secure Environments Group Professor Adrian Dunlop, School of Medicine and Public Health, U…

Buprenorphine and Methadone as Opioid Maintenance Treatments for Heroin-Addicted Patients Induce Oxidative Stress in Blood.

28. Mai 2019 | Substitutionsmittel Verschiedenes

Buprenorphine and Methadone as Opioid Maintenance Treatments for Heroin-Addicted Patients Induce Oxidative Stress in Blood. Leventelis C, Goutzourelas N, Kortsinidou A, Spanidis Y, Toulia G, Kampitsi A, Tsitsimpikou C, Stagos D, Veskoukis AS, Koure…

Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3).

28. Mai 2019 | Buprenorphin

Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3). Zajecka JM, Stanford AD, Memisoglu A, Martin WF, Pathak S. Neuropsychiatr Dis Treat. 2019 Apr 4;15…

Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series.

28. Mai 2019 | Buprenorphin

Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series. Martin YN, Deljou A, Weingarten TN, Schroeder DR, Sprung J. BMC Anesthesiol. 2019 May 8;19(1):68. doi: 10.1186/s12871-019-0745-3. https://ww…

Baden-Württemberg. Ministerium prüft Bedarf weiterer Diamorphin-Ambulanzen

28. Mai 2019 | Diamorphin

Baden-Württemberg. Ministerium prüft Bedarf weiterer Diamorphin-Ambulanzen Zehn Jahre nach dem Start für den flächendeckenden Einsatz künstlichen Heroins auf Kassenkosten prüft das Landessozialministerium Bedarf und Möglichkeiten für weitere Praxen…

Niederlande. Verkenning toekomstscenario’s medische heroïnebehandeling Nijmegen

28. Mai 2019 | Diamorphin

Niederlande. Verkenning toekomstscenario’s medische heroïnebehandeling Nijmegen Sinds 2011 kent de gemeente Nijmegen een unit voor Medische Heroïne Behandeling (MHB), dit in navolging van effectief gebleken experimenten elders in het land. Uit eerd…

Ginseng treatment improves the sexual side effects of methadone maintenance treatment.

28. Mai 2019 | Methadon zur Substitution

Ginseng treatment improves the sexual side effects of methadone maintenance treatment. Farnia V, Alikhani M, Ebrahimi A, Golshani S, Sadeghi Bahmani D, Brand S. Psychiatry Res. 2019 May 2;276:142-150. doi: 10.1016/j.psychres.2019.05.004. Ab…

Comparison of Sexual Function and Serum Testosterone Levels in Men Opiate Addicts, under Methadone Maintenance Therapy, and Healthy Men.

28. Mai 2019 | Methadon zur Substitution

Comparison of Sexual Function and Serum Testosterone Levels in Men Opiate Addicts, under Methadone Maintenance Therapy, and Healthy Men. Agha-Mohammadhasani P, Mokhtaree M, Nazari A, Rahnama A. Addict Health. 2018 Apr;10(2):76-85. doi: 10.221…

Learning from the past, looking to the future - Is there a place for injectable opioid treatment among Australia's responses to opioid misuse?

27. Mai 2019 | Diamorphin

Learning from the past, looking to the future - Is there a place for injectable opioid treatment among Australia's responses to opioid misuse? Belackova V, Salmon AM, Jauncey M, Bell J. Int J Drug Policy. 2019 Apr 8. pii: S0955-3959(19)30094-5. do…

Chronic High-Dose Buprenorphine Does Not Block Subjective High from Diacetylmorphine in a Patient in Heroin-Assisted Treatment.

27. Mai 2019 | Buprenorphin

Chronic High-Dose Buprenorphine Does Not Block Subjective High from Diacetylmorphine in a Patient in Heroin-Assisted Treatment. Vogel M, Köck P, Strasser J, Wiesbeck G, Walter M, Dürsteler KM. J Psychoactive Drugs. 2019 May 2:1-6. doi: 10.1080/027…

Chronic High-Dose Buprenorphine Does Not Block Subjective High from Diacetylmorphine in a Patient in Heroin-Assisted Treatment.

27. Mai 2019 | Diamorphin

Suboxone Treatment and Recovery Trial (STAR-T): Study Protocol for a Randomised Controlled Trial of Opioid Medication Assisted Treatment with Adjunctive Medication Management Using Therapeutic Drug Monitoring and Contingency Management.

27. Mai 2019 | Buprenorphin

Suboxone Treatment and Recovery Trial (STAR-T): Study Protocol for a Randomised Controlled Trial of Opioid Medication Assisted Treatment with Adjunctive Medication Management Using Therapeutic Drug Monitoring and Contingency Management. Elarabi H…

Codeine Addiction and Internet Forum Use and Support: Qualitative Netnographic Study.

27. Mai 2019 | Codein

Codeine Addiction and Internet Forum Use and Support: Qualitative Netnographic Study. Lee E, Cooper RJ. JMIR Ment Health. 2019 Apr 25;6(4):e12354. doi: 10.2196/12354. https://mental.jmir.org/2019/4/e12354/

Berichte an die AkdÄ über Stürze unter der Einnahme von Methadon: Was muss beachtet werden? („Aus der UAW-Datenbank“)

25. Mai 2019 | Methadon in der Krebsmedizin

Berichte an die AkdÄ über Stürze unter der Einnahme von Methadon: Was muss beachtet werden? („Aus der UAW-Datenbank“) Deutsches Ärzteblatt, Jg. 116, Heft 20, 17.05.2019 https://www.akdae.de/Arzneimittelsicherheit/Bekanntgaben/Archiv/2019/20190517…

Kanada. Addressing the opioid crisis through innovative treatment options and investments in frontline projects and research

25. Mai 2019 | Diamorphin

Kanada. Addressing the opioid crisis through innovative treatment options and investments in frontline projects and research Backgrounder New evidence-based treatments available for opioid use disorder On May 1, Health Canada approved a new indic…

Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.

14. Mai 2019 | Substitutionsmittel Verschiedenes

Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy. Gastberger S, Baumgartner MR, Soyka M, Quednow BB, Hulka LM, Herdener M, Seifritz E, Mutschler J. Eur Addict Res…

Craving for heroin: difference between methadone maintenance therapy patients with and without ADHD.

01. Mai 2019 | Methadon zur Substitution

Craving for heroin: difference between methadone maintenance therapy patients with and without ADHD. Coppola M, Sacchetto G, Mondola R. Trends Psychiatry Psychother. 2019 Jan-Mar;41(1):83-86. doi: 10.1590/2237-6089-2017-0159. http://www.scielo.br…

Deutscher Bundestag. Zehn Jahre diamorphingestützte Substitutionsbehandlung – Erfolge und Weiterentwicklungsbedarf

01. Mai 2019 | Diamorphin

Deutscher Bundestag. Zehn Jahre diamorphingestützte Substitutionsbehandlung – Erfolge und Weiterentwicklungsbedarf Kleine Anfrage der Abgeordneten Dr. Kirsten Kappert-Gonther, Kordula Schulz-Asche, Maria Klein-Schmeink, Dr. Bettina Hoffmann…

Deutschland. Nach zehn Jahren drei weitere Ambulanzen für künstliches Heroin

01. Mai 2019 | Diamorphin

Deutschland. Nach zehn Jahren drei weitere Ambulanzen für künstliches Heroin Berlin – Zehn Jahre nach dem offiziellen Startschuss für den flächendeckenden Einsatz künstlichen Heroins auf Kassenkosten sind bundesweit drei weitere Abgabestellen…

Schweiz. Heroin: Die Basler Idee, die stach – ein Wagnis etablierte sich in der ganzen Schweiz

01. Mai 2019 | Diamorphin

Schweiz. Heroin: Die Basler Idee, die stach – ein Wagnis etablierte sich in der ganzen Schweiz Vor 25 Jahren sagte Basel ja zur versuchsweisen Abgabe von Heroin an Süchtige. Was zunächst als Wagnis galt, etablierte sich nach und nach in der ganzen…

Buprenorphine. New long-lasting implant to treat opioid dependence

01. Mai 2019 | Buprenorphin

Buprenorphine. New long-lasting implant to treat opioid dependence EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union (EU) for Sixmo (buprenorphine) as a substitution treatment for opioid…

Buprenorphin-Implantat – eine neue Option bei Opioid-Abhängigkeit

01. Mai 2019 | Buprenorphin

Buprenorphin-Implantat – eine neue Option bei Opioid-Abhängigkeit Neue Optionen gibt es auch bei Opioidabhängigkeit. CHMP-Experten empfahlen, Sixmo® (Buprenorphin) für Substitutionsbehandlungen zuzulassen. Speziell geschulte Ärzte applizieren…

Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder.

01. Mai 2019 | Buprenorphin

Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder. Frost M, Bailey GL, Lintzeris N, Strang J, Dunlop A, Nunes EV, Jansen JB, Frey LC, Weber B, Haber P…

EMA spricht sich für Buprenorphin-Implantat zur Behandlung von Opioidabhängigkeit aus

01. Mai 2019 | Buprenorphin

EMA spricht sich für Buprenorphin-Implantat zur Behandlung von Opioidabhängigkeit aus Amsterdam – Die Substitutionstherapie von Opioidabhängigen kann künftig mit einem subkutanen Implantat durchgeführt werden, aus dem das Ersatzopioid Buprenorphin…

Unter die Haut: Neue Depotspritze zur Substitutionsbehandlung

01. Mai 2019 | Buprenorphin

Unter die Haut: Neue Depotspritze zur Substitutionsbehandlung Seit Anfang Februar ist die Depotspritze Buvidal auf dem Markt, das erste lang wirksame Buprenorphin-Präparat zur Substitutionsbehandlung. Das Mittel wird je nach Dosierung einmal wöchen…

Characterization of the Safety and Pharmacokinetic Profile of D-Methadone, a Novel N-Methyl-D-Aspartate Receptor Antagonist in Healthy, Opioid-Naive Subjects: Results of Two Phase 1 Studies.

21. April 2019 | Methadon zur Substitution

Characterization of the Safety and Pharmacokinetic Profile of D-Methadone, a Novel N-Methyl-D-Aspartate Receptor Antagonist in Healthy, Opioid-Naive Subjects: Results of Two Phase 1 Studies. Bernstein G, Davis K, Mills C, Wang L, McDonnell M, Olden…

Successful treatment with slow-release oral morphine following afentanyl-related overdose: A case report.

19. April 2019 | Morphin ret.

Successful treatment with slow-release oral morphine following afentanyl-related overdose: A case report. Prinsloo G, Ahamad K, Socías ME MD, MSc. Subst Abus. 2019 Mar 4:1-3. doi: 10.1080/08897077.2019.1576086. Abstract https://www.ncbi.nlm.nih…

USA. US Buprenorphine Prices: A Complete List

17. April 2019 | Buprenorphin

USA. US Buprenorphine Prices: A Complete List Average WAC Price (USD) for 30 Units of Buprenorphine by Company. (Filter, USA, 16.04.2019) https://filtermag.org/2019/04/16/us-buprenorphine-prices-a-complete-list/

Arzneimittel und Therapie: „Leipziger Studie stützt Methadon-Hypothese!“ - Kritische Betrachtungen und Statements zu dem neuen Zellkulturversuch

12. April 2019 | Methadon in der Krebsmedizin

Arzneimittel und Therapie: „Leipziger Studie stützt Methadon-Hypothese!“ - Kritische Betrachtungen und Statements zu dem neuen Zellkulturversuch Die Methadon-Forscherin Dr. Claudia Friesen und der Palliativmediziner Dr. Hans-Jörg Hilscher haben sic…

Buvidal. Informationsbroschüre für ÄrztInnen und Ärzte und Patientinnen und Patienten

09. April 2019 | Buprenorphin

Buvidal. Informationsbroschüre für ÄrztInnen und Ärzte und Patientinnen und Patienten Die Firma Camurus teilt mit: „Ärzte, die die Broschüre zu Buvidal in gedruckter Form erhalten möchten, können gerne eine entsprechende Anfrage (unter Angabe ihrer…

Slow release oral morphine versus methadone for the treatment of opioid use disorder.

08. April 2019 | Morphin ret.

Slow release oral morphine versus methadone for the treatment of opioid use disorder. Klimas J, Gorfinkel L, Giacomuzzi SM, Ruckes C, Socías ME, Fairbairn N, Wood E. BMJ Open. 2019 Apr 2;9(4):e025799. doi: 10.1136/bmjopen-2018-025799. https://bmj…

Buvidal (Basisinformationen)

08. April 2019 | Buprenorphin

Buvidal (Basisinformationen) Arznei News, 22.11.2018) https://arznei-news.de/buvidal/#inhalt

Detection of heroin intake in patients in substitution treatment using oral fluid as specimen for drug testing.

08. April 2019 | Substitutionsmittel Verschiedenes

Detection of heroin intake in patients in substitution treatment using oral fluid as specimen for drug testing. Böttcher M, Lierheimer S, Peschel A, Beck O. Drug Alcohol Depend. 2019 Mar 23;198:136-139. doi: 10.1016/j.drugalcdep.2019.02.011. Abst…

Methadon zeigt keine Wirkung in neuer Studie mit Hirntumorgewebe

08. April 2019 | Methadon in der Krebsmedizin

Methadon zeigt keine Wirkung in neuer Studie mit Hirntumorgewebe Leipzig – Im vergangenen Jahr stand Methadon im Fokus der Diskussion als neue Therapiemöglichkeit beim Glioblastom. Nachdem Münchner wie auch Heidelberger Forscher die Wirkung der St…

Bundestag informiert sich über Einsatz von Methadon in der Krebstherapie

04. April 2019 | Methadon in der Krebsmedizin

Bundestag informiert sich über Einsatz von Methadon in der Krebstherapie Ulm / Berlin, 04.04.2019 – Zu einem Informationsgespräch über den Einsatz von Methadon in der Krebstherapie für die Bundestagsabgeordneten kamen die Ulmer Chemikerin Dr…

Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations

04. April 2019 | Buprenorphin

Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations Neale et al. Harm Reduction Journal (2019) 16:25, doi.org/10.1186/s12954-019-0296-4 https://lin…

Leipziger Studie: Methadon bei Krebstherapie von Hirntumoren unwirksam

02. April 2019 | Methadon in der Krebsmedizin

Leipziger Studie: Methadon bei Krebstherapie von Hirntumoren unwirksam Ein Opioid weckt Hoffnung: Methadon wurde nach einer wissenschaftlichen Veröffentlichung als möglicher Heilsbringer in der Krebstherapie gefeiert. Eine Petition forderte s…

Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.

01. April 2019 | Methadon zur Substitution

Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report. Ward HB, Barnett BS, Suzuki J. Subst Abus. 2019 Mar 19:1-6. doi: 10.1080/08897077.2019.1573776. Abstract https://www.ncbi.nlm.nih.gov/pubmed/308…

Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.

01. April 2019 | Buprenorphin

Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study.

01. April 2019 | Methadon zur Substitution

Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study. Victorri-Vigneau C, Verstuyft C, Bouquié R, Laforgue EJ, Hardouin JB, Leboucher J, Le Geay B, Dano C, Challet-Bouju G, Grall-Bronnec M. Br J Cli…

D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro.

01. April 2019 | Methadon in der Krebsmedizin

D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro. Oppermann H, Matusova M, Glasow A, Dietterle J, Baran-Schmidt R, Neumann K, Meixensberger J, Gaunitz F. Cancer Chemother Pharmacol. 2019 Mar 19. doi: 10.1007/s00280-0…

Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.

01. April 2019 | Buprenorphin

Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study. Ling W, Nadipelli VR, Solem CT, Ronquest NA, Yeh YC, Learned SM, Mehra V, Heidbreder C. J Addict Med…

Common elements in opioid use disorder guidelines for buprenorphine prescribing.

01. April 2019 | Buprenorphin

Common elements in opioid use disorder guidelines for buprenorphine prescribing. Atkinson TJ, Pisansky AJB, Miller KL, Yong RJ. Am J Manag Care. 2019 Mar 1;25(3):e88-e97. Abstract https://www.ncbi.nlm.nih.gov/pubmed/30875177

Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review.

01. April 2019 | Substitutionsmittel Verschiedenes

Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review. Butler K, Le Foll B. Front Psychiatry. 2019 Mar 1;10:98. doi: 10.3389/fpsyt.2019.00098. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405638/

A Pilot Crossover Trial of Sleep Medications for Sleep-disturbed Methadone Maintenance Patients.

01. April 2019 | Methadon zur Substitution

A Pilot Crossover Trial of Sleep Medications for Sleep-disturbed Methadone Maintenance Patients. Stein MD, Kurth ME, Anderson BJ, Blevins CE. J Addict Med. 2019 Mar 9. doi: 10.1097/ADM.0000000000000531. Abstract https://www.ncbi.nlm.nih.go…

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine.

16. März 2019 | Substitutionsmittel Verschiedenes

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine. Noble F, Marie N. Front Psychiatry. 2019 Jan 18;9:742. doi: 10.3389/fpsyt.2018.00742. eCollection 2018. Review. https://www.ncbi.nlm.nih.gov/p…

Methadon gegen Krebs - Ethische Aspekte

08. März 2019 | Methadon in der Krebsmedizin

Methadon gegen Krebs - Ethische Aspekte Steger, F., Gierschik, P. & Rubeis, G. Onkologe (2018) 24: 915. doi.org/10.1007/s00761-018-0445-5 Abstract https://link.springer.com/article/10.1007/s00761-018-0445-5

Evaluation of the effects of a monthly buprenorphine depot subcutaneous injection on qt interval during treatment for opioid use disorder.

03. März 2019 | Buprenorphin

Evaluation of the effects of a monthly buprenorphine depot subcutaneous injection on qt interval during treatment for opioid use disorder. Schmith VD, Curd L, Lohmer LRL, Laffont CM, Andorn A, Young MA. Clin Pharmacol Ther. 2019 Feb 22. doi: 10.10…

Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder.

03. März 2019 | Diamorphin

Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder. Oviedo-Joekes E, Palis H, Guh D, Marsh DC, MacDonald S, Harrison S, Brissette S, Anis AH, Schechter MT. J Addict Med. 2019 Feb 7…

Effects of Methadone Maintenance Therapy on Thyroid Function of Adult Men.

03. März 2019 | Methadon zur Substitution

Effects of Methadone Maintenance Therapy on Thyroid Function of Adult Men. Bozchelou S, Delirrad M. Toxicol Res. 2019 Jan;35(1):9-12. doi: 10.5487/TR.2019.35.1.009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354949/

Initiation and Rapid Titration of Methadone in an Acute Care Setting for the Treatment of Opioid Use Disorder: A Case Report.

03. März 2019 | Methadon zur Substitution

Initiation and Rapid Titration of Methadone in an Acute Care Setting for the Treatment of Opioid Use Disorder: A Case Report. Hemmons P, Bach P, Colizza K, Nolan S. J Addict Med. 2019 Feb 5. doi: 10.1097/ADM.0000000000000507. Abstract https://ww…

Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial.

03. März 2019 | Methadon zur Substitution

Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial. Nikoo M, Moazen-Zadeh E, Nikoo N, Javi…

Comparing opium tincture and methadone for medication-assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double-blind randomized controlled trial.

03. März 2019 | Substitutionsmittel Verschiedenes

Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.

02. März 2019 | Methadon zur Substitution

Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study. Lugoboni F, Zamboni L, Cibin M, Tamburin S; Gruppo InterSERT di Collaboraz…

Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.

02. März 2019 | Buprenorphin

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

26. Februar 2019 | Buprenorphin

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Haight, Barbara RAndersen, James L. et al. Lancet. 2019 Feb 18. pii: S0140-6736(18)3…

Monthly buprenorphine injections effective for opioid use disorders

26. Februar 2019 | Buprenorphin

Monthly buprenorphine injections effective for opioid use disorders Study results on long-acting injection formulation now published. (NIH – National Institutes of Health, USA, 19.02.2019) https://www.nih.gov/news-events/news-releases/monthly-bupr…

Buvidal® – die erste lang wirkende Therapieoption bei Opioidabhängigkeit in Deutschland: Wöchentliches und monatliches Buvidal®-Depot jetzt für Patienten in Deutschland verfügbar

12. Februar 2019 | Buprenorphin

Lund/Mannheim, 12. Februar 2019 – Wie Camurus (NASDAQ STO: CAMX) heute bekannt gab, ist das wöchentlich oder monatlich anzuwendende Buvidal® (Buprenorphin-Depotlösung zur subkutanen Injektion) ab sofort in Deutschland verfügbar. Buvidal® ist das ers…

Schweiz. Rauschakzeptierende Substitution in der Schweiz – auch in Deutschland möglich?

10. Februar 2019 | Diamorphin

Schweiz. RauschakzeptierendeSubstitution in der Schweiz – auch in Deutschland möglich? Der JES-Bundesverband freut sich sehr, dass Marc Vogelund Hannes Strassereinen Beitrag über innovative Entwicklungen der Substitutionsbe…

Schweiz. Heroingestützte Behandlung in der Schweiz - Resultate der Erhebung 2017 / Traitement avec prescription d’héroïne en Suisse. Résultats de l’enquête 2017

07. Februar 2019 | Diamorphin

Schweiz. Heroingestützte Behandlung in der Schweiz - Resultate der Erhebung 2017 / Traitement avec prescription d’héroïne en Suisse. Résultats de l’enquête 2017 Hiltebrand, Damian; Dey, Michelle; Bolliger, Heidi; Schaub, Michael P (2018). Zürich: I…

Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?.

04. Februar 2019 | Substitutionsmittel Verschiedenes

Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?. Marsden, J., Tai, B., Ali, R., Hu, L., Rush, A. J., and Volkow, N. (2019) Addiction, doi.org/10.1111/add.14546. https://onl…

Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society

04. Februar 2019 | Methadon zur Substitution

Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society Chou, Roger et al. The Journal of Pain , Volume 15 , Issue 4 , 321 - 337 …

Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society

04. Februar 2019 | Methadon in der Krebsmedizin

Prescribing diamorphine in the United States: Insights from a nationally representative survey.

04. Februar 2019 | Diamorphin

Prescribing diamorphine in the United States: Insights from a nationally representative survey. Kilmer B, Smart R, Taylor J, Caulkins JP. Drug Alcohol Depend. 2019 Jan 4;196:62-65. doi: 10.1016/j.drugalcdep.2018.12.007. https://www.ncbi.nlm.nih.g…

No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study.

04. Februar 2019 | Buprenorphin

No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study. Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JŠ, Krajci…

Buprenorphine for the treatment of posttraumatic stress disorder.

04. Februar 2019 | Buprenorphin

Buprenorphine for the treatment of posttraumatic stress disorder. Lake EP, Mitchell BG, Shorter DI, Kosten T, Domingo CB, Walder AM. Am J Addict. 2019 Jan 21. doi: 10.1111/ajad.12860. Abstract https://www.ncbi.nlm.nih.gov/pubmed/30664299…

Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression.

04. Februar 2019 | Buprenorphin

Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression. Lin C, Karim HT, Pecina M, Aizenstein HJ, Lenze EJ, Blumberger DM, Mulsant BH, Kharasch ED, Reynol…

Co-treatment with L-methadone increases the efficacy of antitumor agents in renal cell carcinoma cells in vitro

04. Februar 2019 | Methadon in der Krebsmedizin

Co-treatment with L-methadone increases the efficacy of antitumor agents in renal cell carcinoma cells in vitro Birgit Stadlbauer, Heike Pohla, Christian Stief, Alexander Buchner The Journal of Urology; Volume 199, Issue 4, Supplement, April 2018…

Co-treatment with L-methadone significantly increases the efficacy of cytostatic drugs in prostate cancer cells

04. Februar 2019 | Methadon in der Krebsmedizin

Co-treatment with L-methadone significantly increases the efficacy of cytostatic drugs in prostate cancer cells Birgit Stadlbauer, Detlef Kozian, Christian Stief, Alexander Buchner The Journal of Urology, Volume 197, Issue 4, Supplement, April 201…

Erfahrungen mit der Umstellung von Methadon-Razemat auf Levomethadon im Therapiealltag. Ergebnisse einer Gesamtanalyse zweier nicht-interventioneller Studien

04. Februar 2019 | Opioidsubstitution

Erfahrungen mit der Umstellung von Methadon-Razemat auf Levomethadon im Therapiealltag. Ergebnisse einer Gesamtanalyse zweier nicht-interventioneller Studien Konrad F. Cimander, Thomas Poehlke und Michael Soyka Suchtmed 17 (1) 7 – 19 (2015), …

Levomethadon in der Substitutionstherapie von opioidabhängigen Patienten

04. Februar 2019 | Opioidsubstitution

Levomethadon in der Substitutionstherapie von opioidabhängigen Patienten E.A. Mueller & W. Kirch DMW Dtsch med Wochenschr 2013; 138(40): 2052-2056 https://www.thieme.de/statics/dokumente/thieme/final/de/dokumente/tw_psychiatrie-psychotherapie…

(R)-methadone versus racemic methadone: what is best for patient care?

04. Februar 2019 | Opioidsubstitution

(R)-methadone versus racemic methadone: what is best for patient care? Elinore F. McCane-Katz Addiction. 2011 Apr; 106(4): 687–688. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3723395/

Fahrtauglichkeit opiatabhängiger Patienten unter Substitution mit Levomethadon und Methadonhydrochloridlösung 1%

04. Februar 2019 | Opioidsubstitution

Fahrtauglichkeit opiatabhängiger Patienten unter Substitution mit Levomethadon und Methadonhydrochloridlösung 1% Christiane Hummel, Astrid Beck, Franz Bentele, Oskar Josef Beck, Markus Backmund Posterpräsentation. Die Ergebnisse dieser Publikation…

STABIL-Studie: Umstellung von Methadon-Razemat auf Levomethadon bei klinisch unzureichender Wirksamkeit

04. Februar 2019 | Opioidsubstitution

STABIL-Studie: Umstellung von Methadon-Razemat auf Levomethadon bei klinisch unzureichender Wirksamkeit Konrad F. Cimander und Thomas Poehlke Suchtmed 12 (4) 187 – 196 (2010) https://praxis-suchtmedizin.ch/praxis-suchtmedizin/images/stories…

Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study.

04. Februar 2019 | Opioidsubstitution

Feasability and safety of transfer from racemic methadone to (R)-methadone in primary care: clinical results from an open study. Soyka M, Zingg C. World J Biol Psychiatry. 2009;10(3):217-24. doi: 10.1080/15622970802416057. Abstract ht…

Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure.

04. Februar 2019 | Opioidsubstitution

Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. Mitchell TB, Dyer KR, Newcombe D, Salter A, Somogyi AA, Bochner F, White JM. Br J Clin Pharmacol. 2004 Dec…

The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine.

04. Februar 2019 | Opioidsubstitution

The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Kristensen K, Christensen CB, Christrup LL. Life Sci. 1995;56(2):PL45-50. Abstract https://www.ncbi.nlm.nih.gov/pubmed/7823756

Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein.

04. Februar 2019 | Opioidsubstitution

Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Eap CB, Cuendet C, Baumann P. Clin Pharmacol Ther. 1990 Mar;47(3):338-46. Abstract https://www…

Temperamental Characteristics and Problem-Solving Skills among Patients on Opioid Agonists.

29. Januar 2019 | Substitutionsmittel Verschiedenes

Temperamental Characteristics and Problem-Solving Skills among Patients on Opioid Agonists. Eslami-Saaraab S, Eslami-Shahrbabaki H, Eslami-Shahrbabaki M, Motaghyan S. Addict Health. 2018 Jan;10(1):24-31. doi: 10.22122/ahj.v10i1.579. https://www.n…

Köln. Heroin auf Rezept – Sonst wäre ich tot (Video)

10. Januar 2019 | Diamorphin

Köln. Heroin auf Rezept – Sonst wäre ich tot (Video) Heroin auf Rezept, das klingt erst mal wie ausgedacht oder wie ein Projekt im drogenliberalen Portugal. Das gibt es aber auch hier in Deutschland an insgesamt zehn Standorten, unt…

Schweiz. Diacetylmorphin / Heroin - Pharmakologie des Diacetylmorphin (DAM)

10. Januar 2019 | Diamorphin

Schweiz. Diacetylmorphin / Heroin - Pharmakologie des Diacetylmorphin (DAM) Das in der Heroingestützten Behandlung benutzte Diacetylmorphin wurde 1874 entdeckt und 1898 von der Firma Bayer unter dem Namen Heroin auf den Markt gebracht. Verord…

Methadone therapy modulate the dendritic cells of heroin addicts.

05. Januar 2019 | Methadon zur Substitution

Methadone therapy modulate the dendritic cells of heroin addicts. Akbari A, Mosayebi G, Samiei AR, Ghazavi A. Int Immunopharmacol. 2019 Jan;66:330-335. doi: 10.1016/j.intimp.2018.11.047. Abstract https://www.ncbi.nlm.nih.gov/pubmed/30521961

Evaluation of an on-site test device for the heroin metabolite 6-acetylmorphine in urine.

30. Dezember 2018 | Diamorphin

Evaluation of an on-site test device for the heroin metabolite 6-acetylmorphine in urine. Picht F, Beck O, Böttcher M. Drug Test Anal. 2018 Dec 20. doi: 10.1002/dta.2559. Abstract https://www.ncbi.nlm.nih.gov/pubmed/30569568

Safe and Appropriate Use of Methadone in Hospice and Palliative Care: Expert Consensus White Paper.

30. Dezember 2018 | Methadon zur Substitution

Safe and Appropriate Use of Methadone in Hospice and Palliative Care: Expert Consensus White Paper. McPherson ML, Walker KA, Davis MP, Bruera E, Reddy A, Paice J, Malotte K, Lockman DK, Wellman C, Salpeter S, Bemben NM, Ray JB, Lapointe BJ, Chou R…

Clinical experience with methadon.

30. Dezember 2018 | Methadon zur Substitution

Clinical experience with methadon. KIRCHHOF AC, DAVID NA. Anesthesiology. 1948 Nov;9(6):585-93. http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1971967

Weitere
akutelle Informationen
zu den Themengebieten

Substitutionsmittel

Initiation and Dose of Methadone Monotherapy vs Combination Therapy, 2015 to 2023.

Methadone treatment for people who use fentanyl: Recommendations.

Kanada. Canada’s Methadone Prescribing Changes With Drug Supply

Evidence on Buprenorphine Dose Limits: A Review.

Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting.

Dose-specific clinical outcomes in patients with opioid use disorder treated with 24-32 mg/day of buprenorphine.

High-Dose Buprenorphine Treatment in the Setting of Fentanyl.

Retention of patients in opioid substitution treatment: A systematic review.

Berlin. Suchtmedizinische Grundversorgung Teil 1nach dem (Muster-)Kursbuch Suchtmedizinische Grundversorgung der Bundesärztekammer (Stand 02.05.2022) - 09.10.2025–10.10.2025

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT).

Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.

Maintenance therapy with opium tincture for injecting drug users; implications for prevention from viral infections.

Changes in self-reported mental health, anxiety and depression among patients in heroin-assisted treatment: Findings from a Norwegian trial project.

Extended-release injectable buprenorphine for the treatment of opioid use disorder among individuals at high risk of overdose: The FASTER-BUP udy.

Accidental Methadone Toxicity in a 3-Year-Old Leading to Severe Cerebellitis and Death: A Case Report.

Methadone-Induced Toxicity - An Unexpected Challenge for the Brain and Heart in ICU Settings: Case Report and Review of the Literature.

Pomegranate Juice Consumption Improves Sleep Quality and Melatonin Concentration of Patients With Opioid Use Disorders Under Medication-Assisted Treatment With Methadone and Buprenorphine: A Randomized Controlled Trial.

UK. Time for a new HAT – Heroin Assisted Treatment

Substitutionstherapie: Depotpräparate schenken Lebensqualität

Cognitive functioning in subjects with Substance Use Disorder: retrospective observational study on the transition from Methadone to Levomethadone

Cognitive functioning in subjects with Substance Use Disorder: retrospective observational study on the transition from Methadone to Levomethadone

Management of Patients in an Unstable Phase of Opioid Use Disorder: Challenges, Goals, and Emerging Evidence on Long-Acting Buprenorphine.

Barriers and facilitators to injectable opioid agonist treatment engagement within a structural vulnerability context: a qualitative study of patient experiences in Vancouver, Canada.

Changing trends in safer opioid supply uptake, dose and hydromorphone volume in Ontario: A population-based cross-sectional study.

Cortisol and β-Endorphin Responses During a Two-Month Exercise Training Program in Patients with an Opioid Use Disorder and on a Substitution Treatment.

Duration of Methadone and Buprenorphine-Naloxone Treatment.

Duration of Methadone and Buprenorphine-Naloxone Treatment.

Pain Management Strategies for Patients Receiving Extended-Release Buprenorphine for Opioid Use Disorder: A Scoping Review.

Essen. Eröffnung der Diamorphin-Ambulanz

Medication experiences in the treatment of opioid use disorders: Insights from Reddit.

Effectiveness of methadone versus buprenorphine in the treatment of opioid use disorder: secondary analyses of prospective cohort study data.

Effectiveness of methadone versus buprenorphine in the treatment of opioid use disorder: secondary analyses of prospective cohort study data.

Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada.

Stimulant use with opioid use disorder medication increases overdose risk for methadone but not buprenorphine/naloxone

Why I Microdose Suboxone, While Continuing to Use Lots of Fentanyl

Memory function in patients with opioid dependence treated with buprenorphine and methadone in comparison with healthy persons.

Memory function in patients with opioid dependence treated with buprenorphine and methadone in comparison with healthy persons.

Hydromorphone Hopes: A Qualitative Study of People Initiating Supervised Short-Acting Injectable Opioid Treatment in Australia.

The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review.

ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder.

Experiences of Women Prescribed Methadone.

Structural Determinants of Buprenorphine Partial Agonism at the μ-Opioid Receptor.

BfArM. Liste der Fertigarzneimittel mit einer Verpflichtung zur regelmäßigen Datenübermittlung nach § 52b Abs. 3f AMG

Approved medications for opioid use disorder : current update.

Rapid Titration of Methadone for Opioid Use Disorder in the Emergency Department: A Case Report.

Do some operations still need more diamorphine? Leslie D, Stranix N. Anaesthesia. 2025 Jun;80(6):723. doi: 10.1111/anae.16535. Epub 2024 Dec 29. PMID: 40350697. https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/epdf/10.1111/ana

Patient-elected low-dose intravenous naloxone for rapid buprenorphine induction: a case report.

A Path Forward for Extended-Release Buprenorphine—Optimizing Implementation Strategies.

Initiating Injectable Buprenorphine in People Hospitalized With Infections: A Randomized Clinical Trial.

USA. Seattle nonprofit rolling out potential ‘game changer’ for fentanyl addiction

buprenorphine/naloxone (Rx)

Relative risks of adverse effects across different opioid agonist treatments—A systematic review and meta-analysis.

A Review of the Prospective Effects of Methadone on Peripheral Neuropathic Pain in Diabetic Patients.

In brief: New labeling for once-monthly subcutaneous buprenorphine (Sublocade).

Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series.

Social Listening for Patient Experiences With Stopping Extended-Release Buprenorphine: Content Analysis of Reddit Messages.

Dosing to Effect With Weekly and Monthly Subcutaneous and Daily Sublingual Buprenorphine: Post Hoc Analysis of a Phase 3 Clinical Trial.

Long acting injectable buprenorphine: Perspectives from service-users, staff and stakeholders.

Escalating Doses of Buprenorphine for the Treatment of Buprenorphine-Induced Opioid Withdrawal.

Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl.

Outpatient Initiation of 7-Day Injectable Buprenorphine: A Direct-to-Inject Case Series.

Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States.

Methadone and Buprenorphine as Medication for Addiction Treatment Diversely Affect Inflammation and Craving Depending on Their Doses.

Methadone and Buprenorphine as Medication for Addiction Treatment Diversely Affect Inflammation and Craving Depending on Their Doses.

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.

Initiation and Dosing of Extended-Release Buprenorphine: A Narrative Review of Emerging Approaches for Patients Who Use Fentanyl.

Trends in Extended-Release and Non-Extended-Release Buprenorphine Dispensing.

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder.

The Impact of CYP2D6 metabolizer phenotypes on the EDDP/methadone metabolic ratio: A comprehensive analysis.

Diversion of diacetylmorphine in heroin-assisted treatment - a focus group study among patients and treatment providers.

Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs.

The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021.

Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study.

Cognitive function among methadone assisted treatment patient in Malaysia.

High BMI is a specific risk factor for drug-related mortality in patients receiving methadone: A case control study.

The effectiveness of Transcranial Photobiomodulation therapy (tPBM) on reducing anxiety, depression, and opioid craving in patients undergoing methadone maintenance treatment: a double-blind, randomized, controlled trial.

Switching to levomethadone improves methadone-induced hyperhidrosis: A case report.